IL-2	B-DNA
gene	I-DNA
expression	O
and	O
NF-kappa	B-protein
B	I-protein
activation	O
through	O
CD28	B-protein
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	B-protein
.	O

Activation	O
of	O
the	O
CD28	B-protein
surface	I-protein
receptor	I-protein
provides	O
a	O
major	O
costimulatory	O
signal	O
for	O
T	O
cell	O
activation	O
resulting	O
in	O
enhanced	O
production	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
and	O
cell	O
proliferation	O
.	O

In	O
primary	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
we	O
show	O
that	O
CD28	B-protein
ligation	O
leads	O
to	O
the	O
rapid	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
which	O
are	O
required	O
for	O
CD28	B-protein
-mediated	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
/	O
CD28-responsive	B-protein
complex	I-protein
and	O
IL-2	B-protein
expression	O
.	O

Delineation	O
of	O
the	O
CD28	B-protein
signaling	O
cascade	O
was	O
found	O
to	O
involve	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
,	O
followed	O
by	O
the	O
activation	O
of	O
phospholipase	B-protein
A2	I-protein
and	O
5-lipoxygenase	B-protein
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	B-protein
metabolites	I-protein
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	B-protein
expression	O
via	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

These	O
findings	O
should	O
be	O
useful	O
for	O
therapeutic	O
strategies	O
and	O
the	O
development	O
of	O
immunosuppressants	O
targeting	O
the	O
CD28	B-protein
costimulatory	O
pathway	O
.	O

The	O
peri-kappa	B-DNA
B	I-DNA
site	I-DNA
mediates	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
2	I-DNA
enhancer	I-DNA
activation	O
in	O
monocytes	B-cell_type
but	O
not	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Human	O
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV-2	O
)	O
,	O
like	O
HIV-1	O
,	O
causes	O
AIDS	O
and	O
is	O
associated	O
with	O
AIDS	O
cases	O
primarily	O
in	O
West	O
Africa	O
.	O

HIV-1	O
and	O
HIV-2	O
display	O
significant	O
differences	O
in	O
nucleic	O
acid	O
sequence	O
and	O
in	O
the	O
natural	O
history	O
of	O
clinical	O
disease	O
.	O

Consistent	O
with	O
these	O
differences	O
,	O
we	O
have	O
previously	O
demonstrated	O
that	O
the	O
enhancer/promoter	B-DNA
region	I-DNA
of	O
HIV-2	O
functions	O
quite	O
differently	O
from	O
that	O
of	O
HIV-1	O
.	O

Whereas	O
activation	O
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
following	O
T-cell	O
stimulation	O
is	O
mediated	O
largely	O
through	O
binding	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
to	O
two	O
adjacent	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
in	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
activation	O
of	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
in	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
is	O
dependent	O
on	O
four	O
cis-acting	B-DNA
elements	I-DNA
:	O
a	O
single	O
kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
two	O
purine-rich	B-DNA
binding	I-DNA
sites	I-DNA
,	O
PuB1	B-DNA
and	O
PuB2	B-DNA
,	O
and	O
a	O
pets	B-DNA
site	I-DNA
.	O

We	O
have	O
now	O
identified	O
a	O
novel	O
cis-acting	B-DNA
element	I-DNA
within	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
,	O
immediately	O
upstream	O
of	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
designated	O
peri-kappa	B-DNA
B	I-DNA
.	O

This	O
site	O
is	O
conserved	O
among	O
isolates	O
of	O
HIV-2	O
and	O
the	O
closely	O
related	O
simian	O
immunodeficiency	O
virus	O
,	O
and	O
transfection	O
assays	O
show	O
this	O
site	O
to	O
mediate	O
HIV-2	B-DNA
enhancer	I-DNA
activation	O
following	O
stimulation	O
of	O
monocytic	B-cell_line
but	O
not	O
T-cell	B-cell_line
lines	I-cell_line
.	O

This	O
is	O
the	O
first	O
description	O
of	O
an	O
HIV-2	B-DNA
enhancer	I-DNA
element	I-DNA
which	O
displays	O
such	O
monocyte	O
specificity	O
,	O
and	O
no	O
comparable	O
enhancer	B-DNA
element	I-DNA
has	O
been	O
clearly	O
defined	O
for	O
HIV-1	O
.	O

While	O
a	O
nuclear	B-protein
factor	I-protein
(	O
s	O
)	O
from	O
both	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
T	B-cell_type
cells	I-cell_type
binds	O
the	O
peri-kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
either	O
a	O
different	O
protein	O
binds	O
to	O
this	O
site	O
in	O
monocytes	B-cell_type
versus	O
T	B-cell_type
cells	I-cell_type
or	O
that	O
the	O
protein	O
recognizing	O
this	O
enhancer	B-DNA
element	I-DNA
undergoes	O
differential	O
modification	O
in	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
,	O
thus	O
supporting	O
the	O
transfection	O
data	O
.	O

Further	O
,	O
while	O
specific	O
constitutive	O
binding	O
to	O
the	O
peri-kappa	B-DNA
B	I-DNA
site	I-DNA
is	O
seen	O
in	O
monocytes	B-cell_type
,	O
stimulation	O
with	O
phorbol	O
esters	O
induces	O
additional	O
,	O
specific	O
binding	O
.	O

Understanding	O
the	O
monocyte-specific	O
function	O
of	O
the	O
peri-kappa	B-protein
B	I-protein
factor	I-protein
may	O
ultimately	O
provide	O
insight	O
into	O
the	O
different	O
role	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
play	O
in	O
HIV	O
pathogenesis	O
.	O

E1A	B-DNA
gene	I-DNA
expression	O
induces	O
susceptibility	O
to	O
killing	O
by	O
NK	B-cell_type
cells	I-cell_type
following	O
immortalization	O
but	O
not	O
adenovirus	O
infection	O
of	O
human	B-cell_type
cells	I-cell_type
.	O

Adenovirus	O
(	O
Ad	O
)	O
infection	O
and	O
E1A	B-protein
transfection	O
were	O
used	O
to	O
model	O
changes	O
in	O
susceptibility	O
to	O
NK	O
cell	O
killing	O
caused	O
by	O
transient	O
vs	O
stable	O
E1A	B-protein
expression	O
in	O
human	B-cell_type
cells	I-cell_type
.	O

Only	O
stably	O
transfected	B-cell_line
target	I-cell_line
cells	I-cell_line
exhibited	O
cytolytic	O
susceptibility	O
,	O
despite	O
expression	O
of	O
equivalent	O
levels	O
of	O
E1A	B-protein
proteins	I-protein
in	O
Ad-infected	B-cell_line
targets	I-cell_line
.	O

The	O
inability	O
of	O
E1A	B-DNA
gene	I-DNA
products	O
to	O
induce	O
cytolytic	O
susceptibility	O
during	O
infection	O
was	O
not	O
explained	O
by	O
an	O
inhibitory	O
effect	O
of	O
viral	O
infection	O
on	O
otherwise	O
susceptible	O
target	B-cell_type
cells	I-cell_type
or	O
by	O
viral	B-DNA
gene	I-DNA
effects	O
on	O
class	B-protein
I	I-protein
MHC	I-protein
antigen	I-protein
expression	O
on	O
target	B-cell_type
cells	I-cell_type
.	O

This	O
differential	O
effect	O
of	O
E1A	B-protein
expression	O
on	O
the	O
cytolytic	O
phenotypes	O
of	O
infected	O
and	O
stably	O
transfected	O
human	B-cell_type
cells	I-cell_type
suggests	O
that	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
provide	O
an	O
effective	O
immunologic	O
barrier	O
against	O
the	O
in	O
vivo	O
survival	O
and	O
neoplastic	O
progression	O
of	O
E1A-immortalized	B-cell_line
cells	I-cell_line
that	O
may	O
emerge	O
from	O
the	O
reservoir	O
of	O
persistently	B-cell_type
infected	I-cell_type
cells	I-cell_type
in	O
the	O
human	O
host	O
.	O

Distinct	O
signaling	O
properties	O
identify	O
functionally	O
different	O
CD4	B-protein
epitopes	I-protein
.	O

The	O
CD4	B-protein
coreceptor	I-protein
interacts	O
with	O
non-polymorphic	B-protein
regions	I-protein
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
II	I-protein
molecules	I-protein
on	O
antigen-presenting	B-cell_type
cells	I-cell_type
and	O
contributes	O
to	O
T	O
cell	O
activation	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
CD4	B-protein
triggering	O
on	O
T	O
cell	O
activating	O
signals	O
in	O
a	O
lymphoma	O
model	O
using	O
monoclonal	B-protein
antibodies	I-protein
(	O
mAb	B-protein
)	O
which	O
recognize	O
different	O
CD4	B-protein
epitopes	I-protein
.	O

We	O
demonstrate	O
that	O
CD4	B-protein
triggering	O
delivers	O
signals	O
capable	O
of	O
activating	O
the	O
NF-AT	B-protein
transcription	I-protein
factor	I-protein
which	O
is	O
required	O
for	O
interleukin-2	B-protein
gene	O
expression	O
.	O

Whereas	O
different	O
anti-CD4	B-protein
mAb	I-protein
or	O
HIV-1	B-protein
gp120	I-protein
could	O
all	O
trigger	O
activation	O
of	O
the	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
p56lck	B-protein
and	O
p59fyn	B-protein
and	O
phosphorylation	O
of	O
the	O
Shc	B-protein
adaptor	I-protein
protein	I-protein
,	O
which	O
mediates	O
signals	O
to	O
Ras	B-protein
,	O
they	O
differed	O
significantly	O
in	O
their	O
ability	O
to	O
activate	O
NF-AT	B-protein
.	O

Lack	O
of	O
full	O
activation	O
of	O
NF-AT	B-protein
could	O
be	O
correlated	O
to	O
a	O
dramatically	O
reduced	O
capacity	O
to	O
induce	O
calcium	O
flux	O
and	O
could	O
be	O
complemented	O
with	O
a	O
calcium	O
ionophore	O
.	O

The	O
results	O
identify	O
functionally	O
distinct	O
epitopes	B-protein
on	O
the	O
CD4	B-protein
coreceptor	I-protein
involved	O
in	O
activation	O
of	O
the	O
Ras/protein	B-protein
kinase	I-protein
C	I-protein
and	O
calcium	O
pathways	O
.	O

Ligand-dependent	O
repression	O
of	O
the	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
GATA-1	B-protein
by	O
the	O
estrogen	B-protein
receptor	I-protein
.	O

High-dose	O
estrogen	O
administration	O
induces	O
anemia	O
in	O
mammals	O
.	O

In	O
chickens	O
,	O
estrogens	O
stimulate	O
outgrowth	O
of	O
bone	B-cell_type
marrow-derived	I-cell_type
erythroid	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
and	O
delay	O
their	O
maturation	O
.	O

This	O
delay	O
is	O
associated	O
with	O
down-regulation	O
of	O
many	O
erythroid	B-DNA
cell-specific	I-DNA
genes	I-DNA
,	O
including	O
alpha-	B-DNA
and	I-DNA
beta-globin	I-DNA
,	O
band	O
3	O
,	O
band	O
4.1	O
,	O
and	O
the	O
erythroid	B-protein
cell-specific	I-protein
histone	I-protein
H5	B-protein
.	O

We	O
show	O
here	O
that	O
estrogens	O
also	O
reduce	O
the	O
number	O
of	O
erythroid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
in	O
primary	B-cell_line
human	I-cell_line
bone	I-cell_line
marrow	I-cell_line
cultures	I-cell_line
.	O

To	O
address	O
potential	O
mechanisms	O
by	O
which	O
estrogens	O
suppress	O
erythropoiesis	O
,	O
we	O
have	O
examined	O
their	O
effects	O
on	O
GATA-1	B-protein
,	O
an	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
majority	O
of	O
erythroid	B-DNA
cell-specific	I-DNA
genes	I-DNA
and	O
is	O
necessary	O
for	O
full	O
maturation	O
of	O
erythrocytes	B-cell_type
.	O

We	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
GATA-1	B-protein
is	O
strongly	O
repressed	O
by	O
the	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
in	O
a	O
ligand-dependent	O
manner	O
and	O
that	O
this	O
repression	O
is	O
reversible	O
in	O
the	O
presence	O
of	O
4-hydroxytamoxifen	O
.	O

ER	B-protein
-mediated	O
repression	O
of	O
GATA-1	B-protein
activity	O
occurs	O
on	O
an	O
artificial	B-DNA
promoter	I-DNA
containing	O
a	O
single	O
GATA-binding	B-DNA
site	I-DNA
,	O
as	O
well	O
as	O
in	O
the	O
context	O
of	O
an	O
intact	B-DNA
promoter	I-DNA
which	O
is	O
normally	O
regulated	O
by	O
GATA-1	B-protein
.	O

GATA-1	B-protein
and	O
ER	B-protein
bind	O
to	O
each	O
other	O
in	O
vitro	O
in	O
the	O
absence	O
of	O
DNA	O
.	O

In	O
coimmunoprecipitation	O
experiments	O
using	O
transfected	O
COS	B-cell_line
cells	I-cell_line
,	O
GATA-1	B-protein
and	O
ER	B-protein
associate	O
in	O
a	O
ligand-dependent	O
manner	O
.	O

Mapping	O
experiments	O
indicate	O
that	O
GATA-1	B-protein
and	O
the	O
ER	B-protein
form	O
at	O
least	O
two	O
contacts	O
,	O
which	O
involve	O
the	O
finger	O
region	O
and	O
the	O
N-terminal	B-protein
activation	I-protein
domain	I-protein
of	O
GATA-1	B-protein
.	O

We	O
speculate	O
that	O
estrogens	O
exert	O
effects	O
on	O
erythropoiesis	O
by	O
modulating	O
GATA-1	B-protein
activity	O
through	O
protein-protein	O
interaction	O
with	O
the	O
ER	B-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Mouse	B-DNA
interleukin-2	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
expression	O
.	O

Interleukin-1	B-protein
and	O
interleukin-2	B-protein
control	O
transcription	O
via	O
distinct	O
cis-acting	B-DNA
elements	I-DNA
.	O

We	O
have	O
shown	O
that	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
and	O
IL-2	B-protein
control	O
IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
transcription	O
in	O
CD4-CD8-	B-cell_line
murine	I-cell_line
T	I-cell_line
lymphocyte	I-cell_line
precursors	I-cell_line
.	O

Here	O
we	O
map	O
the	O
cis-acting	B-DNA
elements	I-DNA
that	O
mediate	O
interleukin	O
responsiveness	O
of	O
the	O
mouse	B-DNA
IL-2R	I-DNA
alpha	I-DNA
gene	I-DNA
using	O
a	O
thymic	B-cell_line
lymphoma-derived	I-cell_line
hybridoma	I-cell_line
(	O
PC60	B-cell_line
)	O
.	O

The	O
transcriptional	O
response	O
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
to	O
stimulation	O
by	O
IL-1	B-protein
+	O
IL-2	B-protein
is	O
biphasic	O
.	O

IL-1	B-protein
induces	O
a	O
rapid	O
,	O
protein	O
synthesis-independent	O
appearance	O
of	O
IL-2R	B-RNA
alpha	I-RNA
mRNA	I-RNA
that	O
is	O
blocked	O
by	O
inhibitors	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

It	O
also	O
primes	O
cells	O
to	O
become	O
IL-2	B-protein
responsive	O
and	O
thereby	O
prepares	O
the	O
second	O
phase	O
,	O
in	O
which	O
IL-2	B-protein
induces	O
a	O
100-fold	O
further	O
increase	O
in	O
IL-2R	B-RNA
alpha	I-RNA
transcripts	I-RNA
.	O

Transient	O
transfection	O
experiments	O
show	O
that	O
several	O
elements	O
in	O
the	O
promoter-proximal	B-DNA
region	I-DNA
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
contribute	O
to	O
IL-1	B-protein
responsiveness	O
,	O
most	O
importantly	O
an	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
conserved	O
in	O
the	O
human	B-DNA
and	I-DNA
mouse	I-DNA
gene	I-DNA
.	O

IL-2	B-protein
responsiveness	O
,	O
on	O
the	O
other	O
hand	O
,	O
depends	O
on	O
a	O
78-nucleotide	B-DNA
segment	I-DNA
1.3	O
kilobases	O
upstream	O
of	O
the	O
major	B-DNA
transcription	I-DNA
start	I-DNA
site	I-DNA
.	O

This	O
segment	O
functions	O
as	O
an	O
IL-2-inducible	B-DNA
enhancer	I-DNA
and	O
lies	O
within	O
a	O
region	O
that	O
becomes	O
DNase	B-protein
I	I-protein
hypersensitive	O
in	O
normal	O
T	B-cell_type
cells	I-cell_type
in	O
which	O
IL-2R	B-protein
alpha	I-protein
expression	O
has	O
been	O
induced	O
.	O

IL-2	B-protein
responsiveness	O
requires	O
three	O
distinct	O
elements	B-DNA
within	O
the	O
enhancer	B-DNA
.	O

Two	O
of	O
these	O
are	O
potential	O
binding	O
sites	O
for	O
STAT	B-protein
proteins	I-protein
.	O

Hematopoietic	B-cell_type
lineage	I-cell_type
commitment	O
:	O
role	O
of	O
transcription	B-protein
factors	I-protein
.	O

This	O
review	O
focuses	O
on	O
the	O
roles	O
of	O
transcription	B-protein
factors	I-protein
in	O
hematopoietic	O
lineage	O
commitment	O
.	O

A	O
brief	O
introduction	O
to	O
lineage	O
commitment	O
and	O
asymmetric	O
cell	O
division	O
is	O
followed	O
by	O
a	O
discussion	O
of	O
several	O
methods	O
used	O
to	O
identify	O
transcription	B-protein
factors	I-protein
important	O
in	O
specifying	O
hematopoietic	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O

Next	O
is	O
presented	O
a	O
discussion	O
of	O
the	O
use	O
of	O
embryonic	B-cell_type
stem	I-cell_type
cells	I-cell_type
in	O
the	O
analysis	O
of	O
hematopoietic	B-DNA
gene	I-DNA
expression	O
and	O
the	O
use	O
of	O
targeted	O
gene	O
disruption	O
to	O
analyze	O
the	O
role	O
of	O
transcription	B-protein
factors	I-protein
in	O
hematopoiesis	O
.	O

Finally	O
,	O
the	O
status	O
of	O
our	O
current	O
knowledge	O
concerning	O
the	O
roles	O
of	O
transcription	B-protein
factors	I-protein
in	O
the	O
commitment	O
to	O
erythroid	B-cell_type
,	I-cell_type
myeloid	I-cell_type
and	I-cell_type
lymphoid	I-cell_type
cell	I-cell_type
types	I-cell_type
is	O
summarized	O
.	O

Epstein-Barr	O
virus	O
replicative	O
gene	O
transcription	O
during	O
de	O
novo	O
infection	O
of	O
human	B-cell_type
thymocytes	I-cell_type
:	O
simultaneous	O
early	O
expression	O
of	O
BZLF-1	B-protein
and	O
its	O
repressor	O
RAZ	B-protein
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
known	O
to	O
infect	O
B	B-cell_type
cells	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
.	O

We	O
and	O
others	O
have	O
shown	O
that	O
EBV	O
can	O
also	O
infect	O
a	O
subset	O
of	O
thymocytes	B-cell_type
.	O

Infection	O
of	O
thymocytes	B-cell_type
was	O
accompanied	O
by	O
the	O
appearance	O
of	O
linear	B-DNA
EBV	I-DNA
genome	I-DNA
within	O
8	O
hr	O
of	O
infection	O
.	O

Circularization	O
of	O
the	O
EBV	B-DNA
genome	I-DNA
was	O
not	O
detected	O
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
infection	O
in	O
B	B-cell_type
cells	I-cell_type
where	O
the	O
genome	O
can	O
circularize	O
within	O
24	O
hr	O
of	O
infection	O
.	O

The	O
appearance	O
of	O
the	O
BamHI	B-protein
ZLF-1	I-protein
gene	I-protein
product	I-protein
,	O
ZEBRA	B-protein
,	O
by	O
RT-PCR	O
,	O
was	O
observed	O
within	O
8	O
hr	O
of	O
infection	O
.	O

The	O
appearance	O
of	O
a	O
novel	O
fusion	B-protein
transcript	I-protein
(	O
RAZ	B-protein
)	O
,	O
which	O
comprised	O
regions	O
of	O
the	O
BZLF-1	B-DNA
locus	I-DNA
and	O
the	O
adjacent	O
BRLF-1	B-DNA
locus	I-DNA
,	O
was	O
detected	O
by	O
RT-PCR	O
.	O

ZEBRA	B-protein
protein	I-protein
was	O
also	O
identified	O
in	O
infected	O
thymocytes	B-cell_type
by	O
immunoprecipitation	O
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
the	O
EBNA-1	B-DNA
gene	I-DNA
in	O
infected	O
thymocytes	B-cell_type
was	O
transcribed	O
from	O
the	O
Fp	B-DNA
promoter	I-DNA
,	O
rather	O
than	O
from	O
the	O
Cp/Wp	B-DNA
promoter	I-DNA
which	O
is	O
used	O
in	O
latently	B-cell_type
infected	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Transcripts	O
encoding	O
gp350/220	B-protein
,	O
the	O
major	B-protein
coat	I-protein
protein	I-protein
of	O
EBV	O
,	O
were	O
identified	O
,	O
but	O
we	O
did	O
not	O
find	O
any	O
evidence	O
of	O
transcription	O
from	O
the	O
LMP-2A	B-DNA
or	O
EBER-1	B-DNA
loci	I-DNA
in	O
infected	O
thymocytes	B-cell_type
.	O

These	O
observations	O
suggest	O
that	O
de	O
novo	O
EBV	O
infection	O
of	O
thymocytes	B-cell_type
differs	O
from	O
infection	O
of	O
B	B-cell_type
cells	I-cell_type
.	O

The	O
main	O
difference	O
is	O
that	O
with	O
thymocytes	B-cell_type
,	O
no	O
evidence	O
could	O
be	O
found	O
that	O
the	O
virus	O
ever	O
circularizes	O
.	O

Rather	O
,	O
EBV	O
remains	O
in	O
a	O
linear	O
configuration	O
from	O
which	O
replicative	B-DNA
genes	I-DNA
are	O
transcribed	O
.	O

Identification	O
and	O
purification	O
of	O
human	B-protein
Stat	I-protein
proteins	I-protein
activated	O
in	O
response	O
to	O
interleukin-2	B-protein
.	O

A	O
key	O
cytokine	B-protein
induced	O
during	O
the	O
immune	O
response	O
is	O
IL-2	B-protein
.	O

Following	O
T	O
cell	O
activation	O
,	O
the	O
genes	O
encoding	O
IL-2	B-protein
and	O
the	O
various	O
chains	O
of	O
its	O
receptor	O
are	O
transcriptionally	O
induced	O
.	O

In	O
turn	O
,	O
secreted	O
IL-2	B-protein
serves	O
to	O
stimulate	O
the	O
proliferation	O
and	O
differentiation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Several	O
recent	O
studies	O
have	O
implicated	O
Jak	O
kinases	O
in	O
the	O
signaling	O
pathway	O
induced	O
by	O
IL-2	B-protein
.	O

Following	O
this	O
lead	O
,	O
we	O
set	O
out	O
to	O
identify	O
transcription	B-protein
factors	I-protein
induced	O
in	O
response	O
to	O
IL-2	B-protein
.	O

Human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
were	O
observed	O
to	O
contain	O
several	O
IL-2	B-protein
-inducible	O
DNA	O
binding	O
activities	O
.	O

Similar	O
activities	O
were	O
also	O
observed	O
in	O
a	O
transformed	B-cell_line
human	I-cell_line
lymphocyte	I-cell_line
line	I-cell_line
,	O
termed	O
YT	B-cell_line
.	O

We	O
have	O
purified	O
these	O
activities	O
and	O
found	O
that	O
the	O
principal	O
IL-2-inducible	B-protein
component	I-protein
bears	O
significant	O
relatedness	O
to	O
a	O
prolactin-induced	B-protein
transcription	I-protein
factor	I-protein
first	O
identified	O
in	O
sheep	B-cell_type
mammary	I-cell_type
gland	I-cell_type
tissue	I-cell_type
.	O

We	O
hypothesize	O
that	O
activation	O
of	O
this	O
protein	O
,	O
designated	O
hStat5	B-protein
,	O
helps	O
govern	O
the	O
biological	O
effects	O
of	O
IL-2	B-protein
during	O
the	O
immune	O
response	O
.	O

E2F-1	B-protein
and	O
a	O
cyclin-like	B-protein
DNA	I-protein
repair	I-protein
enzyme	I-protein
,	O
uracil-DNA	B-protein
glycosylase	I-protein
,	O
provide	O
evidence	O
for	O
an	O
autoregulatory	O
mechanism	O
for	O
transcription	O
.	O

The	O
cell	B-protein
cycle-dependent	I-protein
transcription	I-protein
factor	I-protein
,	O
E2F-1	B-protein
,	O
regulates	O
the	O
cyclin	B-protein
-like	O
species	O
of	O
the	O
DNA	B-protein
repair	I-protein
enzyme	I-protein
uracil-DNA	B-DNA
glycosylase	I-DNA
(	I-DNA
UDG	I-DNA
)	I-DNA
gene	I-DNA
in	O
human	B-cell_line
osteosarcoma	I-cell_line
(	I-cell_line
Saos-2	I-cell_line
)	I-cell_line
cells	I-cell_line
.	O

We	O
demonstrate	O
,	O
through	O
the	O
deletion	O
of	O
the	O
human	B-DNA
UDG	I-DNA
promoter	I-DNA
sequences	I-DNA
,	O
that	O
expression	O
of	O
E2F-1	B-protein
activates	O
the	O
UDG	B-DNA
promoter	I-DNA
through	O
several	O
E2F	B-DNA
sites	I-DNA
.	O

The	O
major	B-DNA
putative	I-DNA
downstream	I-DNA
site	I-DNA
for	O
E2F	B-protein
,	O
located	O
in	O
the	O
first	B-DNA
exon	I-DNA
,	O
serves	O
as	O
a	O
target	O
for	O
E2F-1/DP1	B-protein
complex	I-protein
binding	O
in	O
vitro	O
.	O

We	O
also	O
provide	O
evidence	O
for	O
the	O
functional	O
relationship	O
between	O
the	O
cyclin-like	B-protein
UDG	I-protein
gene	I-protein
product	I-protein
and	O
E2F	B-protein
.	O

High	O
levels	O
of	O
UDG	B-protein
expression	O
in	O
a	O
transient	O
transfection	O
assay	O
result	O
in	O
the	O
down-regulation	O
of	O
transcriptional	O
activity	O
through	O
elements	B-DNA
specific	O
for	O
E2F	B-protein
-mediated	O
transcription	O
.	O

Overexpression	O
of	O
UDG	B-protein
in	O
Saos	B-cell_line
2	I-cell_line
cells	I-cell_line
was	O
observed	O
to	O
delay	O
growth	O
late	O
in	O
G1	O
phase	O
and	O
transiently	O
arrest	O
these	O
cells	O
from	O
progressing	O
into	O
the	O
S	O
phase	O
.	O

This	O
hypothetical	O
model	O
integrates	O
one	O
mechanism	O
of	O
DNA	O
repair	O
with	O
the	O
cell	O
cycle	O
control	O
of	O
gene	O
transcription	O
,	O
likely	O
through	O
E2F	B-protein
.	O

This	O
implicates	O
E2F	B-protein
as	O
a	O
multifunctional	O
target	O
for	O
proteins	O
and	O
enzymes	O
,	O
possibly	O
,	O
responsive	O
to	O
DNA	O
damage	O
through	O
the	O
negative	O
effect	O
of	O
UDG	B-protein
on	O
E2F	B-protein
-mediated	O
transcriptional	O
activity	O
.	O

Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IFN-gamma	B-protein
production	O
induced	O
by	O
IL-2	B-protein
and	O
IL-12	B-protein
in	O
a	O
human	B-cell_line
NK	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
is	O
an	O
important	O
immunoregulatory	B-protein
protein	I-protein
produced	O
predominantly	O
by	O
T	B-cell_type
cells	I-cell_type
and	O
large	B-cell_type
granular	I-cell_type
lymphocytes	I-cell_type
(	O
LGL	B-cell_type
)	O
in	O
response	O
to	O
different	O
extracellular	O
signals	O
.	O

In	O
particular	O
,	O
two	O
interleukins	B-protein
(	O
ILs	B-protein
)	O
,	O
IL-2	B-protein
and	O
IL-12	B-protein
,	O
have	O
been	O
shown	O
to	O
be	O
potent	O
inducers	O
of	O
IFN-gamma	B-protein
gene	O
expression	O
in	O
both	O
T	B-cell_type
cells	I-cell_type
and	O
LGL	B-cell_type
.	O

Although	O
it	O
has	O
been	O
reported	O
that	O
there	O
are	O
some	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
produce	O
IFN-gamma	B-protein
in	O
response	O
to	O
IL-2	O
and	O
IL-12	O
stimulation	O
,	O
there	O
has	O
as	O
yet	O
been	O
no	O
report	O
of	O
a	O
natural	B-cell_line
killer	I-cell_line
(	I-cell_line
NK	I-cell_line
)	I-cell_line
cell	I-cell_line
line	I-cell_line
that	O
responds	O
in	O
a	O
similar	O
manner	O
.	O

In	O
this	O
report	O
we	O
present	O
evidence	O
that	O
the	O
cell	B-cell_line
line	I-cell_line
NK3.3	I-cell_line
derived	O
from	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
,	O
responds	O
to	O
both	O
IL-2	B-protein
and	O
IL-12	B-protein
,	O
as	O
measured	O
by	O
increases	O
in	O
IFN-gamma	B-protein
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
cytoplasmic	O
mRNA	O
and	O
protein	O
expression	O
.	O

In	O
addition	O
,	O
when	O
used	O
together	O
IL-2	B-protein
and	O
IL-12	B-protein
synergized	O
in	O
the	O
induction	O
of	O
IFN-gamma	B-protein
and	O
GM-CSF	B-protein
and	O
this	O
synergy	O
was	O
attributed	O
to	O
an	O
increased	O
accumulation	O
and	O
stability	O
of	O
the	O
IFN-gamma	B-RNA
and	I-RNA
GM-CSF	I-RNA
mRNAs	I-RNA
.	O

To	O
investigate	O
the	O
signaling	O
pathways	O
involved	O
in	O
the	O
gene	O
induction	O
,	O
five	O
inhibitors	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
,	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
,	O
cycloheximide	O
,	O
genistein	O
,	O
and	O
staurosporine	O
A	O
,	O
were	O
used	O
in	O
analyzing	O
the	O
effects	O
of	O
IL-2	B-protein
and	O
IL-12	B-protein
on	O
NK3.3	B-cell_line
cells	I-cell_line
.	O

The	O
results	O
suggest	O
that	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
but	O
not	O
new	O
protein	O
synthesis	O
,	O
is	O
required	O
for	O
IL-2	B-protein
induction	O
of	O
IFN-gamma	B-RNA
and	I-RNA
GM-CSF	I-RNA
cytoplasmic	I-RNA
mRNA	I-RNA
.	O

In	O
contrast	O
,	O
IL-12	B-protein
induction	O
of	O
IFN-gamma	B-RNA
cytoplasmic	I-RNA
mRNA	I-RNA
appears	O
to	O
only	O
partially	O
depend	O
on	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O

Furthermore	O
,	O
both	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
and	O
genistein	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
could	O
suppress	O
IL-2	B-protein
and	O
IL-12	B-protein
signaling	O
but	O
CsA	O
was	O
generally	O
inactive	O
.	O

It	O
also	O
was	O
observed	O
that	O
suppression	O
of	O
cytokine	B-DNA
gene	I-DNA
expression	O
by	O
these	O
agents	O
was	O
independent	O
of	O
the	O
inhibition	O
of	O
proliferation	O
.	O

In	O
addition	O
,	O
IL-2	B-protein
but	O
not	O
IL-12	B-protein
induced	O
nuclear	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
and	O
AP1	B-protein
,	O
and	O
regulation	O
of	O
the	O
nuclear	O
levels	O
of	O
these	O
two	O
DNA	B-protein
binding	I-protein
protein	I-protein
complexes	I-protein
is	O
correlated	O
with	O
IFN-gamma	O
and	O
GM-CSF	O
gene	O
expression	O
.	O

These	O
data	O
indicate	O
that	O
IL-2	B-protein
and	O
IL-12	B-protein
may	O
have	O
distinct	O
signaling	O
pathways	O
leading	O
to	O
the	O
induction	O
of	O
IFN-gamma	B-protein
and	O
GM-CSF	B-protein
gene	O
expression	O
,	O
and	O
that	O
the	O
NK3.3	B-cell_line
cell	I-cell_line
line	I-cell_line
may	O
serve	O
as	O
a	O
novel	O
model	O
for	O
dissecting	O
the	O
biochemical	O
and	O
molecular	O
events	O
involved	O
in	O
these	O
pathways	O
.	O

A	O
functional	O
T-cell	B-protein
receptor	I-protein
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	B-protein
activity	O
.	O

Stimulation	O
of	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
induces	O
activation	O
of	O
multiple	O
tyrosine	B-protein
kinases	I-protein
,	O
resulting	O
in	O
phosphorylation	O
of	O
numerous	O
intracellular	O
substrates	O
.	O

One	O
substrate	O
is	O
p95vav	B-protein
,	O
which	O
is	O
expressed	O
exclusively	O
in	O
hematopoietic	B-cell_type
and	I-cell_type
trophoblast	I-cell_type
cells	I-cell_type
.	O

It	O
contains	O
a	O
number	O
of	O
structural	B-protein
motifs	I-protein
,	O
including	O
Src	B-protein
homology	I-protein
2	I-protein
,	I-protein
Src	I-protein
homology	I-protein
3	I-protein
,	I-protein
and	I-protein
pleckstrin	I-protein
homology	I-protein
domains	I-protein
and	O
a	O
putative	B-protein
guanine	I-protein
nucleotide	I-protein
exchange	I-protein
domain	I-protein
.	O

The	O
role	O
of	O
p95vav	B-protein
in	O
TCR	B-protein
-mediated	O
signaling	O
processes	O
is	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
p95vav	B-protein
alone	O
in	O
Jurkat	O
T	B-cell_type
cells	I-cell_type
leads	O
to	O
activation	O
of	O
the	O
nuclear	B-protein
factors	I-protein
,	O
including	O
NFAT	B-protein
,	O
involved	O
in	O
interleukin-2	B-protein
expression	O
.	O

Furthermore	O
,	O
p95vav	B-protein
synergizes	O
with	O
TCR	B-protein
stimulation	O
in	O
inducing	O
NFAT-	O
and	O
interleukin-2-dependent	O
transcription	O
.	O

In	O
contrast	O
,	O
NFAT	B-protein
activation	O
by	O
a	O
G-protein-coupled	B-protein
receptor	I-protein
is	O
not	O
modulated	O
by	O
p95vav	B-protein
overexpression	O
,	O
suggesting	O
that	O
the	O
effect	O
is	O
specific	O
to	O
the	O
TCR	B-protein
signaling	O
pathways	O
.	O

Although	O
removal	O
of	O
the	O
first	B-protein
67	I-protein
amino	I-protein
acids	I-protein
of	O
p95vav	B-protein
activates	O
its	O
transforming	O
potential	O
in	O
NIH	B-cell_line
3T3	I-cell_line
cells	I-cell_line
,	O
this	O
region	O
appears	O
to	O
be	O
required	O
for	O
its	O
function	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
further	O
demonstrate	O
that	O
the	O
p95vav	B-protein
-induced	O
NFAT	B-protein
activation	O
is	O
not	O
mimicked	O
by	O
Ras	B-protein
activation	O
,	O
though	O
its	O
function	O
is	O
dependent	O
upon	O
Ras	B-protein
and	O
Raf	B-protein
.	O

Furthermore	O
,	O
the	O
activating	O
function	O
of	O
p95vav	B-protein
is	O
blocked	O
by	O
FK506	O
,	O
suggesting	O
that	O
its	O
activity	O
also	O
depends	O
on	O
calcineurin	B-protein
.	O

To	O
further	O
dissect	O
p95vav	B-protein
involvement	O
in	O
TCR	B-protein
signaling	O
,	O
we	O
analyzed	O
various	O
Jurkat	B-cell_line
mutants	I-cell_line
deficient	O
in	O
TCR	B-protein
signaling	O
function	O
or	O
TCR	B-protein
expression	O
and	O
showed	O
that	O
an	O
intact	O
TCR	B-protein
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	B-protein
to	O
function	O
.	O

However	O
,	O
overexpression	O
of	O
p95vav	B-protein
does	O
not	O
appear	O
to	O
influence	O
TCR	B-protein
-induced	O
protein	O
tyrosine	O
phosphorylation	O
or	O
increases	O
in	O
cytoplasmic	O
free	O
calcium	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
p95vav	B-protein
plays	O
an	O
important	O
role	O
at	O
an	O
yet	O
unidentified	O
proximal	O
position	O
in	O
the	O
TCR	B-protein
signaling	O
cascade	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
promoter	O
activity	O
by	O
AML1-related	B-protein
transcription	I-protein
factor	I-protein
,	O
PEBP2	B-protein
.	O

The	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
gene	I-DNA
promoter	I-DNA
contains	O
a	O
consensus	O
sequence	O
for	O
the	O
polyomavirus	B-protein
enhancer	I-protein
binding-protein	I-protein
2	I-protein
(	I-protein
PEBP2	I-protein
)	I-protein
transcription	I-protein
factor	I-protein
,	O
which	O
consists	O
of	O
alpha	B-protein
and	I-protein
beta	I-protein
subunits	I-protein
.	O

There	O
are	O
at	O
least	O
two	O
genes	O
,	O
alpha	B-DNA
A	I-DNA
and	O
alpha	B-DNA
B	I-DNA
,	O
encoding	O
the	O
alpha	B-protein
subunit	I-protein
.	O

alpha	B-DNA
B	I-DNA
is	O
the	O
mouse	B-DNA
homologue	I-DNA
of	O
human	B-DNA
AML1	I-DNA
gene	I-DNA
detected	O
at	O
the	O
breakpoints	O
of	O
t	O
(	O
8	O
;	O
21	O
)	O
and	O
t	O
(	O
3	O
;	O
21	O
)	O
myeloid	O
leukemias	O
.	O

We	O
examined	O
alpha	B-protein
A1	I-protein
(	O
an	O
alpha	B-protein
A-gene	I-protein
product	I-protein
)	O
and	O
alpha	B-protein
B1	I-protein
and	O
alpha	B-protein
B2	I-protein
(	O
two	O
alpha	B-protein
B-encoded	I-protein
isomers	I-protein
)	O
for	O
their	O
effects	O
on	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
.	O

PEBP2	B-protein
alpha	I-protein
A1	I-protein
,	O
alpha	B-protein
B1	I-protein
,	O
and	O
alpha	B-protein
B2	I-protein
proteins	I-protein
bound	O
the	O
PEBP2	B-DNA
site	I-DNA
within	O
the	O
mouse	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
.	O

PEBP2	B-protein
alpha	I-protein
A1	I-protein
and	O
alpha	B-protein
B1	I-protein
enhanced	O
the	O
expression	O
of	O
the	O
GM-CSF	B-DNA
promoter-driven	I-DNA
reporter	I-DNA
plasmid	I-DNA
in	O
unstimulated	B-cell_line
and	I-cell_line
12-O-tetradecanoylphorbol	I-cell_line
13-acetate/phytohemagglutinin-stimulated	I-cell_line
human	I-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

In	O
contrast	O
,	O
the	O
promoter	O
activity	O
was	O
suppressed	O
by	O
alpha	B-protein
B2	I-protein
.	O

Coexpression	O
of	O
alpha	B-protein
B1	I-protein
and	O
alpha	B-protein
B2	I-protein
showed	O
that	O
the	O
promoter	O
activity	O
could	O
be	O
determined	O
by	O
the	O
alpha	B-protein
B1	I-protein
/alpha	B-protein
B2	I-protein
ratio	O
.	O

Jurkat	O
cell	O
extract	O
contained	O
PEBP2	B-protein
site-binding	I-protein
protein	I-protein
(	O
s	O
)	O
that	O
cross-reacted	O
with	O
antimouse	B-protein
alpha	I-protein
A1	I-protein
antibodies	I-protein
.	O

Northern	O
blot	O
analysis	O
indicated	O
the	O
expression	O
of	O
human	O
PEBP2	B-protein
alpha	I-protein
A	I-protein
,	O
alpha	B-DNA
B	I-DNA
(	O
AML1	B-DNA
)	O
,	O
and	O
beta	B-DNA
genes	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Although	O
further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
precise	O
role	O
of	O
PEBP2	B-protein
in	O
the	O
GM-CSF	B-protein
promoter	O
activity	O
,	O
the	O
present	O
findings	O
suggested	O
the	O
importance	O
of	O
the	O
relative	O
ratio	O
of	O
different	O
PEBP2	B-protein
isoforms	I-protein
in	O
regulating	O
the	O
levels	O
of	O
the	O
promoter	O
activity	O
.	O

IFN-gamma	B-protein
priming	O
of	O
monocytes	B-cell_type
enhances	O
LPS-induced	O
TNF	B-protein
production	O
by	O
augmenting	O
both	O
transcription	O
and	O
MRNA	O
stability	O
.	O

The	O
induction	O
of	O
cytokine	B-protein
expression	O
in	O
monocytes	B-cell_type
/	O
macrophages	B-cell_type
by	O
bacterial	B-protein
endotoxin	I-protein
or	O
lipopolysaccharide	O
is	O
a	O
critical	O
,	O
highly	O
regulated	O
host	O
defence	O
response	O
.	O

The	O
augmentation	O
of	O
LPS	O
responses	O
by	O
interferon	B-protein
gamma	I-protein
(	O
IFN-gamma	B-protein
)	O
,	O
referred	O
to	O
as	O
priming	O
,	O
is	O
well	O
established	O
.	O

However	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
priming	O
occurs	O
is	O
poorly	O
defined	O
.	O

Using	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
induction	O
as	O
a	O
model	O
,	O
experiments	O
were	O
designed	O
to	O
analyse	O
in	O
detail	O
the	O
priming	O
effect	O
on	O
the	O
LPS	O
response	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Priming	O
by	O
IFN-gamma	B-protein
was	O
primarily	O
manifested	O
at	O
the	O
level	O
of	O
TNF	B-RNA
mRNA	I-RNA
accumulation	O
.	O

IFN-gamma	B-protein
pre-treatment	O
affected	O
the	O
magnitude	O
rather	O
than	O
the	O
sensitivity	O
of	O
the	O
LPS	O
response	O
.	O

Priming	O
occurred	O
after	O
several	O
hours	O
of	O
treatment	O
,	O
and	O
the	O
primed	O
state	O
was	O
induced	O
by	O
either	O
IFN-gamma	B-protein
or	O
GM-CSF	B-protein
,	O
but	O
not	O
M-CSF	B-protein
.	O

Primed	O
monocytes	B-cell_type
transcribed	O
TNF	B-RNA
mRNA	I-RNA
at	O
a	O
higher	O
rate	O
than	O
freshly	O
isolated	O
monocytes	B-cell_type
upon	O
activation	O
with	O
LPS	O
.	O

The	O
increased	O
transcriptional	O
rate	O
correlated	O
with	O
a	O
marked	O
increase	O
in	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activity	O
in	O
these	O
cells	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
consensus	B-DNA
NF-kappa	I-DNA
B	I-DNA
oligonucleotide	I-DNA
.	O

An	O
additional	O
significant	O
finding	O
was	O
than	O
TNF	B-RNA
mRNA	I-RNA
induced	O
in	O
primed	B-cell_line
cells	I-cell_line
was	O
much	O
more	O
stable	O
than	O
in	O
unprimed	B-cell_line
cells	I-cell_line
(	O
T1/2	O
increased	O
6-8-fold	O
)	O
.	O

Consistent	O
with	O
the	O
increased	O
mRNA	B-RNA
stability	O
,	O
the	O
duration	O
of	O
mRNA	B-RNA
accumulation	O
was	O
longer	O
following	O
LPS	O
stimulation	O
in	O
primed	O
monocytes	B-cell_type
,	O
in	O
addition	O
to	O
being	O
of	O
greater	O
magnitude	O
.	O

Finally	O
,	O
primed	O
and	O
unprimed	O
cells	O
possessed	O
a	O
differential	O
sensitivity	O
to	O
the	O
kinase	O
inhibitor	O
H-89	O
.	O

H-89	O
substantially	O
suppressed	O
LPS-induced	O
TNF	B-RNA
mRNA	I-RNA
accumulation	O
in	O
unprimed	B-cell_line
cells	I-cell_line
,	O
but	O
had	O
no	O
effect	O
on	O
primed	B-cell_line
monocytes	I-cell_line
following	O
LPS	O
stimulation	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

A	O
Myc-associated	B-DNA
zinc	I-DNA
finger	I-DNA
protein	I-DNA
binding	I-DNA
site	I-DNA
is	O
one	O
of	O
four	O
important	O
functional	B-DNA
regions	I-DNA
in	O
the	O
CD4	B-DNA
promoter	I-DNA
.	O

The	O
CD4	B-DNA
promoter	I-DNA
plays	O
an	O
important	O
role	O
in	O
the	O
developmental	O
control	O
of	O
CD4	B-protein
transcription	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
minimal	O
CD4	B-DNA
promoter	I-DNA
has	O
four	O
factor	B-DNA
binding	I-DNA
sites	I-DNA
,	O
each	O
of	O
which	O
is	O
required	O
for	O
full	O
function	O
.	O

Using	O
biochemical	O
and	O
mutagenesis	O
analyses	O
,	O
we	O
determined	O
that	O
multiple	O
nuclear	B-protein
factors	I-protein
bind	O
to	O
these	O
independent	O
sites	O
.	O

We	O
determined	O
that	O
an	O
initiator-like	B-DNA
sequence	I-DNA
present	O
at	O
the	O
cap	B-DNA
site	I-DNA
and	O
an	O
Ets	B-DNA
consensus	I-DNA
sequence	I-DNA
are	O
required	O
for	O
full	O
promoter	B-DNA
function	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
Myc-associated	B-protein
zinc	I-protein
finger	I-protein
protein	I-protein
(	O
MAZ	B-protein
)	O
appears	O
to	O
be	O
the	O
predominant	B-protein
factor	I-protein
binding	O
to	O
one	O
of	O
these	O
sites	O
.	O

This	O
last	O
site	O
closely	O
resembles	O
the	O
ME1a1	B-DNA
G3AG4AG3	I-DNA
motif	I-DNA
previously	O
shown	O
to	O
be	O
a	O
critical	O
element	O
in	O
the	O
P2	B-DNA
promoter	I-DNA
of	O
the	O
c-myc	B-DNA
gene	I-DNA
.	O

We	O
therefore	O
believe	O
that	O
the	O
MAZ	B-protein
transcription	I-protein
factor	I-protein
is	O
also	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
developmental	O
expression	O
of	O
the	O
CD4	B-DNA
gene	I-DNA
.	O

Erythropoietin	B-protein
stimulates	O
transcription	O
of	O
the	O
TAL1/SCL	B-DNA
gene	I-DNA
and	O
phosphorylation	O
of	O
its	O
protein	B-protein
products	I-protein
.	O

Activation	O
of	O
the	O
TAL1	B-DNA
(	I-DNA
or	I-DNA
SCL	I-DNA
)	I-DNA
gene	I-DNA
,	O
originally	O
identified	O
through	O
its	O
involvement	O
by	O
a	O
recurrent	O
chromosomal	O
translocation	O
,	O
is	O
the	O
most	O
frequent	O
molecular	O
lesion	O
recognized	O
in	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
.	O

The	O
protein	B-protein
products	I-protein
of	O
this	O
gene	O
contain	O
the	O
basic-helix-loop-helix	B-protein
motif	I-protein
characteristic	O
of	O
a	O
large	O
family	O
of	O
transcription	B-protein
factors	I-protein
that	O
bind	O
to	O
the	O
canonical	B-DNA
DNA	I-DNA
sequence	I-DNA
CANNTG	I-DNA
as	O
protein	B-protein
heterodimers	I-protein
.	O

TAL1	B-protein
expression	O
by	O
erythroid	B-cell_type
cells	I-cell_type
in	O
vivo	O
and	O
in	O
chemical-induced	B-cell_line
erythroleukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
vivo	O
suggested	O
the	O
gene	O
might	O
regulate	O
aspects	O
of	O
erythroid	O
differentiation	O
.	O

Since	O
the	O
terminal	O
events	O
of	O
erythropoiesis	O
are	O
controlled	O
by	O
the	O
glycoprotein	B-protein
hormone	I-protein
erythropoietin	I-protein
(	O
Epo	B-protein
)	O
,	O
we	O
investigated	O
whether	O
the	O
expression	O
or	O
activity	O
of	O
the	O
TAL1	B-DNA
gene	I-DNA
and	O
its	O
protein	B-protein
products	I-protein
were	O
affected	O
by	O
Epo	B-protein
in	O
splenic	B-cell_type
erythroblasts	I-cell_type
from	O
mice	O
infected	O
with	O
an	O
anemia-inducing	O
strain	O
of	O
Friend	O
virus	O
(	O
FVA	O
cells	O
)	O
.	O

Epo	B-protein
elicited	O
a	O
rapid	O
,	O
dose-related	O
increase	O
in	O
TAL1	B-RNA
mRNA	I-RNA
by	O
increasing	O
transcription	O
of	O
the	O
gene	O
and	O
stabilizing	O
one	O
of	O
its	O
mRNAs	B-RNA
.	O

An	O
Epo	B-protein
-inducible	O
TAL1	B-protein
DNA	O
binding	O
activity	O
was	O
identified	O
in	O
FVA	O
cell	O
nuclear	O
extracts	O
that	O
subsequently	O
decayed	O
despite	O
accumulating	O
mRNA	B-RNA
and	O
protein	O
.	O

Induction	O
of	O
DNA	O
binding	O
activity	O
was	O
associated	O
temporally	O
with	O
Epo	B-protein
-induced	O
phosphorylation	O
of	O
nuclear	B-protein
TAL1	I-protein
protein	I-protein
.	O

These	O
results	O
indicate	O
that	O
Epo	B-protein
acts	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
on	O
the	O
TAL1	B-protein
locus	O
in	O
Friend	B-cell_line
virus-induced	I-cell_line
erythroblasts	I-cell_line
and	O
establish	O
a	O
link	O
between	O
Epo	B-protein
signaling	O
mechanisms	O
and	O
a	O
member	O
of	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
the	O
differentiation	O
of	O
diverse	B-cell_type
cell	I-cell_type
lineages	I-cell_type
.	O

Nonradioactive	O
quantification	O
of	O
glucocorticoid	B-protein
receptor	I-protein
expression	O
during	O
differentiation	O
of	O
human	O
monocytic	B-cell_type
cells	I-cell_type
(	O
U937	B-cell_line
)	O
.	O

We	O
describe	O
a	O
method	O
for	O
relative	O
quantification	O
of	O
specific	O
mRNA	B-RNA
using	O
a	O
nonradioactive	O
assay	O
based	O
on	O
DNA	O
strand	O
competition	O
between	O
identical	O
sequences	O
of	O
biotin-	O
and	O
fluorescein-labeled	O
amplicon	O
(	O
probe	O
)	O
and	O
unlabeled	O
amplicon	O
(	O
target	O
)	O
during	O
hybridization	O
.	O

As	O
the	O
target	O
quantity	O
increased	O
,	O
that	O
of	O
the	O
double-labeled	O
probe	O
decreased	O
in	O
accordance	O
with	O
the	O
mass	O
action	O
law	O
.	O

This	O
technique	O
was	O
successfully	O
applied	O
to	O
evaluate	O
differences	O
in	O
glucocorticoid	B-protein
receptor	I-protein
expression	O
in	O
U937	B-cell_line
cells	I-cell_line
before	O
and	O
after	O
the	O
addition	O
of	O
potent	O
differentiation	O
inducers	O
:	O
12-O-tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
and	O
a	O
combination	O
of	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1	O
,	O
25-dihydroxyvitamin	O
D2	O
(	O
VD	O
)	O
.	O

We	O
observed	O
that	O
TPA	O
treatment	O
was	O
associated	O
with	O
an	O
increase	O
in	O
specific	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
and	O
up-regulation	O
of	O
GR	B-RNA
mRNA	I-RNA
while	O
no	O
enhanced	O
GR	B-protein
expression	O
was	O
perceived	O
with	O
RA/VD	O
treatment	O
.	O

Induction	O
of	O
Sp1	B-protein
phosphorylation	O
and	O
NF-kappa	B-DNA
B-independent	I-DNA
HIV	I-DNA
promoter	I-DNA
domain	O
activity	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
stimulated	O
by	O
okadaic	O
acid	O
.	O

In	O
contrast	O
to	O
the	O
purely	O
enhancer-dependent	O
effect	O
of	O
cytokines	B-protein
such	O
as	O
TNF	B-protein
on	O
the	O
activity	O
of	O
the	O
HIV	B-DNA
regulatory	I-DNA
region	I-DNA
(	O
LTR	B-DNA
)	O
,	O
we	O
observed	O
that	O
okadaic	O
acid	O
(	O
OKA	O
)	O
activates	O
HIV	O
transcription	O
through	O
both	O
the	O
enhancer	O
,	O
responding	O
to	O
the	O
factor	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
the	O
promoter	B-DNA
domain	I-DNA
of	O
the	O
LTR	B-DNA
.	O

The	O
inducibility	O
of	O
HIV	B-DNA
LTR-driven	I-DNA
luciferase	I-DNA
expression	I-DNA
constructs	I-DNA
in	O
lymphoblastoid	B-cell_type
cells	I-cell_type
stimulated	O
by	O
OKA	O
depended	O
on	O
both	O
functional	B-DNA
Sp1	I-DNA
binding	I-DNA
elements	I-DNA
and	O
the	O
ability	O
of	O
the	O
TATA	B-DNA
box	I-DNA
to	O
bind	O
the	O
protein	O
TBP	B-protein
.	O

In	O
both	O
transformed	B-cell_type
and	I-cell_type
normal	I-cell_type
lymphocytes	I-cell_type
,	O
OKA	O
stimulation	O
induced	O
intense	O
phosphorylation	O
of	O
the	O
constitutively	O
expressed	O
Sp1	B-protein
protein	I-protein
in	O
the	O
nucleus	O
,	O
a	O
property	O
of	O
OKA	O
not	O
shared	O
by	O
TNF	B-protein
,	O
phorbol	O
ester	O
,	O
or	O
PHA	B-protein
and	O
interleukin	B-protein
2	I-protein
.	O

Responsiveness	O
of	O
LTR	B-DNA
constructs	I-DNA
deleted	O
of	O
kappa	B-DNA
B	I-DNA
elements	I-DNA
to	O
HIV	B-protein
Tat	I-protein
expression	O
was	O
increased	O
upon	O
OKA	O
but	O
not	O
TNF	B-protein
stimulation	O
.	O

Our	O
results	O
suggest	O
that	O
SP1	B-protein
phosphorylation	O
induced	O
by	O
OKA	O
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
serine-threonine	B-protein
phosphatase	I-protein
PP2A	B-protein
,	O
facilitates	O
the	O
formation	O
of	O
a	O
transcription	B-protein
complex	I-protein
involving	O
general	O
transcription	B-protein
factors	I-protein
,	O
HIV	B-protein
Tat	I-protein
,	O
and	O
Sp1	B-protein
proteins	I-protein
.	O

The	O
formation	O
of	O
this	O
complex	O
would	O
increase	O
,	O
independently	O
of	O
an	O
in	O
synergy	O
with	O
NF-kappa	B-protein
B	I-protein
,	O
the	O
low	O
basal	O
activity	O
of	O
the	O
HIV	B-DNA
LTR	I-DNA
observed	O
in	O
normal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
role	O
of	O
shared	B-protein
receptor	I-protein
motifs	I-protein
and	O
common	B-protein
Stat	I-protein
proteins	I-protein
in	O
the	O
generation	O
of	O
cytokine	B-protein
pleiotropy	O
and	O
redundancy	O
by	O
IL-2	B-protein
,	O
IL-4	B-protein
,	O
IL-7	B-protein
,	O
IL-13	B-protein
,	O
and	O
IL-15	B-protein
.	O

To	O
understand	O
the	O
molecular	O
bases	O
for	O
cytokine	O
redundancy	O
and	O
pleiotropy	O
,	O
we	O
have	O
compared	O
the	O
Stat	B-protein
proteins	I-protein
activated	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBLs	B-cell_type
)	O
by	O
cytokines	B-protein
with	O
shared	O
and	O
distinct	O
actions	O
.	O

Interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
rapidly	O
activated	O
Stat5	B-protein
in	O
fresh	O
PBL	B-cell_type
,	O
and	O
Stat3	B-protein
and	O
Stat5	B-protein
in	O
preactivated	B-cell_type
PBL	I-cell_type
.	O

IL-7	B-protein
and	O
IL-15	B-protein
induced	O
the	O
same	O
complexes	O
as	O
IL-2	B-protein
,	O
a	O
feature	O
explained	O
by	O
the	O
existence	O
of	O
similar	O
tyrosine-phosphorylated	B-protein
motifs	I-protein
in	O
the	O
cytoplasmic	B-protein
domains	I-protein
of	O
IL-2R	B-protein
beta	I-protein
and	O
IL-7R	B-protein
that	O
can	O
serve	O
as	O
docking	O
sites	O
for	O
Stat	B-protein
proteins	I-protein
.	O

IL-13	B-protein
Induced	O
the	O
same	O
complexes	O
as	O
IL-4	B-protein
,	O
a	O
finding	O
explained	O
by	O
our	O
studies	O
implicating	O
IL-4R	B-protein
as	O
a	O
shared	O
component	O
of	O
the	O
receptors	B-protein
.	O

These	O
studies	O
demonstrate	O
that	O
a	O
single	O
cytokine	B-protein
can	O
activate	O
different	O
combinations	O
of	O
Stat	B-protein
proteins	I-protein
under	O
different	O
physiological	O
conditions	O
,	O
and	O
also	O
indicate	O
two	O
mechanisms	O
by	O
which	O
distinct	O
cytokines	B-protein
can	O
activate	O
the	O
same	O
Stat	B-protein
protein	I-protein
.	O

Control	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
proteolysis	O
by	O
site-specific	O
,	O
signal-induced	O
phosphorylation	O
.	O

I	B-protein
kappa	I-protein
B-alpha	I-protein
inhibits	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
by	O
retaining	O
it	O
in	O
the	O
cytoplasm	O
.	O

Various	O
stimuli	O
,	O
typically	O
those	O
associated	O
with	O
stress	O
or	O
pathogens	O
,	O
rapidly	O
inactivate	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
.	O

This	O
liberates	O
NF-kappa	B-protein
B	I-protein
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
initiate	O
transcription	O
of	O
genes	B-DNA
important	O
for	O
the	O
defense	O
of	O
the	O
organism	O
.	O

Activation	O
of	O
NF-kappa	B-protein
B	I-protein
correlates	O
with	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
and	O
requires	O
the	O
proteolysis	O
of	O
this	O
inhibitor	O
.	O

When	O
either	O
serine-32	O
or	O
serine-36	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
was	O
mutated	O
,	O
the	O
protein	O
did	O
not	O
undergo	O
signal-induced	O
phosphorylation	O
or	O
degradation	O
,	O
and	O
NF-kappa	B-protein
B	I-protein
could	O
not	O
be	O
activated	O
.	O

These	O
results	O
suggest	O
that	O
phosphorylation	O
at	O
one	O
or	O
both	O
of	O
these	O
residues	O
is	O
critical	O
for	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Regulation	O
of	O
transcription	O
of	O
the	O
human	B-DNA
erythropoietin	I-DNA
receptor	I-DNA
gene	I-DNA
by	O
proteins	O
binding	O
to	O
GATA-1	B-DNA
and	I-DNA
Sp1	I-DNA
motifs	I-DNA
.	O

Erythropoietin	B-protein
(	O
Epo	B-protein
)	O
,	O
the	O
primary	O
regulator	O
of	O
the	O
production	O
of	O
erythroid	B-cell_type
cells	I-cell_type
,	O
acts	O
by	O
binding	O
to	O
a	O
cell	B-protein
surface	I-protein
receptor	I-protein
(	O
EpoR	B-protein
)	O
on	O
erythroid	B-cell_type
progenitors	I-cell_type
.	O

We	O
used	O
deletion	O
analysis	O
and	O
transfection	O
assays	O
with	O
reporter	B-DNA
gene	I-DNA
constructs	I-DNA
to	O
examine	O
the	O
transcription	B-DNA
control	I-DNA
elements	I-DNA
in	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
human	B-DNA
EpoR	I-DNA
gene	I-DNA
.	O

In	O
erythroid	B-cell_type
cells	I-cell_type
most	O
of	O
the	O
transcription	O
activity	O
was	O
contained	O
in	O
a	O
150	B-DNA
bp	I-DNA
promoter	I-DNA
fragment	O
with	O
binding	B-DNA
sites	I-DNA
for	O
transcription	B-protein
factors	I-protein
AP2	B-protein
,	O
Sp1	B-protein
and	O
the	O
erythroid-specific	B-protein
GATA-1	I-protein
.	O

The	O
150	B-DNA
bp	I-DNA
hEpoR	I-DNA
promoter	I-DNA
exhibited	O
high	O
and	O
low	O
activity	O
in	O
erythroid	O
OCIM1	B-cell_line
and	O
K562	B-cell_line
cells	I-cell_line
,	O
respectively	O
,	O
reflecting	O
the	O
high	O
and	O
low	O
levels	O
of	O
constitutive	O
hEpoR	B-protein
expression	O
.	O

The	O
GATA-1	B-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
in	O
this	O
promoter	O
lacking	O
a	O
TATA	B-DNA
sequence	I-DNA
were	O
necessary	O
for	O
a	O
high	O
level	O
of	O
transcription	O
activation	O
.	O

Protein-DNA	O
binding	O
studies	O
suggested	O
that	O
Sp1	B-protein
and	O
two	O
other	O
CCGCCC	B-protein
binding	I-protein
proteins	I-protein
from	O
erythroid	B-cell_type
and	I-cell_type
non-erythroid	I-cell_type
cells	I-cell_type
could	O
bind	O
to	O
the	O
Sp1	B-DNA
binding	I-DNA
motif	I-DNA
.	O

By	O
increasing	O
GATA-1	B-protein
levels	O
via	O
co-transfection	O
,	O
we	O
were	O
able	O
to	O
transactivate	O
the	O
hEpoR	B-DNA
promoter	I-DNA
in	O
K562	B-cell_line
cells	I-cell_line
and	O
non-erythroid	B-cell_type
cells	I-cell_type
,	O
but	O
not	O
in	O
the	O
highly	O
active	O
OCIM1	B-cell_type
cells	I-cell_type
,	O
although	O
GATA-1	B-RNA
mRNA	I-RNA
levels	O
were	O
comparable	O
in	O
OCIM1	B-cell_line
and	O
K562	B-cell_line
.	O

Interestingly	O
,	O
when	O
we	O
mutated	O
the	O
Sp1	B-DNA
site	I-DNA
,	O
resulting	O
in	O
a	O
marked	O
decrease	O
in	O
hEpoR	B-DNA
promoter	I-DNA
activity	O
,	O
we	O
could	O
restore	O
transactivation	O
by	O
increasing	O
GATA-1	B-protein
levels	O
in	O
OCIM1	B-cell_type
cells	I-cell_type
.	O

These	O
data	O
suggest	O
that	O
while	O
GATA-1	B-protein
can	O
transactivate	O
the	O
EpoR	B-DNA
promoter	I-DNA
,	O
the	O
level	O
of	O
hEpoR	B-DNA
gene	I-DNA
expression	O
does	O
not	O
depend	O
on	O
GATA-1	B-protein
alone	O
.	O

Rather	O
,	O
hEpoR	B-protein
transcription	O
activity	O
depends	O
on	O
coordination	O
between	O
Sp1	B-protein
and	O
GATA-1	B-protein
with	O
other	O
cell-specific	B-protein
factors	I-protein
,	O
including	O
possibly	O
other	O
Sp1-like	B-protein
binding	I-protein
proteins	I-protein
,	O
to	O
provide	O
high	O
level	O
,	O
tissue-specific	O
expression	O
.	O

Overexpression	O
of	O
DR-nm23	B-protein
,	O
a	O
protein	O
encoded	O
by	O
a	O
member	O
of	O
the	O
nm23	B-DNA
gene	I-DNA
family	I-DNA
,	O
inhibits	O
granulocyte	B-cell_type
differentiation	O
and	O
induces	O
apoptosis	O
in	O
32Dc13	B-cell_line
myeloid	I-cell_line
cells	I-cell_line
.	O

Chronic	O
myelogenous	O
leukemia	O
evolves	O
in	O
two	O
clinically	O
distinct	O
stages	O
:	O
a	O
chronic	O
and	O
a	O
blast	O
crisis	O
phase	O
.	O

The	O
molecular	O
changes	O
associated	O
with	O
chronic	O
phase	O
to	O
blast	O
crisis	O
transition	O
are	O
largely	O
unknown	O
.	O

We	O
have	O
identified	O
a	O
cDNA	B-DNA
clone	I-DNA
,	O
DR-nm23	B-protein
,	O
differentially	O
expressed	O
in	O
a	O
blast-crisis	B-DNA
cDNA	I-DNA
library	I-DNA
,	I-DNA
which	O
has	O
approximately	O
70	O
%	O
sequence	O
similarity	O
to	O
the	O
putative	B-DNA
metastatic	I-DNA
suppressor	I-DNA
genes	I-DNA
,	O
nm23-H1	B-DNA
and	O
nm23-H2	B-DNA
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
similarity	O
to	O
the	O
proteins	O
encoded	O
by	O
these	O
two	O
latter	O
genes	O
is	O
approximately	O
65	O
%	O
and	O
includes	O
domains	O
and	O
amino	O
acid	O
residues	O
(	O
the	O
leucine	B-protein
zipper-like	I-protein
and	O
the	O
RGD	B-protein
domain	I-protein
,	O
a	O
serine	O
and	O
a	O
histidine	O
residue	O
in	O
the	O
NH2-	B-protein
and	O
in	O
the	O
COOH-terminal	B-protein
portion	I-protein
of	O
the	O
protein	O
,	O
respectively	O
)	O
postulated	O
to	O
be	O
important	O
for	O
nm23	B-protein
function	O
.	O

DR-nm23	B-RNA
mRNA	I-RNA
is	O
preferentially	O
expressed	O
at	O
early	O
stages	O
of	O
myeloid	O
differentiation	O
of	O
highly	B-cell_line
purified	I-cell_line
CD34+	I-cell_line
cells	I-cell_line
.	O

Its	O
constitutive	O
expression	O
in	O
the	O
myeloid	B-cell_line
precursor	I-cell_line
32Dc13	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
which	O
is	O
growth-factor	O
dependent	O
for	O
both	O
proliferation	O
and	O
differentiation	O
,	O
results	O
in	O
inhibition	O
of	O
granulocytic	O
differentiation	O
induced	O
by	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
and	O
causes	O
apoptotic	O
cell	O
death	O
.	O

These	O
results	O
are	O
consistent	O
with	O
a	O
role	O
for	O
DR-nm23	B-protein
in	O
normal	O
hematopoiesis	O
and	O
raise	O
the	O
possibility	O
that	O
its	O
overexpression	O
contributes	O
to	O
differentiation	O
arrest	O
,	O
a	O
feature	O
of	O
blastic	O
transformation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O

An	O
interferon-gamma	B-DNA
activation	I-DNA
sequence	I-DNA
mediates	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IgG	B-DNA
Fc	I-DNA
receptor	I-DNA
type	I-DNA
IC	I-DNA
gene	I-DNA
by	O
interferon-gamma	B-protein
.	O

Expression	O
of	O
the	O
IgG	B-protein
Fc	I-protein
receptor	I-protein
type	I-protein
I	I-protein
(	O
Fc	B-protein
gamma	I-protein
RI	I-protein
)	O
on	O
myeloid	B-cell_type
cells	I-cell_type
is	O
dramatically	O
increased	O
by	O
treatment	O
with	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
.	O

We	O
observed	O
that	O
Fc	B-protein
gamma	I-protein
RI	I-protein
transcript	O
levels	O
in	O
monoblast-like	B-cell_line
U937	I-cell_line
cells	I-cell_line
were	O
elevated	O
within	O
3	O
hr	O
and	O
peaked	O
12	O
hr	O
after	O
exposure	O
to	O
IFN-gamma	B-protein
.	O

Treatment	O
of	O
U937	B-cell_line
with	O
IFN-gamma	B-protein
for	O
9	O
hr	O
in	O
the	O
presence	O
of	O
cycloheximide	O
led	O
to	O
super-induction	O
of	O
Fc	B-protein
gamma	I-protein
RI	I-protein
expression	O
.	O

Nuclear	O
run-on	O
analysis	O
revealed	O
that	O
the	O
rate	O
of	O
Fc	B-protein
gamma	I-protein
RI	I-protein
transcription	O
was	O
increased	O
by	O
IFN-gamma	B-protein
.	O

Genomic	O
sequence	O
upstream	O
of	O
the	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
gene	I-DNA
was	O
cloned	O
and	O
subjected	O
to	O
primer	O
extension	O
analysis	O
,	O
which	O
demonstrated	O
a	O
single	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
without	O
a	O
TATA	B-DNA
box	I-DNA
.	O

Transient	O
transfections	O
of	O
CAT	B-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
containing	O
various	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
promoter	I-DNA
sequences	I-DNA
into	O
U937	B-cell_line
cells	I-cell_line
revealed	O
that	O
a	O
20-bp	B-DNA
region	I-DNA
surrounding	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
(	O
-7	O
to	O
+13	O
)	O
was	O
capable	O
of	O
mediating	O
transcription	O
initiation	O
and	O
that	O
an	O
IFN-gamma	B-DNA
responsive	I-DNA
element	I-DNA
(	O
GIRE	B-DNA
)	O
was	O
present	O
within	O
74	B-DNA
bp	I-DNA
upstream	I-DNA
of	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O

A	O
17-bp	B-DNA
sequence	I-DNA
between	O
positions	O
-51	O
and	O
-35	O
conferred	O
IFN-gamma	B-protein
responsiveness	O
on	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

Double-stranded	B-DNA
GIRE	I-DNA
sequence	I-DNA
,	O
but	O
not	O
a	O
scrambled	B-DNA
sequence	I-DNA
,	O
was	O
specifically	O
bound	O
by	O
nuclear	B-protein
proteins	I-protein
from	O
IFN-gamma	B-cell_line
treated	I-cell_line
U937	I-cell_line
cells	I-cell_line
.	O

Gel	O
shift	O
experiments	O
further	O
showed	O
that	O
the	O
STAT1	B-protein
alpha	I-protein
protein	I-protein
bound	O
to	O
the	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
GIRE	I-DNA
in	O
response	O
to	O
IFN-gamma	B-protein
treatment	O
of	O
U937	B-cell_line
cells	I-cell_line
.	O

The	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
GIRE	I-DNA
is	O
homologous	O
to	O
the	O
IFN-gamma	B-DNA
activation	I-DNA
sequence	I-DNA
(	O
GAS	B-DNA
)	O
of	O
the	O
guanylate	B-protein
binding	I-protein
protein	I-protein
and	O
to	O
X	B-DNA
box	I-DNA
elements	I-DNA
of	O
class	B-DNA
II	I-DNA
MHC	I-DNA
genes	I-DNA
.	O

Our	O
results	O
demonstrate	O
that	O
transcriptional	O
regulation	O
of	O
the	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
gene	I-DNA
by	O
IFN-gamma	B-protein
involves	O
the	O
binding	O
of	O
STAT1	B-protein
alpha	I-protein
to	O
a	O
17-bp	B-DNA
GAS	I-DNA
homology	I-DNA
in	O
the	O
proximal	B-DNA
promoter	I-DNA
.	O

Constitutively	O
activated	O
Jak	B-protein
-STAT	B-protein
pathway	O
in	O
T	B-cell_type
cells	I-cell_type
transformed	O
with	O
HTLV-I	O
.	O

Human	O
T	O
cell	O
lymphotropic	O
virus	O
I	O
(	O
HTLV-I	O
)	O
is	O
the	O
etiological	O
agent	O
for	O
adult	O
T	O
cell	O
leukemia	O
and	O
tropical	O
spastic	O
paraparesis	O
(	O
also	O
termed	O
HTLV-I-associated	O
myelopathy	O
)	O
.	O

HTLV-I-infected	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
exhibit	O
an	O
initial	O
phase	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
-dependent	O
growth	O
;	O
over	O
time	O
,	O
by	O
an	O
unknown	O
mechanism	O
,	O
the	O
cells	O
become	O
IL-2	B-protein
-independent	O
.	O

Whereas	O
the	O
Jak	B-protein
kinases	I-protein
Jak1	B-protein
and	O
Jak3	B-protein
and	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B-protein
proteins	I-protein
Stat3	B-protein
and	O
Stat5	B-protein
are	O
activated	O
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
response	O
to	O
IL-2	B-protein
,	O
this	O
signaling	O
pathway	O
was	O
constitutively	O
activated	O
in	O
HTLV-I-transformed	B-cell_line
cells	I-cell_line
.	O

In	O
HTLV-I-infected	B-cell_line
cord	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
,	O
the	O
transition	O
from	O
IL-2	B-protein
-dependent	O
to	O
IL-2	B-protein
-independent	O
growth	O
correlated	O
with	O
the	O
acquisition	O
of	O
a	O
constitutively	O
activated	O
Jak	B-protein
-STAT	B-protein
pathway	O
,	O
which	O
suggests	O
that	O
this	O
pathway	O
participates	O
in	O
HTLV-I-mediated	O
T	O
cell	O
transformation	O
.	O

Nitric	O
oxide	O
decreases	O
cytokine	B-protein
-induced	O
endothelial	O
activation	O
.	O

Nitric	O
oxide	O
selectively	O
reduces	O
endothelial	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
and	O
proinflammatory	B-protein
cytokines	I-protein
.	O

To	O
test	O
the	O
hypothesis	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
limits	O
endothelial	O
activation	O
,	O
we	O
treated	O
cytokine-stimulated	B-cell_line
human	I-cell_line
saphenous	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
with	O
several	O
NO	O
donors	O
and	O
assessed	O
their	O
effects	O
on	O
the	O
inducible	O
expression	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
.	O

In	O
a	O
concentration-dependent	O
manner	O
,	O
NO	O
inhibited	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
alpha-stimulated	O
VCAM-1	B-protein
expression	O
by	O
35-55	O
%	O
as	O
determined	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
and	O
flow	O
cytometry	O
.	O

This	O
inhibition	O
was	O
paralleled	O
by	O
reduced	O
monocyte	O
adhesion	O
to	O
endothelial	O
monolayers	O
in	O
nonstatic	O
assays	O
,	O
was	O
unaffected	O
by	O
cGMP	O
analogues	O
,	O
and	O
was	O
quantitatively	O
similar	O
after	O
stimulation	O
by	O
either	O
IL-1	B-protein
alpha	I-protein
,	O
IL-1	B-protein
beta	I-protein
,	O
IL-4	B-protein
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
,	O
or	O
bacterial	O
lipopolysaccharide	O
.	O

NO	O
also	O
decreased	O
the	O
endothelial	O
expression	O
of	O
other	O
leukocyte	B-protein
adhesion	I-protein
molecules	I-protein
(	O
E-selectin	B-protein
and	O
to	O
a	O
lesser	O
extent	O
,	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
)	O
and	O
secretable	O
cytokines	B-protein
(	O
IL-6	B-protein
and	O
IL-8	B-protein
)	O
.	O

Inhibition	O
of	O
endogenous	O
NO	O
production	O
by	O
L-N-monomethyl-arginine	O
also	O
induced	O
the	O
expression	O
of	O
VCAM-1	B-protein
,	O
but	O
did	O
not	O
augment	O
cytokine-induced	O
VCAM-1	B-protein
expression	O
.	O

Nuclear	O
run-on	O
assays	O
,	O
transfection	O
studies	O
using	O
various	O
VCAM-1	B-DNA
promoter	I-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
that	O
NO	O
represses	O
VCAM-1	B-protein
gene	O
transcription	O
,	O
in	O
part	O
,	O
by	O
inhibiting	O
NF-kappa	B-protein
B	I-protein
.	O

We	O
propose	O
that	O
NO	O
's	O
ability	O
to	O
limit	O
endothelial	O
activation	O
and	O
inhibit	O
monocyte	O
adhesion	O
may	O
contribute	O
to	O
some	O
of	O
its	O
antiatherogenic	O
and	O
antiinflammatory	O
properties	O
within	O
the	O
vessel	O
wall	O
.	O

MIP1	B-protein
alpha	I-protein
nuclear	I-protein
protein	I-protein
(	O
MNP	B-protein
)	O
,	O
a	O
novel	O
transcription	B-protein
factor	I-protein
expressed	O
in	O
hematopoietic	O
cells	O
that	O
is	O
crucial	O
for	O
transcription	O
of	O
the	O
human	B-DNA
MIP-1	I-DNA
alpha	I-DNA
gene	I-DNA
.	O

Murine	B-protein
macrophage	I-protein
inflammatory	I-protein
protein	I-protein
1	I-protein
alpha	I-protein
(	O
MIP-1	B-protein
alpha	I-protein
)	O
and	O
its	O
human	B-protein
equivalent	I-protein
(	O
GOS19	B-protein
,	O
LD78	B-protein
,	O
or	O
AT464	B-protein
)	O
are	O
members	O
of	O
the	O
-C-C	B-protein
family	I-protein
of	O
low-molecular-weight	B-protein
chemokines	I-protein
.	O

Secreted	O
from	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
,	O
bone	O
marrow-derived	B-protein
MIP-1	I-protein
alpha/GOS19	I-protein
inhibits	O
primitive	B-cell_type
hematopoietic	I-cell_type
stem	I-cell_type
cells	I-cell_type
and	O
appears	O
to	O
be	O
involved	O
in	O
the	O
homeostatic	O
control	O
of	O
stem	B-cell_type
cell	I-cell_type
proliferation	O
.	O

It	O
also	O
induces	O
chemotaxis	O
and	O
inflammatory	O
responses	O
in	O
mature	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
which	O
control	O
the	O
expression	O
of	O
MIP-1	B-protein
alpha	I-protein
/GOS19	B-protein
.	O

Previous	O
work	O
has	O
shown	O
that	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
a	O
set	O
of	O
widely	O
expressed	O
transcription	B-protein
factors	I-protein
(	O
the	O
ICK-1	B-protein
family	I-protein
)	O
affect	O
the	O
GOS19	B-DNA
promoter	I-DNA
.	O

One	O
member	O
,	O
ICK-1A	B-protein
,	O
behaves	O
as	O
a	O
strong	B-protein
negative	I-protein
regulator	I-protein
.	O

In	O
this	O
communication	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
pathway	O
of	O
induction	O
in	O
the	O
macrophage	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	B-cell_line
is	O
different	O
from	O
that	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Furthermore	O
,	O
we	O
show	O
that	O
the	O
ICK-1	B-DNA
binding	I-DNA
site	I-DNA
does	O
not	O
confer	O
negative	O
regulation	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O

We	O
provide	O
evidence	O
for	O
an	O
additional	O
binding	B-DNA
site	I-DNA
,	O
the	O
MIP-1	B-DNA
alpha	I-DNA
nuclear	I-DNA
protein	I-DNA
(	I-DNA
MNP	I-DNA
)	I-DNA
site	I-DNA
,	O
which	O
overlaps	O
the	O
ICK-1	B-DNA
site	I-DNA
.	O

Interaction	O
of	O
nuclear	O
extracts	O
from	O
various	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
tissue	O
with	O
the	O
MNP	B-DNA
site	I-DNA
leads	O
to	O
the	O
formation	O
of	O
fast-migrating	B-protein
protein-DNA	I-protein
complexes	I-protein
with	O
similar	O
but	O
distinct	O
electrophoretic	O
mobilities	O
.	O

A	O
mutation	O
of	O
the	O
MNP	B-DNA
site	I-DNA
which	O
does	O
not	O
abrogate	O
ICK-1	O
binding	O
inactivates	O
the	O
GOS19.1	B-DNA
promoter	I-DNA
in	O
U937	B-cell_line
cells	I-cell_line
and	O
reduces	O
its	O
activity	O
by	O
fourfold	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

We	O
propose	O
that	O
the	O
MNP	B-protein
protein	I-protein
(	O
s	O
)	O
binding	O
at	O
the	O
MNP	B-DNA
site	I-DNA
constitutes	O
a	O
novel	O
transcription	B-protein
factor	I-protein
(	O
s	O
)	O
expressed	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

The	O
effect	O
of	O
Toremifene	O
on	O
the	O
expression	O
of	O
some	O
genes	O
in	O
human	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

Toremifene	O
exerts	O
multiple	O
and	O
varied	O
effects	O
on	O
the	O
gene	O
expression	O
of	O
human	B-cell_type
peripheral	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

After	O
short-term	O
,	O
in	O
vitro	O
exposure	O
to	O
therapeutical	O
levels	O
,	O
distinct	O
changes	O
in	O
P-glycoprotein	O
,	O
steroid	O
receptors	O
,	O
p53	O
and	O
Bcl-2	O
expression	O
take	O
place	O
.	O

In	O
view	O
of	O
the	O
increasing	O
use	O
of	O
antiestrogens	O
in	O
cancer	O
therapy	O
and	O
prevention	O
,	O
there	O
is	O
obvious	O
merit	O
in	O
long-term	O
in	O
vivo	O
studies	O
to	O
be	O
conducted	O
.	O

The	O
interleukin-5	B-protein
/receptor	O
interaction	O
activates	O
Lyn	B-protein
and	I-protein
Jak2	I-protein
tyrosine	I-protein
kinases	I-protein
and	O
propagates	O
signals	O
via	O
the	O
Ras-Raf-1-MAP	B-protein
kinase	I-protein
and	O
the	O
Jak	B-protein
-STAT	B-protein
pathways	O
in	O
eosinophils	B-cell_type
.	O

We	O
have	O
shown	O
that	O
the	O
interaction	O
of	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-5	I-protein
with	O
the	O
receptor	O
activates	O
Lyn	B-protein
tyrosine	I-protein
kinase	I-protein
within	O
1	O
min	O
and	O
Jak2	B-protein
tyrosine	I-protein
kinase	I-protein
within	O
1-3	O
min	O
.	O

IL-5	B-protein
also	O
stimulates	O
GTP	O
binding	O
to	O
p21ras	B-protein
.	O

The	O
signal	O
is	O
subsequently	O
propagated	O
through	O
the	O
activation	O
of	O
Raf-1	B-protein
,	O
MEK	B-protein
,	O
and	O
MAP	B-protein
kinases	I-protein
as	O
shown	O
by	O
their	O
increased	O
autophosphorylation	O
in	O
vitro	O
and	O
phosphorylation	O
in	O
situ	O
.	O

Jak2	B-protein
kinase	I-protein
has	O
been	O
shown	O
to	O
phosphorylate	O
STAT	B-protein
nuclear	I-protein
proteins	I-protein
.	O

The	O
activation	O
of	O
STAT	B-protein
nuclear	I-protein
factors	I-protein
was	O
studied	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
gamma	B-DNA
activation	I-DNA
site	I-DNA
(	O
GAS	B-DNA
)	O
probe	O
.	O

We	O
found	O
that	O
IL-5	B-protein
induces	O
two	O
GAS-binding	B-protein
proteins	I-protein
in	O
eosinophils	B-cell_type
,	O
one	O
of	O
which	O
is	O
STAT1	B-protein
.	O

We	O
conclude	O
that	O
IL-5	B-protein
induced	O
signals	O
are	O
propagated	O
through	O
two	O
distinct	O
pathways	O
:	O
(	O
1	O
)	O
Lyn	B-protein
--	O
>	O
Ras	B-protein
--	O
>	O
Raf-1	B-protein
--	O
>	O
MEK	B-protein
--	O
>	O
MAP	B-protein
kinase	I-protein
and	O
(	O
2	O
)	O
Jak2	B-protein
--	O
>	O
STAT1	B-protein
.	O

The	O
retinoblastoma	B-protein
gene	I-protein
product	I-protein
negatively	O
regulates	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
human	B-protein
cytomegalovirus	I-protein
IE2	I-protein
protein	I-protein
.	O

The	O
IE2	B-protein
gene	I-protein
product	I-protein
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
is	O
one	O
of	O
a	O
few	O
viral	B-protein
regulatory	I-protein
proteins	I-protein
expressed	O
immediately	O
upon	O
infection	O
of	O
the	O
host	B-cell_type
cell	I-cell_type
.	O

It	O
is	O
a	O
potent	O
transcriptional	B-protein
activator	I-protein
of	O
many	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
promoters	I-DNA
.	O

We	O
found	O
that	O
the	O
retinoblastoma	B-protein
susceptibility	I-protein
gene	I-protein
product	I-protein
(	O
Rb	B-protein
)	O
dramatically	O
suppressed	O
this	O
IE2	B-protein
transactivation	O
of	O
various	B-DNA
promoters	I-DNA
.	O

However	O
,	O
unlike	O
another	O
tumor	B-protein
suppressor	I-protein
protein	I-protein
,	O
p53	B-protein
,	O
Rb	B-protein
did	O
not	O
have	O
any	O
significant	O
effect	O
on	O
basal	O
levels	O
of	O
transcription	O
,	O
suggesting	O
that	O
Rb	B-protein
specifically	O
interacts	O
with	O
IE2	B-protein
rather	O
than	O
other	O
cellular	B-protein
factors	I-protein
involved	O
in	O
the	O
general	O
transcription	O
machinery	O
.	O

We	O
found	O
by	O
protein-affinity	O
chromatography	O
that	O
Rb	B-protein
in	O
nuclear	O
extracts	O
or	O
produced	O
by	O
in	O
vitro	O
translation	O
directly	O
bound	O
to	O
IE2	B-protein
.	O

Our	O
results	O
suggest	O
that	O
Rb	B-protein
may	O
regulate	O
the	O
life	O
cycle	O
of	O
HCMV	O
,	O
which	O
is	O
endemic	O
in	O
the	O
human	O
population	O
.	O

Furthermore	O
,	O
these	O
data	O
may	O
provide	O
new	O
insights	O
into	O
the	O
slow	O
rate	O
of	O
HCMV	O
DNA	O
replication	O
in	O
cells	O
and	O
the	O
possible	O
involvement	O
of	O
HCMV	O
in	O
tumorigenesis	O
.	O

Expression	O
of	O
the	O
nucleoside	B-protein
diphosphate	I-protein
kinase	I-protein
in	O
human	O
skin	O
cancers	O
:	O
an	O
immunohistochemical	O
study	O
.	O

Expression	O
of	O
nucleoside	B-protein
diphosphate	I-protein
(	I-protein
NDP	I-protein
)	I-protein
kinase	I-protein
,	O
which	O
is	O
homologous	O
to	O
the	O
nm23	B-protein
gene	I-protein
product	I-protein
in	O
a	O
variety	O
of	O
species	O
,	O
has	O
been	O
found	O
to	O
be	O
inversely	O
associated	O
with	O
metastatic	O
potential	O
.	O

However	O
,	O
the	O
relationship	O
remains	O
controversial	O
according	O
to	O
the	O
tumor	B-cell_type
cell	I-cell_type
types	I-cell_type
and	O
experimental	O
system	O
,	O
with	O
conflicting	O
results	O
from	O
different	O
research	O
groups	O
.	O

In	O
order	O
to	O
determine	O
whether	O
NDP	B-protein
kinase	I-protein
expression	O
serves	O
as	O
a	O
marker	O
for	O
metastatic	O
potential	O
in	O
human	O
skin	O
cancer	O
,	O
we	O
assessed	O
the	O
levels	O
of	O
NDP	B-protein
kinase	I-protein
expression	O
in	O
9	O
keratoacanthomas	O
(	O
KAs	O
)	O
,	O
26	O
squamous	O
cell	O
carcinomas	O
(	O
SCCs	O
)	O
,	O
and	O
25	O
basal	O
cell	O
carcinomas	O
(	O
BCCs	O
)	O
using	O
immunohistochemistry	O
.	O

The	O
expression	O
of	O
NDP	B-protein
kinase	I-protein
was	O
intense	O
in	O
KA	O
and	O
SCC	O
compared	O
with	O
BCC	O
.	O

However	O
,	O
the	O
difference	O
of	O
NDP	B-protein
kinase	I-protein
expression	O
between	O
KA	O
and	O
SCC	O
was	O
not	O
statistically	O
significant	O
.	O

And	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
NDP	B-protein
kinase	I-protein
expression	O
between	O
SCC	O
with	O
metastasis	O
and	O
SCC	O
without	O
metastasis	O
.	O

Our	O
results	O
contradict	O
the	O
hypothesis	O
concerning	O
the	O
possible	O
role	O
of	O
nm23	B-DNA
gene	I-DNA
as	O
a	O
metastatic	O
suppressor	O
gene	O
in	O
human	O
skin	O
cancer	O
.	O

The	O
mechanism	O
of	O
overexpression	O
in	O
various	O
tumor	B-cell_type
cell	I-cell_type
types	I-cell_type
and	O
its	O
biological	O
significance	O
in	O
cutaneous	O
carcinogenesis	O
remain	O
to	O
be	O
determined	O
.	O

RB	B-protein
and	O
a	O
novel	O
E2F-1	B-protein
binding	I-protein
protein	I-protein
in	O
MHC	B-cell_line
class	I-cell_line
II	I-cell_line
deficient	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
and	O
normal	O
IFN-gamma	B-protein
induction	O
of	O
the	O
class	B-DNA
IL	I-DNA
transactivator	I-DNA
CIITA	B-DNA
in	O
class	B-cell_line
II	I-cell_line
non-inducible	I-cell_line
RB-defective	I-cell_line
tumor	I-cell_line
lines	I-cell_line
.	O

The	O
major	B-DNA
histocompatibility	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
encode	O
cell	B-protein
surface	I-protein
proteins	I-protein
that	O
bind	O
antigenic	O
peptide	O
for	O
presentation	O
to	O
T-cells	B-cell_type
.	O

The	O
class	B-protein
II	I-protein
proteins	I-protein
are	O
expressed	O
constitutively	O
on	O
B-cells	B-cell_type
and	O
EBV-transformed	B-cell_line
B-cells	I-cell_line
,	I-cell_line
and	O
are	O
inducible	O
by	O
IFN-gamma	B-protein
on	O
a	O
wide	O
variety	O
of	O
cell	B-cell_type
types	I-cell_type
.	O

Retinoblastoma	B-protein
protein	I-protein
(	O
RB	B-protein
)	O
is	O
a	O
tumor	O
suppressor	O
and	O
functions	O
as	O
a	O
transcriptional	B-protein
repressor	I-protein
by	O
binding	O
and	O
inactivating	O
the	O
transactivator	B-DNA
E2F-I	I-DNA
.	O

RB-defective	B-cell_line
tumor	I-cell_line
lines	I-cell_line
are	O
non-inducible	O
for	O
MHC	B-protein
class	I-protein
II	I-protein
by	O
IFN-gamma	B-protein
,	O
or	O
very	O
weakly	O
inducible	O
,	O
but	O
transfection	O
of	O
2	O
different	O
lines	O
with	O
RB	B-DNA
expression	I-DNA
vectors	I-DNA
re-establishes	O
or	O
substantially	O
enhances	O
class	O
II	O
inducibility	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
RB	B-protein
status	O
of	O
a	O
series	O
of	O
B-cell	O
mutants	O
that	O
are	O
defective	O
in	O
class	O
II	O
expression	O
,	O
generated	O
either	O
in	O
vitro	O
or	O
derived	O
from	O
Bare	O
Lymphocyte	O
Syndrome	O
(	O
BLS	O
)	O
patients	O
.	O

Nuclear	O
matrix-bound	O
RB	B-protein
was	O
detectable	O
in	O
all	O
cases	O
,	O
indicating	O
that	O
loss	O
of	O
RB	B-protein
is	O
not	O
responsible	O
for	O
decreased	O
class	O
II	O
expression	O
in	O
these	O
lines	O
.	O

A	O
second	O
E2F-I	O
binding	O
protein	O
,	O
most	O
likely	O
DP-I	O
,	O
was	O
also	O
apparently	O
normal	O
in	O
both	O
class	O
II-positive	O
and	O
-negative	O
B-cell	O
lines	O
.	O

We	O
also	O
examined	O
the	O
IFN-gamma	B-protein
induction	O
of	O
CIITA	B-DNA
in	O
RB	B-protein
-defective	O
lines	O
.	O

CIITA	B-DNA
is	O
a	O
class	B-DNA
II	I-DNA
gene	I-DNA
transactivator	I-DNA
known	O
to	O
be	O
defective	O
in	O
one	O
form	O
of	O
BLS	O
and	O
to	O
be	O
required	O
for	O
the	O
induction	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
by	O
IFN-gamma	B-protein
.	O

CIITA	B-RNA
mRNA	I-RNA
is	O
normally	O
inducible	O
by	O
IFN-gamma	B-protein
in	O
class	B-cell_line
II	I-cell_line
non-inducible	I-cell_line
,	I-cell_line
RB-defective	I-cell_line
lines	I-cell_line
,	O
and	O
in	O
one	O
line	O
,	O
re-expression	O
of	O
RB	B-protein
has	O
no	O
effect	O
on	O
CIITA	B-RNA
mRNA	I-RNA
induction	O
levels	O
.	O

Thus	O
,	O
the	O
block	O
in	O
MHC	O
class	O
II	O
inducibility	O
in	O
RB-defective	B-cell_line
cells	I-cell_line
is	O
not	O
due	O
to	O
a	O
block	O
in	O
CIITA	B-DNA
inducibility	O
.	O

Interleukin	B-protein
12	I-protein
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
STAT4	B-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

Interleukin	B-protein
12	I-protein
(	O
IL-12	B-protein
)	O
is	O
an	O
important	O
immunoregulatory	B-protein
cytokine	I-protein
whose	O
receptor	O
is	O
a	O
member	O
of	O
the	O
hematopoietin	B-protein
receptor	I-protein
superfamily	I-protein
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
stimulation	O
of	O
human	B-cell_type
T	I-cell_type
and	I-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
with	O
IL-12	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-protein
family	I-protein
tyrosine	I-protein
kinase	I-protein
JAK2	B-protein
and	O
Tyk2	B-protein
,	O
implicating	O
these	O
kinases	B-protein
in	O
the	O
immediate	O
biochemical	O
response	O
to	O
IL-12	B-protein
.	O

Recently	O
,	O
transcription	B-protein
factors	I-protein
known	O
as	O
STATs	B-protein
(	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	O
have	O
been	O
shown	O
to	O
be	O
tyrosine	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
a	O
number	O
of	O
cytokines	B-protein
that	O
bind	O
hematopoietin	B-protein
receptors	I-protein
and	O
activate	O
JAK	B-protein
kinases	I-protein
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
IL-12	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
a	O
recently	O
identified	O
STAT	B-protein
family	I-protein
member	I-protein
,	O
STAT4	B-protein
,	O
and	O
show	O
that	O
STAT4	B-protein
expression	O
is	O
regulated	O
by	O
T-cell	O
activation	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
IL-12	B-protein
stimulates	O
formation	O
of	O
a	O
DNA-binding	B-protein
complex	I-protein
that	O
recognizes	O
a	O
DNA	O
sequence	O
previously	O
shown	O
to	O
bind	O
STAT	B-protein
proteins	I-protein
and	O
that	O
this	O
complex	O
contains	O
STAT4	B-protein
.	O

These	O
data	O
,	O
and	O
the	O
recent	O
demonstration	O
of	O
JAK	B-protein
phosphorylation	O
by	O
IL-12	B-protein
,	O
identify	O
a	O
rapid	O
signal-transduction	O
pathway	O
likely	O
to	O
mediate	O
IL-12	B-protein
-induced	O
gene	O
expression	O
.	O

Temperature-induced	O
down-regulation	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
leucocyte	I-cell_type
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

OBJECTIVE	O
:	O
Activation	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
is	O
of	O
vital	O
importance	O
during	O
critical	O
illness	O
.	O

We	O
have	O
studied	O
the	O
adaptive	O
mechanisms	O
which	O
occur	O
at	O
the	O
level	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
glucocorticoid	O
target	O
tissues	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

DESIGN	O
:	O
The	O
effects	O
of	O
hypercortisolaemia	O
,	O
hyperthermia	O
and	O
cellular	O
composition	O
on	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
per	O
cell	O
and	O
their	O
affinity	O
were	O
evaluated	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
leucocytes	I-cell_type
of	O
control	O
subjects	O
and	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

SUBJECTS	O
:	O
Fifteen	O
patients	O
(	O
age	O
25-79	O
)	O
with	O
sepsis	O
or	O
septic	O
shock	O
who	O
were	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
were	O
studied	O
.	O

The	O
control	O
group	O
consisted	O
of	O
24	O
healthy	O
laboratory	O
employees	O
.	O

MEASUREMENTS	O
:	O
The	O
binding	O
capacity	O
and	O
affinity	O
of	O
the	O
glucocorticoid	B-protein
receptors	I-protein
were	O
measured	O
and	O
compared	O
to	O
clinical	O
data	O
and	O
the	O
plasma	O
cortisol	O
concentrations	O
.	O

RESULTS	O
:	O
Hypercortisolaemia	O
,	O
in	O
vitro	O
,	O
resulted	O
in	O
a	O
decreased	O
affinity	O
and	O
a	O
decreased	O
binding	O
capacity	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

In	O
vitro	O
,	O
hyperthermia	O
as	O
well	O
as	O
variations	O
in	O
the	O
cellular	O
composition	O
did	O
not	O
influence	O
the	O
glucocorticoid	O
receptor	O
.	O

In	O
vivo	O
,	O
there	O
was	O
no	O
change	O
in	O
the	O
number	O
of	O
receptors	O
per	O
cell	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
as	O
compared	O
to	O
healthy	O
controls	O
.	O

However	O
,	O
a	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
was	O
observed	O
.	O

There	O
was	O
a	O
weak	O
but	O
significant	O
negative	O
correlation	O
between	O
body	O
temperature	O
and	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
the	O
patient	O
group	O
.	O

There	O
was	O
no	O
relation	O
between	O
circulating	O
cortisol	O
concentrations	O
and	O
glucocorticoid	B-protein
receptor	I-protein
affinity	O
and	O
number	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
no	O
obvious	O
regulation	O
of	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
by	O
plasma	O
cortisol	O
concentrations	O
in	O
vivo	O
.	O

The	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
together	O
with	O
the	O
negative	O
correlation	O
between	O
hyperthermia	O
and	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
suggest	O
that	O
hypothalamic-pituitary-adrenal	O
axis	O
activation	O
during	O
critical	O
illness	O
is	O
accompanied	O
by	O
peripheral	O
adaptation	O
in	O
glucocorticoid	B-protein
receptor	I-protein
number	O
and	O
affinity	O
.	O

Integrin-mediated	O
tyrosine	O
phosphorylation	O
and	O
cytokine	B-protein
message	O
induction	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

A	O
possible	O
signaling	O
role	O
for	O
the	O
Syk	B-protein
tyrosine	I-protein
kinase	I-protein
.	O

Activation	O
of	O
cytoplasmic	B-protein
tyrosine	I-protein
kinases	I-protein
is	O
an	O
important	O
aspect	O
of	O
signal	O
transduction	O
mediated	O
by	O
integrins	B-protein
.	O

In	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	I-cell_line
,	O
either	O
integrin	B-protein
-dependent	O
cell	O
adhesion	O
to	O
fibronectin	B-protein
or	O
ligation	O
of	O
beta	O
1	O
integrins	O
with	O
antibodies	B-protein
causes	O
a	O
rapid	O
and	O
intense	O
tyrosine	O
phosphorylation	O
of	O
two	O
sets	O
of	O
proteins	O
of	O
about	O
65-75	B-protein
and	I-protein
120-125	I-protein
kDa	I-protein
.	O

In	O
addition	O
,	O
integrin	B-protein
ligation	O
leads	O
to	O
nuclear	O
translocation	O
of	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
,	O
to	O
activation	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
driven	O
by	O
a	O
promoter	B-DNA
containing	O
NF-kappa	B-DNA
B	I-DNA
sites	I-DNA
,	O
and	O
to	O
increased	O
levels	O
of	O
mRNAs	B-RNA
for	O
immediate-early	B-DNA
genes	I-DNA
,	O
including	O
the	O
cytokine	B-protein
interleukin	I-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
beta	I-protein
.	O

The	O
tyrosine	O
kinase	O
inhibitors	O
genistein	O
and	O
herbimycin	O
A	O
block	O
both	O
integrin	B-protein
-mediated	O
tyrosine	O
phosphorylation	O
and	O
increases	O
in	O
IL-1	B-protein
beta	I-protein
message	O
levels	O
,	O
indicating	O
a	O
causal	O
relationship	O
between	O
the	O
two	O
events	O
.	O

The	O
components	O
tyrosine	O
phosphorylated	O
subsequent	O
to	O
cell	O
adhesion	O
include	O
paxillin	B-protein
,	O
pp125FAK	B-protein
,	O
and	O
the	O
SH2	B-protein
domain	I-protein
containing	I-protein
tyrosine	I-protein
kinase	I-protein
Syk	I-protein
.	O

In	O
contrast	O
,	O
integrin	B-protein
ligation	O
with	O
antibodies	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
Syk	B-protein
but	O
not	O
of	O
FAK	B-protein
or	O
paxillin	B-protein
.	O

In	O
adhering	B-cell_type
cells	I-cell_type
,	O
pre-treatment	O
with	O
cytochalasin	O
D	O
suppresses	O
tyrosine	O
phosphorylation	O
of	O
FAK	B-protein
and	O
paxillin	B-protein
but	O
not	O
of	O
Syk	B-protein
,	O
while	O
IL-1	B-protein
beta	I-protein
message	O
induction	O
is	O
unaffected	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
Syk	B-protein
tyrosine	O
kinase	O
may	O
be	O
an	O
important	O
component	O
of	O
an	O
integrin	B-protein
signaling	O
pathway	O
in	O
monocytic	B-cell_type
cells	I-cell_type
,	O
leading	O
to	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
to	O
increased	O
levels	O
of	O
cytokine	B-protein
messages	O
.	O

Inhibition	O
of	O
dexamethasone	O
binding	O
to	O
human	B-protein
glucocorticoid	I-protein
receptor	I-protein
by	O
New	O
World	O
primate	O
cell	O
extracts	O
.	O

To	O
determine	O
if	O
New	O
World	O
primates	O
express	O
an	O
inhibitor	O
that	O
influences	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
binding	O
characteristics	O
,	O
we	O
examined	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
in	O
cytosol	O
prepared	O
from	O
B95-8	B-cell_line
lymphoid	I-cell_line
cells	I-cell_line
,	O
derived	O
from	O
the	O
cotton	O
top	O
tamarin	O
(	O
Saguinus	O
oedipus	O
)	O
,	O
in	O
combination	O
with	O
cytosol	O
prepared	O
from	O
human	O
or	O
rat	O
tissues	O
.	O

B95-8	O
cytosol	O
inhibited	O
specific	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
(	O
P	O
<	O
0.01	O
)	O
when	O
mixed	O
with	O
cytosol	O
prepared	O
from	O
either	O
a	O
human	B-cell_line
lymphoid	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
HL	B-cell_line
)	O
or	O
rat	O
thymus	O
.	O

The	O
inhibitory	O
activity	O
was	O
heat	O
labile	O
and	O
trypsin	B-protein
sensitive	O
.	O

Peak	O
inhibitory	O
activity	O
was	O
found	O
in	O
the	O
150-200	O
kd	O
fractions	O
after	O
Sephacryl	O
G-200	O
ultrafiltration	O
.	O

Scatchard	O
analysis	O
of	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
using	O
mixed	O
cytosol	O
showed	O
a	O
diminished	O
GR	B-protein
apparent	O
binding	O
affinity	O
when	O
compared	O
to	O
HL	O
cytosol	O
.	O

Kinetic	O
studies	O
using	O
mixed	O
cytosol	O
indicated	O
that	O
B95-8	O
cytosol	O
did	O
not	O
affect	O
the	O
apparent	O
dissociation	O
rate	O
of	O
[	O
3H	O
]	O
dexamethasone	O
.	O

These	O
data	O
demonstrate	O
that	O
B95-8	B-cell_type
cells	I-cell_type
contain	O
a	O
competitive	O
inhibitor	O
that	O
prevents	O
binding	O
of	O
dexamethasone	O
to	O
its	O
cognate	B-protein
receptor	I-protein
.	O

Disruption	O
of	O
a	O
GATA	B-DNA
motif	I-DNA
in	O
the	O
Duffy	B-DNA
gene	I-DNA
promoter	I-DNA
abolishes	O
erythroid	B-DNA
gene	I-DNA
expression	O
in	O
Duffy-negative	O
individuals	O
.	O

The	O
mRNA	B-RNA
for	O
the	O
Duffy	B-protein
blood	I-protein
group	I-protein
antigen	I-protein
,	O
the	O
erythrocyte	B-protein
receptor	I-protein
for	O
the	O
Plasmodium	O
vivax	O
malaria	O
parasite	O
,	O
has	O
recently	O
been	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
widely	O
expressed	O
chemokine	B-protein
receptor	I-protein
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
Duffy	B-DNA
antigen/chemokine	I-DNA
receptor	I-DNA
gene	I-DNA
(	O
DARC	B-DNA
)	O
is	O
composed	O
of	O
a	O
single	O
exon	B-DNA
and	O
that	O
most	O
Duffy-negative	O
blacks	O
carry	O
a	O
silent	B-DNA
FY*B	I-DNA
allele	I-DNA
with	O
a	O
single	O
T	O
to	O
C	O
substitution	O
at	O
nucleotide	O
-46	O
.	O

This	O
mutation	O
impairs	O
the	O
promoter	O
activity	O
in	O
erythroid	B-cell_type
cells	I-cell_type
by	O
disrupting	O
a	O
binding	B-DNA
site	I-DNA
for	O
the	O
GATA1	B-protein
erythroid	I-protein
transcription	I-protein
factor	I-protein
.	O

With	O
the	O
recent	O
characterization	O
of	O
the	O
FY*A	B-DNA
and	I-DNA
FY*B	I-DNA
alleles	I-DNA
,	O
these	O
findings	O
provide	O
the	O
molecular	O
basis	O
of	O
the	O
Duffy	O
blood	O
group	O
system	O
and	O
an	O
explanation	O
for	O
the	O
erythroid-specific	O
repression	O
of	O
the	O
DARC	B-DNA
gene	I-DNA
in	O
Duffy-negative	O
individuals	O
.	O

Activation	O
of	O
pp90rsk	B-protein
and	O
early	B-DNA
growth	I-DNA
response-1	I-DNA
gene	I-DNA
expression	O
by	O
pokeweed	B-protein
mitogen	I-protein
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
pokeweed	B-protein
mitogen	I-protein
(	O
PWM	B-protein
)	O
on	O
the	O
induction	O
of	O
early	B-DNA
growth	I-DNA
response-1	I-DNA
gene	I-DNA
(	O
EGR-1	B-DNA
)	O
in	O
normal	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

PWM	B-protein
regulates	O
EGR-1	B-DNA
gene	O
expression	O
by	O
both	O
transcriptional	O
and	O
post-transcriptional	O
mechanisms	O
.	O

Transient	O
transfection	O
assays	O
with	O
EGR-1	B-DNA
promoter	I-DNA
fragments	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
demonstrated	O
that	O
PWM	B-protein
induced	O
EGR-1	B-DNA
transcription	O
is	O
conferred	O
by	O
the	O
CArG	B-DNA
motif	I-DNA
(	O
C	B-DNA
C	I-DNA
[	I-DNA
AT	I-DNA
]	I-DNA
6GG	I-DNA
)	O
in	O
the	O
EGR-1	B-DNA
promoter	I-DNA
.	O

The	O
results	O
further	O
demonstrated	O
the	O
activation	O
of	O
S6	B-protein
kinase	I-protein
(	O
pp90rsk	B-protein
)	O
,	O
evidenced	O
by	O
phosphorylation	O
of	O
S6	B-protein
and	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
peptides	O
,	O
in	O
PWM	B-cell_line
treated	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
PWM	B-protein
is	O
able	O
to	O
initiate	O
an	O
intracytoplasmic	O
signalling	O
cascade	O
and	O
EGR-1	B-DNA
induction	O
in	O
normal	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

A	O
conserved	B-DNA
motif	I-DNA
in	O
the	O
promoters	B-DNA
of	O
several	O
cytokines	B-protein
expressed	O
by	O
human	B-cell_line
Th2-type	I-cell_line
lymphocytes	I-cell_line
.	O

We	O
have	O
recently	O
found	O
a	O
novel	O
conserved	B-DNA
motif	I-DNA
in	O
the	O
promoters	B-DNA
of	O
several	O
T-cell-expressed	B-protein
cytokines	I-protein
[	O
human	B-protein
interleukin-2	I-protein
,	I-protein
-4	I-protein
,	I-protein
-5	I-protein
and	I-protein
-13	I-protein
and	O
human	B-protein
and	I-protein
mouse	I-protein
granulocyte/macrophage-colony	I-protein
stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
]	O
.	O

It	O
contains	O
a	O
core	B-DNA
sequence	I-DNA
CTTGG	O
...	O
CCAAG	O
which	O
is	O
present	O
as	O
part	O
of	O
larger	O
palindromic	B-DNA
sequences	I-DNA
in	O
each	O
gene	O
.	O

This	O
suggest	O
that	O
they	O
may	O
interact	O
with	O
a	O
new	O
family	O
of	O
trans-acting	B-protein
factors	I-protein
.	O

In	O
transfection	O
assays	O
,	O
the	O
human	B-DNA
GM-CSF	I-DNA
element	I-DNA
has	O
a	O
strong	O
positive	O
effect	O
on	O
the	O
expression	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
by	O
the	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	B-cell_line
J6	I-cell_line
upon	O
stimulation	O
.	O

In	O
DNA	O
mobility	O
shift	O
assays	O
,	O
this	O
sequence	O
can	O
give	O
either	O
six	O
different	O
specific	O
bands	O
which	O
are	O
competed	O
out	O
by	O
different	O
parts	O
of	O
the	O
sequence	O
or	O
one	O
specific	O
band	O
which	O
is	O
competed	O
out	O
by	O
each	O
of	O
the	O
inverted	O
repeats	O
,	O
depending	O
on	O
the	O
reconstitution	O
conditions	O
.	O

In	O
different	O
genes	B-DNA
,	O
the	O
core	B-DNA
sequences	I-DNA
are	O
separated	O
by	O
integer	O
numbers	O
of	O
helical	O
turns	O
.	O

Considering	O
the	O
strong	O
positive	O
regulatory	O
effect	O
of	O
this	O
element	B-DNA
and	O
its	O
presence	O
in	O
several	O
T-cell-expressed	B-DNA
cytokine	I-DNA
genes	I-DNA
,	O
it	O
may	O
be	O
crucial	O
to	O
the	O
coordinated	O
expression	O
of	O
these	O
cytokines	B-protein
in	O
T	B-cell_type
helper	I-cell_type
cells	I-cell_type
.	O

cDNA	B-DNA
cloning	O
of	O
a	O
NGFI-B/nur77-related	B-protein
transcription	I-protein
factor	I-protein
from	O
an	O
apoptotic	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

A	O
human	B-cell_line
T	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
PEER	B-cell_line
,	O
dies	O
by	O
apoptosis	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
calcium	O
ionophore	O
.	O

A	O
new	O
gene	B-DNA
,	O
TINUR	B-DNA
,	O
was	O
cloned	O
from	O
apoptotic	B-cell_line
PEER	I-cell_line
cells	I-cell_line
.	O

The	O
expression	O
of	O
the	O
TINUR	B-DNA
gene	I-DNA
is	O
induced	O
within	O
1	O
h	O
after	O
the	O
cross-linking	O
of	O
the	O
T	B-protein
cell	I-protein
Ag	I-protein
receptor	I-protein
complex	I-protein
.	O

TINUR	B-DNA
belongs	O
to	O
the	O
NGFI-B/nur77	B-protein
family	I-protein
of	O
the	O
steroid	B-protein
receptor	I-protein
superfamily	I-protein
and	O
is	O
an	O
orphan	B-protein
receptor	I-protein
.	O

TINUR	B-DNA
binds	O
to	O
the	O
same	O
DNA	B-DNA
sequence	I-DNA
as	O
NGFI-B/nur77	B-protein
.	O

We	O
also	O
propose	O
that	O
the	O
NGFI-B/nur77	B-protein
family	I-protein
can	O
be	O
classified	O
into	O
two	O
subtypes	O
.	O

Aspirin	O
inhibits	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
mobilization	O
and	O
monocyte	O
adhesion	O
in	O
stimulated	B-cell_line
human	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
.	O

BACKGROUND	O
:	O
The	O
induction	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
and	O
E-selectin	B-protein
by	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF	B-protein
)	O
is	O
mediated	O
by	O
mobilization	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O

Since	O
salicylates	O
have	O
been	O
reported	O
to	O
inhibit	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
preventing	O
the	O
degradation	O
of	O
its	O
inhibitor	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
we	O
studied	O
a	O
potential	O
inhibition	O
of	O
this	O
pathway	O
by	O
acetylsalicylate	O
(	O
aspirin	O
)	O
in	O
human	B-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVECs	B-cell_line
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Gel-shift	O
analyses	O
demonstrated	O
dose-dependent	O
inhibition	O
of	O
TNF	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
mobilization	O
by	O
aspirin	O
at	O
concentrations	O
ranging	O
from	O
1	O
to	O
10	O
mmol/L	O
.	O

Induction	O
of	O
VCAM-1	B-protein
and	O
E-selectin	B-protein
surface	O
expression	O
by	O
TNF	B-protein
was	O
dose-dependently	O
reduced	O
by	O
aspirin	O
over	O
the	O
same	O
range	O
,	O
while	O
induction	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
was	O
hardly	O
affected	O
.	O

Aspirin	O
appeared	O
to	O
prevent	O
VCAM-1	B-protein
transcription	O
,	O
since	O
it	O
dose-dependently	O
inhibited	O
induction	O
of	O
VCAM-1	B-RNA
mRNA	I-RNA
by	O
TNF	B-protein
.	O

As	O
a	O
functional	O
consequence	O
,	O
adhesion	O
of	O
U937	B-cell_line
monocytes	I-cell_line
to	O
TNF-stimulated	B-cell_line
HUVECs	I-cell_line
was	O
markedly	O
reduced	O
by	O
aspirin	O
due	O
to	O
suppression	O
of	O
VCAM-1	B-protein
and	O
E-selectin	B-protein
upregulation	O
.	O

These	O
effects	O
of	O
aspirin	O
were	O
not	O
related	O
to	O
the	O
inhibition	O
of	O
cyclooxygenase	B-protein
activity	O
,	O
since	O
indomethacin	O
was	O
ineffective	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
aspirin	O
inhibits	O
NF-kappa	B-protein
B	I-protein
mobilization	O
,	O
induction	O
of	O
VCAM-1	B-protein
and	O
E-selectin	B-protein
,	O
and	O
subsequent	O
monocyte	O
adhesion	O
in	O
endothelial	B-cell_type
cells	I-cell_type
stimulated	O
by	O
TNF	B-protein
,	O
thereby	O
providing	O
an	O
additional	O
mechanism	O
for	O
therapeutic	O
effects	O
of	O
aspirin	O
.	O

Activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
phosphatase	B-protein
inhibitors	O
involves	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
at	O
phosphatase	B-protein
2A-sensitive	I-protein
sites	I-protein
.	O

Activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
various	O
cellular	O
stimuli	O
involves	O
the	O
phosphorylation	O
and	O
subsequent	O
degradation	O
of	O
its	O
inhibitor	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
although	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
serine/threonine	B-protein
phosphatases	I-protein
in	O
the	O
regulation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
phosphorylation	O
was	O
investigated	O
.	O

Our	O
studies	O
demonstrate	O
that	O
incubation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
low	O
concentrations	O
(	O
approximately	O
1-5	O
nM	O
)	O
of	O
calyculin	O
A	O
or	O
okadaic	O
acid	O
,	O
potent	O
inhibitors	O
of	O
protein	B-protein
phosphatase	I-protein
type	I-protein
1	I-protein
(	I-protein
PP-1	I-protein
)	I-protein
and	I-protein
type	I-protein
2A	I-protein
(	O
PP-2A	B-protein
)	O
,	O
induces	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
even	O
in	O
the	O
absence	O
of	O
any	O
cellular	O
stimulus	O
.	O

This	O
action	O
of	O
the	O
phosphatase	O
inhibitors	O
,	O
which	O
is	O
associated	O
with	O
the	O
activation	O
of	O
the	O
RelA.p50	B-protein
NF-kappa	I-protein
B	I-protein
heterodimer	I-protein
,	O
is	O
not	O
affected	O
by	O
agents	O
that	O
block	O
the	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
phosphorylation	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O

Furthermore	O
,	O
the	O
phosphorylated	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
from	O
calyculin	B-cell_line
A-treated	I-cell_line
cells	I-cell_line
,	O
but	O
not	O
that	O
from	O
TNF-alpha-stimulated	B-cell_line
cells	I-cell_line
,	O
is	O
sensitive	O
to	O
PP-2A	B-protein
in	O
vitro	O
,	O
suggesting	O
the	O
existence	O
of	O
fundamental	O
differences	O
in	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
induced	O
by	O
the	O
two	O
different	O
NF-kappa	B-protein
B	I-protein
inducers	O
.	O

However	O
,	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
phosphorylation	O
by	O
both	O
TNF-alpha	B-protein
and	O
the	O
phosphatase	O
inhibitors	O
is	O
associated	O
with	O
the	O
subsequent	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

We	O
further	O
demonstrate	O
that	O
TNF-alpha-	O
and	O
calyculin	O
A-induced	O
I	O
kappa	O
B	O
alpha	O
degradation	O
exhibits	O
similar	O
but	O
not	O
identical	O
sensitivities	O
to	O
a	O
proteasome	O
inhibitor	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
mediated	O
through	O
both	O
the	O
TNF-alpha	B-protein
-inducible	O
and	O
the	O
PP-2A-opposing	B-protein
kinases	I-protein
,	O
may	O
serve	O
to	O
target	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
for	O
proteasome	B-protein
-mediated	O
degradation	O
.	O

Sp1	B-protein
functions	O
in	O
a	O
chromatin	B-DNA
-dependent	O
manner	O
to	O
augment	O
human	B-DNA
alpha-globin	I-DNA
promoter	I-DNA
activity	O
.	O

The	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
human	B-DNA
alpha-globin	I-DNA
gene	I-DNA
is	O
highly	O
G	O
+	O
C	O
rich	O
and	O
contains	O
multiple	O
copies	O
of	O
the	O
consensus	B-DNA
sequence	I-DNA
for	O
the	O
Sp1	B-DNA
binding	I-DNA
site	I-DNA
.	O

We	O
investigated	O
the	O
role	O
of	O
this	O
G	B-DNA
+	I-DNA
C-rich	I-DNA
region	I-DNA
in	O
augmenting	O
alpha-globin	B-DNA
promoter	I-DNA
activity	O
in	O
the	O
presence	O
of	O
the	O
far-upstream	B-DNA
alpha-globin	I-DNA
enhancer	I-DNA
,	O
HS-40	B-DNA
.	O

We	O
show	O
that	O
in	O
transiently	B-cell_line
transfected	I-cell_line
erythroid	I-cell_line
cells	I-cell_line
,	O
deletion	O
of	O
the	O
alpha-globin	B-DNA
G	I-DNA
+	I-DNA
C-rich	I-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
has	O
no	O
effect	O
on	O
alpha-globin	B-DNA
promoter	I-DNA
activity	O
.	O

However	O
,	O
upon	O
stable	O
integration	O
into	O
chromatin	B-DNA
,	O
deletion	O
of	O
this	O
region	O
causes	O
a	O
nearly	O
90	O
%	O
decrease	O
in	O
promoter	O
activity	O
compared	O
with	O
expression	O
from	O
an	O
alpha-globin	B-DNA
promoter	I-DNA
retaining	O
this	O
region	O
.	O

These	O
results	O
suggest	O
that	O
the	O
alpha-globin	B-DNA
G	I-DNA
+	I-DNA
C-rich	I-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
augments	O
alpha-globin	B-DNA
promoter	I-DNA
activity	O
in	O
a	O
chromatin	B-DNA
-dependent	O
manner	O
.	O

We	O
further	O
show	O
that	O
this	O
G	B-DNA
+	I-DNA
C-rich	I-DNA
region	I-DNA
is	O
required	O
for	O
the	O
activation	O
of	O
alpha-globin	B-DNA
gene	I-DNA
expression	O
during	O
erythroid	O
differentiation	O
.	O

Finally	O
,	O
we	O
show	O
by	O
both	O
footprint	O
analysis	O
and	O
functional	O
assays	O
that	O
the	O
ability	O
of	O
the	O
G	B-DNA
+	I-DNA
C-rich	I-DNA
region	I-DNA
to	O
increase	O
alpha-globin	B-DNA
promoter	I-DNA
activity	O
from	O
a	O
stably	O
integrated	O
alpha-globin	B-DNA
gene	I-DNA
is	O
mediated	O
by	O
its	O
multiple	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
transcription	B-protein
factor	I-protein
Sp1	B-protein
.	O

Costimulation	O
of	O
human	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
with	O
LFA-3	B-protein
and	O
B7	B-protein
induce	O
distinct	O
effects	O
on	O
AP-1	O
and	O
NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
.	O

We	O
have	O
earlier	O
shown	O
that	O
stimulation	O
of	O
human	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
with	O
SEA	O
presented	O
on	O
Chinese	B-cell_line
hamster	I-cell_line
ovary	I-cell_line
(	I-cell_line
CHO	I-cell_line
)	I-cell_line
-DR	I-cell_line
transfectants	I-cell_line
coexpressing	O
either	O
B7	B-protein
or	O
LFA-3	B-protein
resulted	O
in	O
distinct	O
cytokine	B-protein
profiles	O
.	O

We	O
now	O
demonstrate	O
that	O
B7	B-protein
,	O
but	O
not	O
LFA-3	B-protein
,	O
strongly	O
costimulated	O
IL-2	B-protein
transcription	O
and	O
mRNA	O
expression	O
in	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Maximal	O
increase	O
in	O
IL-2	B-protein
transcription	O
was	O
recorded	O
with	O
CHO-DR/B7/LFA-3	B-protein
,	O
suggesting	O
a	O
cooperative	O
effect	O
of	O
B7	B-protein
and	O
LFA-3	B-protein
at	O
the	O
transcriptional	O
level	O
.	O

Gel-shift	O
analysis	O
demonstrated	O
that	O
stimulation	O
of	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
CHO-DR	B-protein
and	O
staphylococcal	O
enterotoxin	O
A	O
was	O
sufficient	O
to	O
induce	O
significant	O
amounts	O
of	O
NF-kappa	B-protein
B	I-protein
binding	O
proteins	O
,	O
whereas	O
induction	O
of	O
AP-1	B-protein
binding	I-protein
proteins	I-protein
required	O
costimulation	O
.	O

LFA-3	B-protein
induced	O
moderate	O
levels	O
of	O
AP-1	B-protein
,	O
but	O
did	O
not	O
influence	O
the	O
levels	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
while	O
B7	B-protein
costimulation	O
strongly	O
induced	O
both	O
AP-1	B-protein
and	O
substantially	O
enhanced	O
NF-kappa	B-protein
B	I-protein
binding	I-protein
proteins	I-protein
.	O

The	O
CHO-DR/B7/LFA-3	B-cell_line
triple	I-cell_line
transfectant	I-cell_line
induced	O
a	O
further	O
increase	O
in	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
binding	B-protein
proteins	I-protein
compared	O
with	O
the	O
double	B-cell_line
transfectants	I-cell_line
.	O

The	O
level	O
of	O
Oct-1	B-protein
binding	I-protein
proteins	I-protein
remained	O
similar	O
in	O
all	O
samples	O
.	O

Super-shift	O
analysis	O
revealed	O
that	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
of	O
costimulated	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
contained	O
large	O
amounts	O
of	O
p50	B-protein
,	O
substantial	O
amounts	O
of	O
p65	B-protein
,	O
and	O
marginal	O
levels	O
of	O
c-Rel	B-protein
proteins	I-protein
.	O

The	O
AP-1	B-protein
binding	I-protein
proteins	I-protein
contained	O
c-Jun	B-protein
,	O
Jun-D	B-protein
,	O
and	O
Fra-1	B-protein
,	O
but	O
marginal	O
amounts	O
of	O
Jun-B	B-protein
and	O
c-Fos	B-protein
.	O

Our	O
results	O
indicate	O
distinct	O
effects	O
of	O
B7	B-protein
and	O
LFA-3	B-protein
costimulation	O
on	O
the	O
activity	O
of	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
.	O

These	O
may	O
partly	O
account	O
for	O
the	O
differential	O
effects	O
of	O
B7	B-protein
and	O
LFA-3	B-protein
costimulation	O
on	O
IL-2	B-protein
expression	O
.	O

The	O
Ah	B-protein
receptor	I-protein
recognizes	O
DNA	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
B	B-protein
cell	I-protein
transcription	I-protein
factor	I-protein
,	O
BSAP	B-protein
:	O
a	O
possible	O
mechanism	O
for	O
dioxin-mediated	O
alteration	O
of	O
CD19	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
inhibits	O
murine	O
and	O
human	O
B	O
lymphocyte	O
immunoglobulin	O
production	O
through	O
an	O
unknown	O
mechanism	O
.	O

This	O
study	O
investigated	O
the	O
effect	O
of	O
TCDD	O
on	O
expression	O
of	O
the	O
CD19	B-DNA
gene	I-DNA
in	O
a	O
human	B-cell_line
B	I-cell_line
lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
TCDD	O
treatment	O
decreased	O
steady	O
state	O
levels	O
of	O
CD19	B-RNA
mRNA	I-RNA
by	O
67	O
%	O
in	O
the	O
IM-9	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Using	O
a	O
gel	O
mobility	O
shift	O
assay	O
,	O
we	O
identified	O
a	O
DNA-binding	B-protein
complex	I-protein
in	O
IM-9	O
nuclear	O
extracts	O
that	O
by	O
several	O
criteria	O
appears	O
to	O
be	O
the	O
Ah	B-protein
receptor	I-protein
.	O

In	O
addition	O
,	O
the	O
Ah	B-protein
receptor	I-protein
complex	I-protein
recognized	O
a	O
DNA	B-DNA
binding	I-DNA
site	I-DNA
for	O
B	B-protein
cell	I-protein
lineage-specific	I-protein
activator	I-protein
protein	I-protein
(	O
BSAP	B-protein
)	O
in	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
human	O
CD19	B-DNA
gene	I-DNA
which	O
is	O
similar	O
to	O
the	O
consensus	B-DNA
Ah	I-DNA
receptor	I-DNA
DNA	I-DNA
binding	I-DNA
site	I-DNA
.	O

These	O
results	O
suggest	O
that	O
the	O
AhR	B-protein
could	O
interfere	O
with	O
BSAP	B-protein
-stimulated	O
CD19	B-DNA
gene	I-DNA
transcription	O
by	O
competition	O
for	O
a	O
common	O
DNA	B-DNA
binding	I-DNA
site	I-DNA
.	O

Inhibitory	O
action	O
of	O
nm23	B-protein
proteins	I-protein
on	O
induction	O
of	O
erythroid	O
differentiation	O
of	O
human	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

We	O
recently	O
identified	O
a	O
differentiation	B-protein
inhibitory	I-protein
factor	I-protein
(	O
I-factor	B-protein
)	O
in	O
mouse	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
M1	I-cell_line
cells	I-cell_line
as	O
a	O
murine	B-protein
homolog	I-protein
of	O
the	O
human	B-protein
nm23-H2	I-protein
gene	I-protein
product	I-protein
.	O

nm23	B-DNA
genes	I-DNA
encode	O
proteins	O
that	O
participate	O
in	O
tumor	O
metastasis	O
regulation	O
and	O
in	O
various	O
fundamental	O
cellular	O
processes	O
,	O
although	O
their	O
mechanisms	O
of	O
action	O
are	O
still	O
unknown	O
.	O

Although	O
all	O
nm23	B-protein
proteins	I-protein
contain	O
nucleoside	B-protein
diphosphate	I-protein
(	I-protein
NDP	I-protein
)	I-protein
kinase	I-protein
activity	O
,	O
it	O
has	O
not	O
been	O
established	O
that	O
the	O
enzyme	O
activity	O
mediated	O
the	O
various	O
functions	O
of	O
nm23	B-protein
proteins	I-protein
.	O

In	O
the	O
present	O
experiment	O
,	O
we	O
examined	O
the	O
effect	O
of	O
nm23	B-protein
proteins	I-protein
on	O
various	O
differentiation	O
induction	O
systems	O
of	O
human	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
including	O
HL-60	B-cell_line
,	I-cell_line
U937	I-cell_line
,	I-cell_line
HEL/S	I-cell_line
,	I-cell_line
KU812F	I-cell_line
,	I-cell_line
K562	I-cell_line
,	I-cell_line
and	I-cell_line
HEL	I-cell_line
cells	I-cell_line
.	O

Native	B-protein
human	I-protein
erythrocyte	I-protein
NDP	I-protein
kinase	I-protein
protein	I-protein
inhibited	O
the	O
induction	O
of	O
erythroid	O
differentiation	O
of	O
HEL	B-cell_line
,	I-cell_line
KU812	I-cell_line
and	I-cell_line
K562	I-cell_line
cells	I-cell_line
,	O
but	O
not	O
the	O
induction	O
of	O
monocytic	O
or	O
granulocytic	O
differentiation	O
of	O
HL-60	B-cell_line
,	I-cell_line
U937	I-cell_line
and	I-cell_line
HEL/S	I-cell_line
cells	I-cell_line
.	O

The	O
erythroid	O
differentiation	O
of	O
HEL	B-cell_line
cells	I-cell_line
was	O
inhibited	O
by	O
recombinant	B-protein
human	I-protein
nm23-H1	I-protein
,	I-protein
-H2	I-protein
,	I-protein
mouse	I-protein
nm23-M1	I-protein
,	I-protein
and	I-protein
-M2	I-protein
proteins	I-protein
.	O

Moreover	O
,	O
both	O
the	O
mutant	B-protein
nm23-H2His	I-protein
protein	I-protein
and	O
truncated	B-protein
nm23-H2	I-protein
protein	I-protein
containing	O
N-terminal	B-protein
(	I-protein
1-60	I-protein
)	I-protein
peptide	I-protein
,	O
which	O
do	O
not	O
have	O
NDP	B-protein
kinase	I-protein
activity	O
,	O
also	O
inhibited	O
erythroid	O
differentiation	O
of	O
HEL	B-cell_line
cells	I-cell_line
.	O

These	O
results	O
suggest	O
that	O
(	O
1	O
)	O
the	O
differentiation	O
inhibitory	O
activity	O
of	O
I-factor/nm23	B-protein
protein	I-protein
is	O
not	O
restricted	O
to	O
monocytic	O
differentiation	O
of	O
M1	B-cell_line
cells	I-cell_line
,	O
(	O
2	O
)	O
the	O
inhibitory	O
activity	O
is	O
exhibited	O
without	O
species	O
specificity	O
,	O
and	O
(	O
3	O
)	O
the	O
differentiation	O
inhibitory	O
activity	O
of	O
the	O
nm23/NDP	B-protein
kinase	I-protein
protein	I-protein
is	O
independent	O
of	O
its	O
enzyme	O
activity	O
and	O
requires	O
the	O
presence	O
of	O
N-terminal	O
peptides	O
.	O

Lipopolysaccharide-induced	O
E-selectin	B-protein
expression	O
requires	O
continuous	O
presence	O
of	O
LPS	O
and	O
is	O
inhibited	O
by	O
bactericidal/permeability-increasing	B-protein
protein	I-protein
.	O

Endothelial	B-cell_type
cells	I-cell_type
stimulated	O
by	O
LPS	O
express	O
E-selectin	B-protein
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
neutrophil	B-cell_type
adhesion	O
during	O
inflammation	O
.	O

E-selectin	B-protein
is	O
induced	O
within	O
1-2	O
h	O
,	O
peaks	O
at	O
4-6	O
h	O
,	O
and	O
gradually	O
returns	O
to	O
basal	O
level	O
by	O
24	O
h	O
.	O

rBPI21	B-protein
,	O
a	O
recombinant	B-protein
N-terminal	I-protein
fragment	I-protein
of	O
human	B-protein
bactericidal/permeability-increasing	I-protein
protein	I-protein
(	O
BPI	B-protein
)	O
,	O
inhibited	O
LPS-induced	O
E-selectin	B-protein
expression	O
when	O
added	O
at	O
the	O
same	O
time	O
as	O
,	O
and	O
up	O
to	O
6	O
h	O
after	O
,	O
LPS	O
.	O

Delayed	O
administration	O
of	O
rBPI21	B-protein
also	O
affected	O
LPS-mediated	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
,	O
NF-kappa	B-protein
B	I-protein
.	O

Two	O
to	O
4	O
h	O
following	O
LPS	O
addition	O
to	O
endothelial	B-cell_type
cells	I-cell_type
,	O
when	O
NF-kappa	B-protein
B	I-protein
was	O
already	O
activated	O
,	O
addition	O
of	O
rBPI21	B-protein
resulted	O
in	O
marked	O
reduction	O
of	O
NF-kappa	B-protein
B	I-protein
detectable	O
at	O
4	O
or	O
6	O
h	O
.	O

These	O
results	O
indicate	O
that	O
endothelial	O
activation	O
requires	O
continuous	O
presence	O
of	O
LPS	O
,	O
and	O
rBPI21	B-protein
acts	O
to	O
reverse	O
LPS-mediated	O
endothelial	O
activation	O
by	O
interrupting	O
the	O
on-going	O
LPS	O
signal	O
.	O

GM-CSF	B-protein
and	O
IL-2	B-protein
share	O
common	O
control	O
mechanisms	O
in	O
response	O
to	O
costimulatory	O
signals	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Antigen	O
complexed	O
with	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
I	I-protein
or	I-protein
II	I-protein
molecules	I-protein
on	O
the	O
surface	O
of	O
antigen	B-cell_type
presenting	I-cell_type
cells	I-cell_type
interacts	O
with	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
on	O
the	O
surface	O
of	O
T	B-cell_type
cells	I-cell_type
and	O
initiates	O
an	O
activation	O
cascade	O
.	O

So	O
called	O
costimulatory	O
signals	O
,	O
mediated	O
by	O
other	O
cell	O
surface	O
interactions	O
or	O
soluble	B-protein
cytokines	I-protein
produced	O
by	O
antigen	B-cell_type
presenting	I-cell_type
cells	I-cell_type
,	O
are	O
also	O
required	O
for	O
complete	O
T	O
cell	O
activation	O
.	O

High	O
levels	O
of	O
cytokine	B-protein
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
also	O
required	O
both	O
TCR	B-protein
and	O
costimulatory	O
signals	O
.	O

The	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
requires	O
sequences	O
in	O
the	O
promoter	B-DNA
as	O
well	O
as	O
a	O
powerful	O
enhancer	B-DNA
located	O
3kb	O
upstream	O
to	O
respond	O
to	O
TCR	B-protein
-like	O
signals	O
.	O

These	O
promoter	B-DNA
and	I-DNA
enhancer	I-DNA
regions	I-DNA
are	O
mainly	O
activated	O
by	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
.	O

The	O
activation	O
of	O
NFAT	B-protein
by	O
TCR	B-protein
signals	O
has	O
been	O
well	O
described	O
for	O
interleukin-2	O
(	O
IL-2	B-protein
)	O
and	O
IL-4	O
gene	O
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Costimulatory	O
signals	O
,	O
such	O
as	O
activation	O
of	O
the	O
CD28	B-protein
cell	I-protein
surface	I-protein
molecule	I-protein
on	O
T	B-cell_type
cells	I-cell_type
,	O
lead	O
to	O
activation	O
through	O
a	O
distinct	O
region	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
promoter	I-DNA
.	O

This	O
region	O
is	O
termed	O
the	O
CK-1	B-DNA
or	O
CD28RE	B-DNA
and	O
appears	O
to	O
bind	O
specific	O
members	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

Human	O
T	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
infects	O
T	B-cell_type
cells	I-cell_type
and	O
can	O
lead	O
to	O
increase	O
GM-CSF	B-protein
expression	O
.	O

We	O
have	O
found	O
that	O
the	O
HTLV-1	B-protein
transactivator	I-protein
protein	I-protein
,	O
tax	B-protein
,	O
acts	O
as	O
a	O
costimulatory	O
signal	O
for	O
GM-CSF	O
and	O
IL-2	O
gene	O
transcription	O
,	O
in	O
that	O
it	O
can	O
cooperate	O
with	O
TCR	B-protein
signals	O
to	O
mediate	O
high	O
level	O
gene	O
expression	O
.	O

Tax	O
activates	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
through	O
the	O
CK-1	B-DNA
/CD28RE	B-DNA
region	O
and	O
also	O
activates	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
binding	O
to	O
this	O
region	O
.	O

However	O
,	O
other	O
transcription	B-protein
factors	I-protein
or	O
coactivators	O
of	O
NF-kappa	B-protein
B	I-protein
are	O
required	O
for	O
tax	B-protein
activation	O
but	O
these	O
remain	O
to	O
be	O
identified	O
.	O

The	O
CK-1	B-DNA
/CD28RE	B-DNA
of	O
GM-CSF	B-protein
shows	O
a	O
high	O
degree	O
of	O
similarity	O
to	O
the	O
IL-2	B-protein
CD28RE	B-DNA
and	O
the	O
IL-3	B-DNA
gene	I-DNA
also	O
contains	O
a	O
related	O
region	O
.	O

This	O
observation	O
,	O
together	O
with	O
the	O
fact	O
that	O
both	O
GM-CSF	B-protein
and	O
IL-2	B-protein
respond	O
to	O
TCR	B-protein
signals	O
via	O
NFAT	B-protein
,	O
implies	O
a	O
high	O
degree	O
of	O
conservation	O
in	O
the	O
regulation	O
of	O
cytokine	B-protein
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Danazol	O
decreases	O
transcription	O
of	O
estrogen	B-DNA
receptor	I-DNA
gene	I-DNA
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

1.	O
Administration	O
of	O
danazol	O
for	O
over	O
one	O
month	O
reduced	O
the	O
levels	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
and	O
its	O
mRNA	B-RNA
to	O
approximately	O
50	O
and	O
20	O
%	O
,	O
respectively	O
in	O
monocytes	B-cell_type
.	O

2.	O
Danazol	O
did	O
not	O
alter	O
the	O
degradation	O
rate	O
of	O
ER	B-RNA
mRNA	I-RNA
in	O
monocytes	B-cell_type
.	O

3.	O
Danazol	O
decreased	O
the	O
transcription	O
rate	O
of	O
ER	B-DNA
gene	I-DNA
to	O
approximately	O
50	O
%	O
in	O
monocytes	B-cell_type
in	O
a	O
run-on	O
assay	O
.	O

4.	O
Danazol	O
may	O
release	O
estrogen	O
predominance	O
via	O
the	O
reduction	O
of	O
transcription	O
for	O
ER	B-DNA
gene	I-DNA
,	O
which	O
leads	O
to	O
the	O
reduction	O
of	O
ER	B-RNA
mRNA	I-RNA
and	O
ER	B-protein
expressions	O
in	O
monocytes	B-cell_type
.	O

Functional	O
characterization	O
of	O
novel	O
IL-2	B-protein
transcriptional	O
inhibitors	O
.	O

IL-2	B-protein
-mediated	O
T	B-cell_type
cell	I-cell_type
proliferation	O
is	O
a	O
critical	O
early	O
event	O
in	O
the	O
inflammatory	O
process	O
.	O

Formation	O
of	O
the	O
NFAT-1	B-protein
transcriptional	I-protein
complex	I-protein
on	O
the	O
IL-2	B-DNA
promoter	I-DNA
is	O
essential	O
for	O
IL-2	B-protein
transcription	O
.	O

Using	O
a	O
cell	O
line	O
that	O
is	O
stably	O
transfected	O
with	O
a	O
trimer	O
of	O
the	O
NFAT-1	B-DNA
regulatory	I-DNA
element	I-DNA
linked	O
to	O
a	O
lac-Z	B-DNA
reporter	I-DNA
gene	I-DNA
,	O
we	O
screened	O
for	O
inhibitors	O
of	O
NFAT	B-protein
-1-mediated	O
beta-galactosidase	B-protein
activity	O
.	O

WIN	O
61058	O
and	O
WIN	O
53071	O
were	O
identified	O
as	O
microM	O
inhibitors	O
.	O

These	O
compounds	O
also	O
inhibited	O
beta-galactosidase	B-RNA
mRNA	I-RNA
levels	O
.	O

Similar	O
inhibition	O
of	O
NFAT	B-protein
-1-mediated	O
gene	O
expression	O
was	O
observed	O
in	O
a	O
second	O
cell	B-cell_line
line	I-cell_line
,	O
which	O
is	O
stably	O
transfected	O
with	O
NFAT-1	B-DNA
regulatory	I-DNA
elements	I-DNA
linked	O
to	O
the	O
reporter	B-DNA
gene	I-DNA
for	I-DNA
sCD8	I-DNA
.	O

At	O
10	O
microM	O
,	O
both	O
compounds	O
inhibited	O
IL-2	O
mRNA	O
and	O
protein	O
levels	O
in	O
the	O
NFAT-1-linked	B-cell_line
lac-Z	I-cell_line
transfectants	I-cell_line
,	O
and	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

Both	O
compounds	O
inhibited	O
the	O
mixed	O
lymphocyte	O
reaction	O
,	O
and	O
this	O
inhibition	O
was	O
reversed	O
by	O
exogenous	O
IL-2	B-protein
.	O

WIN	O
53071	O
inhibited	O
IL-2	B-protein
production	O
induced	O
in	O
the	O
calcium-dependent	O
PMA	O
and	O
ionomycin	O
pathway	O
.	O

Conversely	O
,	O
calcium-independent	B-protein
anti-CD28	I-protein
Ab	I-protein
and	O
PMA-induced	O
IL-2	B-protein
production	O
was	O
resistant	O
.	O

Both	O
compounds	O
altered	O
the	O
NFAT-1	B-protein
transcriptional	I-protein
complex	I-protein
,	O
causing	O
its	O
retarded	O
mobility	O
on	O
gels	O
.	O

By	O
these	O
functional	O
criteria	O
,	O
we	O
believe	O
we	O
have	O
identified	O
two	O
structurally	O
distinct	O
,	O
novel	O
inhibitors	O
of	O
NFAT	B-protein
-1-mediated	O
transcription	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
vacuolar	B-DNA
H	I-DNA
(	I-DNA
+	I-DNA
)	I-DNA
-ATPase	I-DNA
B2	I-DNA
subunit	I-DNA
gene	I-DNA
in	O
differentiating	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
.	O

Monocyte-macrophage	O
differentiation	O
was	O
used	O
as	O
a	O
model	O
system	O
for	O
studying	O
gene	O
regulation	O
of	O
the	O
human	B-protein
vacuolar	I-protein
H	I-protein
(	I-protein
+	I-protein
)	I-protein
-ATPase	I-protein
(	O
V-ATPase	B-protein
)	O
.	O

We	O
examined	O
mRNA	B-RNA
levels	O
of	O
various	O
V-ATPase	B-protein
subunits	O
during	O
differentiation	O
of	O
both	O
native	B-cell_type
monocytes	I-cell_type
and	O
the	O
cell	B-cell_line
line	I-cell_line
THP-1	B-cell_line
,	O
and	O
found	O
that	O
transcriptional	O
and	O
post-transcriptional	O
mechanisms	O
could	O
account	O
for	O
increases	O
in	O
cell	O
V-ATPase	B-protein
content	O
.	O

From	O
nuclear	O
runoff	O
experiments	O
,	O
we	O
found	O
that	O
one	O
subunit	O
in	O
particular	O
,	O
the	O
B2	B-protein
isoform	I-protein
(	O
Mr	O
=	O
56	O
,	O
000	O
)	O
,	O
was	O
amplified	O
primarily	O
by	O
transcriptional	O
means	O
.	O

We	O
have	O
begun	O
to	O
examine	O
the	O
structure	O
of	O
the	O
B2	B-DNA
subunit	I-DNA
promoter	I-DNA
region	I-DNA
.	O

Isolation	O
and	O
sequencing	O
of	O
the	O
first	B-DNA
exon	I-DNA
and	O
5'-flanking	B-DNA
region	I-DNA
of	O
this	O
gene	O
reveal	O
a	O
TATA-less	B-DNA
promoter	I-DNA
with	O
a	O
high	O
G	O
+	O
C	O
content	O
.	O

Primer	O
extension	O
and	O
ribonuclease	B-protein
protection	O
analyses	O
indicate	O
a	O
single	O
major	B-DNA
transcriptional	I-DNA
start	I-DNA
site	I-DNA
.	O

We	O
transfected	O
promoter-luciferase	B-DNA
reporter	I-DNA
plasmids	I-DNA
into	O
THP-1	B-cell_line
cells	I-cell_line
to	O
define	O
sequences	O
that	O
mediate	O
transcriptional	O
control	O
during	O
monocyte	O
differentiation	O
.	O

We	O
found	O
that	O
sequences	O
downstream	O
from	O
the	O
transcriptional	O
start	O
site	O
were	O
sufficient	O
to	O
confer	O
increased	O
expression	O
during	O
THP-1	B-cell_line
differentiation	O
.	O

DNase	B-protein
I	I-protein
footprinting	O
and	O
sequence	O
analysis	O
revealed	O
the	O
existence	O
of	O
multiple	O
AP2	B-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
5'-untranslated	B-DNA
and	I-DNA
proximal	I-DNA
coding	I-DNA
regions	I-DNA
.	O

Synergy	O
between	O
signal	O
transduction	O
pathways	O
is	O
obligatory	O
for	O
expression	O
of	O
c-fos	B-DNA
in	O
B	B-cell_line
and	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
:	O
implication	O
for	O
c-fos	B-DNA
control	O
via	O
surface	B-protein
immunoglobulin	I-protein
and	O
T	B-protein
cell	I-protein
antigen	I-protein
receptors	I-protein
.	O

Expression	O
of	O
the	O
protooncogene	B-DNA
c-fos	I-DNA
is	O
controlled	O
by	O
three	O
main	O
regulatory	O
pathways	O
involving	O
kinase	B-protein
C	I-protein
,	O
cAMP	O
,	O
and	O
calcium	O
.	O

Kinase	B-protein
C	I-protein
mediates	O
its	O
effects	O
via	O
phosphorylation	O
of	O
serum	B-protein
response	I-protein
factor	I-protein
(	O
SRF	B-protein
)	O
which	O
interacts	O
with	O
the	O
serum	B-DNA
response	I-DNA
element	I-DNA
(	O
SRE	B-DNA
)	O
;	O
cAMP	O
and	O
calcium	O
mediate	O
their	O
effects	O
via	O
phosphorylation	O
of	O
CREB	B-protein
(	O
cAMP	B-protein
regulatory	I-protein
element	I-protein
binding	I-protein
protein	I-protein
)	O
presumably	O
by	O
activation	O
of	O
a	O
protein	B-protein
kinase	I-protein
A	I-protein
or	O
calmodulin-regulated	B-protein
kinase	I-protein
.	O

We	O
have	O
examined	O
the	O
function	O
of	O
these	O
elements	O
in	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
(	O
Ramos	B-cell_line
and	O
Daudi	B-cell_line
)	O
as	O
well	O
as	O
a	O
T	B-cell_line
lymphocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
Jurkat	B-cell_line
)	O
.	O

We	O
have	O
found	O
that	O
stimulation	O
of	O
any	O
one	O
of	O
these	O
pathways	O
alone	O
has	O
little	O
or	O
no	O
effect	O
on	O
c-fos	B-DNA
induction	O
.	O

However	O
,	O
kinase	B-protein
C	I-protein
activation	O
(	O
PMA	O
stimulation	O
)	O
combined	O
with	O
either	O
cAMP	O
(	O
forskolin	O
plus	O
MIX	O
)	O
or	O
calcium	O
stimulation	O
(	O
ionophore	O
)	O
leads	O
to	O
greatly	O
enhanced	O
c-fos	B-DNA
induction	O
.	O

By	O
contrast	O
,	O
cAMP	O
in	O
the	O
presence	O
of	O
calcium	O
shows	O
no	O
synergy	O
in	O
c-fos	B-DNA
induction	O
.	O

Okadaic	O
acid	O
augments	O
PMA-	O
as	O
well	O
as	O
calcium-mediated	O
activation	O
of	O
c-fos	B-DNA
,	O
and	O
has	O
little	O
or	O
no	O
effect	O
when	O
combined	O
with	O
cAMP	O
.	O

The	O
main	O
difference	O
between	O
Ramos	B-cell_line
(	O
B	B-cell_type
cells	I-cell_type
)	O
and	O
Jurkat	B-cell_line
(	O
T	B-cell_type
cells	I-cell_type
)	O
in	O
the	O
regulation	O
of	O
c-fos	B-DNA
is	O
that	O
cAMP	O
plus	O
calcium	O
is	O
strongly	O
synergistic	O
in	O
Jurkat	B-cell_line
and	O
is	O
without	O
effect	O
in	O
Ramos	B-cell_line
.	O

Analysis	O
of	O
AP-1	B-protein
activity	O
using	O
gel	O
mobility	O
shift	O
assays	O
confirms	O
that	O
the	O
requirements	O
for	O
synergy	O
in	O
c-fos	B-RNA
mRNA	I-RNA
induction	O
are	O
paralleled	O
by	O
requirements	O
for	O
synergy	O
in	O
induction	O
of	O
AP-1	B-protein
activity	O
.	O

Signaling	O
in	O
B	B-cell_type
cells	I-cell_type
due	O
to	O
anti-Ig	B-protein
stimulation	O
involves	O
both	O
kinase	B-protein
C	I-protein
activation	O
and	O
release	O
of	O
intracellular	O
calcium	O
,	O
and	O
results	O
in	O
c-fos	B-RNA
mRNA	I-RNA
induction	O
.	O

Our	O
results	O
indicate	O
that	O
synergy	O
between	O
the	O
kinase	B-protein
C	I-protein
activation	O
and	O
calcium	O
is	O
needed	O
for	O
efficient	O
c-fos	B-DNA
induction	O
since	O
neither	O
of	O
these	O
two	O
alone	O
induces	O
c-fos	B-DNA
well	O
.	O

That	O
synergy	O
of	O
signaling	O
pathways	O
is	O
relevant	O
for	O
the	O
anti-Ig	B-protein
induction	O
of	O
c-fos	B-DNA
is	O
supported	O
by	O
the	O
fact	O
that	O
cAMP-inducing	O
agents	O
and	O
okadaic	O
acid	O
further	O
enhance	O
anti-Ig	B-protein
induction	O
of	O
c-fos	B-DNA
.	O

These	O
results	O
suggest	O
that	O
cell-specific	O
patterns	O
of	O
synergy	O
are	O
an	O
essential	O
feature	O
for	O
c-fos	B-DNA
induction	O
and	O
may	O
be	O
relevant	O
for	O
c-fos	B-DNA
control	O
through	O
B	B-protein
and	I-protein
T	I-protein
cell	I-protein
antigen	I-protein
receptors	I-protein
.	O

Multiple	O
signals	O
are	O
required	O
for	O
function	O
of	O
the	O
human	B-DNA
granulocyte-macrophage	I-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
human	B-DNA
granulocyte-macrophage	I-DNA
CSF	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
gene	I-DNA
is	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
in	O
response	O
to	O
TCR	B-protein
activation	O
that	O
can	O
be	O
mimicked	O
by	O
treatment	O
of	O
the	O
cells	O
with	O
PMA	O
and	O
Ca2+	O
ionophore	O
.	O

The	O
gene	O
contains	O
a	O
proximal	B-DNA
functional	I-DNA
promoter	I-DNA
region	I-DNA
(	O
-620	B-DNA
to	I-DNA
+34	I-DNA
)	O
,	O
as	O
well	O
as	O
a	O
powerful	O
enhancer	B-DNA
located	O
3	O
kb	O
upstream	O
,	O
both	O
of	O
which	O
are	O
involved	O
in	O
the	O
response	O
of	O
the	O
gene	O
to	O
TCR	B-protein
activation	O
.	O

The	O
proximal	B-DNA
promoter	I-DNA
contains	O
a	O
region	O
termed	O
CLEO	B-DNA
(	O
-54	B-DNA
to	I-DNA
-31	I-DNA
)	O
that	O
consists	O
of	O
a	O
purine-rich	B-DNA
element	I-DNA
abutting	O
an	O
activator	B-DNA
protein-1	I-DNA
(	I-DNA
AP-1	I-DNA
)	I-DNA
-like	I-DNA
site	I-DNA
,	O
as	O
well	O
as	O
an	O
upstream	B-DNA
nuclear	I-DNA
factor-kappa	I-DNA
B	I-DNA
(	I-DNA
NF-kappa	I-DNA
B	I-DNA
)	I-DNA
site	I-DNA
(	O
-85	B-DNA
to	I-DNA
-76	I-DNA
)	O
and	O
a	O
CK-1	B-DNA
element	I-DNA
(	O
-101	B-DNA
to	I-DNA
-92	I-DNA
)	O
.	O

We	O
show	O
in	O
this	O
work	O
that	O
mutations	O
in	O
either	O
the	O
purine-rich	B-DNA
region	I-DNA
of	O
the	O
CLEO	B-DNA
element	I-DNA
or	O
the	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
result	O
in	O
reduced	O
PMA/Ca2+	O
activation	O
of	O
a	O
620-bp	B-DNA
human	I-DNA
GM-CSF	I-DNA
promoter-luciferase	I-DNA
reporter	I-DNA
construct	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
65	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O

The	O
major	O
inducible	B-protein
protein	I-protein
complex	I-protein
that	O
binds	O
to	O
the	O
human	B-DNA
CLEO	I-DNA
(	I-DNA
hCLEO	I-DNA
)	I-DNA
element	I-DNA
is	O
an	O
AP-1-like	B-protein
complex	I-protein
that	O
is	O
inducible	O
by	O
PMA	O
alone	O
,	O
but	O
shows	O
increased	O
binding	O
in	O
response	O
to	O
PMA	O
together	O
with	O
Ca2+	O
ionophore	O
.	O

Although	O
the	O
binding	O
of	O
this	O
complex	O
is	O
not	O
cyclosporin-sensitive	O
,	O
promoter	O
induction	O
is	O
inhibited	O
by	O
cyclosporin	O
treatment	O
.	O

A	O
second	O
weak	O
inducible	O
complex	O
resembling	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
was	O
also	O
observed	O
binding	O
to	O
the	O
hCLEO	B-DNA
region	I-DNA
.	O

By	O
using	O
recombinant	B-protein
proteins	I-protein
,	O
we	O
confirmed	O
that	O
AP-1	B-protein
,	O
NF-ATp	B-protein
,	O
and	O
a	O
higher	O
order	O
NF-ATp/AP-1	B-protein
complex	I-protein
could	O
all	O
form	O
with	O
the	O
hCLEO	B-DNA
element	I-DNA
,	O
and	O
we	O
have	O
also	O
defined	O
the	O
sequence	O
requirements	O
for	O
binding	O
of	O
each	O
of	O
these	O
complexes	O
.	O

We	O
found	O
that	O
expression	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	B-protein
could	O
substitute	O
for	O
Ca2+	O
ionophore	O
and	O
synergize	O
with	O
PMA	O
to	O
activate	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
,	O
and	O
conversely	O
that	O
mutant-activated	B-protein
Ras	I-protein
could	O
substitute	O
for	O
PMA	O
and	O
cooperate	O
with	O
Ca2+	O
ionophore	O
.	O

Co-expression	O
of	O
Ras	B-protein
and	O
calcineurin	B-protein
,	O
however	O
,	O
did	O
not	O
activate	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
,	O
but	O
required	O
the	O
additional	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
.	O

These	O
results	O
imply	O
that	O
at	O
least	O
three	O
signals	O
are	O
required	O
to	O
activate	O
the	O
GM-CSF	B-DNA
proximal	I-DNA
promoter	I-DNA
,	O
and	O
that	O
the	O
signals	O
impinge	O
on	O
distinct	O
transcription	B-protein
factors	I-protein
that	O
bind	O
to	O
the	O
hCLEO	B-DNA
and	I-DNA
NF-kappa	I-DNA
B	I-DNA
regions	I-DNA
of	O
the	O
promoter	B-DNA
.	O

IL-10	O
induces	O
the	O
tyrosine	O
phosphorylation	O
of	O
tyk2	B-protein
and	O
Jak1	B-protein
and	O
the	O
differential	O
assembly	O
of	O
STAT1	B-protein
alpha	I-protein
and	O
STAT3	B-protein
complexes	I-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
.	O

IL-10	B-protein
affects	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
by	O
driving	O
the	O
progression	O
of	O
immune	O
responsiveness	O
such	O
that	O
Th2	O
lymphocyte-mediated	O
effects	O
predominate	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
in	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
IL-10	B-protein
stimulates	O
tyrosine	O
phosphorylation	O
of	O
the	O
signal	B-protein
transducers	I-protein
and	O
activators	B-protein
of	I-protein
transcription	I-protein
,	O
STAT1	B-protein
alpha	I-protein
and	O
STAT3	B-protein
,	O
in	O
a	O
differential	O
manner	O
such	O
that	O
the	O
relative	O
formation	O
of	O
homo-	B-protein
and	I-protein
heterodimers	I-protein
varies	O
between	O
the	O
two	O
cell	O
types	O
.	O

Moreover	O
,	O
monocytes	B-cell_type
express	O
a	O
novel	O
IL-10-stimulated	B-protein
STAT	I-protein
protein	I-protein
with	O
an	O
M	O
(	O
r	O
)	O
of	O
70	B-protein
kDa	I-protein
that	O
is	O
recognized	O
by	O
the	O
anti-STAT3	B-protein
Ab	I-protein
but	O
is	O
not	O
observed	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

IL-10	B-protein
treatment	O
of	O
both	O
T	B-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
results	O
in	O
the	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
tyk2	B-protein
and	O
Jak1	B-protein
,	O
but	O
not	O
Jak2	B-protein
or	O
Jak3	B-protein
.	O

Selective	O
modulation	O
of	O
immune	O
responsiveness	O
by	O
IL-10	B-protein
in	O
cells	O
such	O
as	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
may	O
result	O
in	O
part	O
from	O
the	O
differential	O
activation	O
of	O
STAT	B-protein
protein	I-protein
pairs	I-protein
.	O

Use	O
of	O
new	O
biologic	O
markers	O
in	O
the	O
ovulation	O
induction	O
.	O

Biological	O
markers	O
of	O
ovulation	O
,	O
after	O
a	O
great	O
in	O
the	O
past	O
,	O
have	O
been	O
fallen	O
into	O
disuse	O
for	O
the	O
large	O
diffusion	O
of	O
biochemical	O
and	O
biophysical	O
ones	O
.	O

However	O
,	O
the	O
real	O
effect	O
of	O
hormones	O
involved	O
in	O
ovulation	O
is	O
expressed	O
by	O
biological	O
modifications	O
on	O
target	B-cell_type
tissues	I-cell_type
.	O

To	O
explore	O
the	O
modifications	O
of	O
not	O
reproductive	O
target	O
tissues	O
as	O
ovulation	O
markers	O
we	O
studied	O
the	O
behaviour	O
of	O
Albuminemia	O
,	O
Platelet	B-protein
Factor	I-protein
IV	I-protein
(	O
as	O
indicator	O
of	O
Platelet	O
Aggregation	O
)	O
,	O
Type	B-protein
II	I-protein
estrogenic	I-protein
receptors	I-protein
in	O
42	O
ovulation	O
induced	O
women	O
,	O
undergoing	O
our	O
observation	O
.	O

33	O
of	O
them	O
had	O
ovulation	O
and	O
9	O
developed	O
a	O
LUF	O
syndrome	O
,	O
constituting	O
two	O
biological	O
models	O
of	O
an	O
opposite	O
situation	O
for	O
the	O
three	O
markers	O
observed	O
.	O

All	O
the	O
markers	O
considered	O
were	O
sufficiently	O
sensitive	O
,	O
but	O
among	O
them	O
,	O
Platelet	B-protein
Factor	I-protein
IV	I-protein
was	O
the	O
most	O
reliable	O
to	O
the	O
hormonal	O
ovulatory	O
situation	O
.	O

Abnormal	O
regulation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
lpr	O
CD4-CD8-	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
results	O
in	O
constitutive	O
expression	O
of	O
a	O
novel	B-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells-binding	I-protein
factor	I-protein
.	O

The	O
inert	O
quality	O
of	O
MRL-Ipr/Ipr	B-cell_line
(	I-cell_line
Ipr	I-cell_line
)	I-cell_line
peripheral	I-cell_line
CD4-CD8-	I-cell_line
(	I-cell_line
CD4-8-	I-cell_line
)	I-cell_line
T	I-cell_line
cells	I-cell_line
manifests	O
primarily	O
as	O
an	O
inability	O
to	O
proliferate	O
or	O
produce	O
IL-2	B-protein
in	O
response	O
to	O
TCR	B-protein
or	O
mitogenic	O
stimulation	O
.	O

Yet	O
these	O
same	O
cells	O
do	O
initiate	O
early	O
TCR	B-protein
-mediated	O
signaling	O
events	O
,	O
such	O
as	O
generation	O
of	O
inositol	O
phosphates	O
and	O
increased	O
intracellular	O
calcium	O
.	O

They	O
also	O
display	O
constitutively	O
high	O
levels	O
of	O
p59fyn	B-protein
and	O
CD3	B-protein
zeta	I-protein
tyrosine	O
phosphorylation	O
.	O

The	O
generation	O
of	O
second	O
messengers	O
in	O
T	B-cell_type
cells	I-cell_type
normally	O
leads	O
to	O
downstream	O
signaling	O
that	O
results	O
in	O
transcriptional	O
activation	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O

We	O
,	O
therefore	O
,	O
compared	O
the	O
activation	O
state	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
promoter	I-DNA
region	I-DNA
in	O
freshly	O
isolated	O
and	O
stimulated	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
with	O
that	O
of	O
normal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Levels	O
of	O
the	O
octamer	O
,	O
NF-kappa	B-protein
B	I-protein
(	O
p50-p65	B-protein
heterodimer	I-protein
)	O
,	O
and	O
AP-1	B-protein
transcriptional	I-protein
factors	I-protein
are	O
constitutively	O
elevated	O
in	O
freshly	O
isolated	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
consistent	O
with	O
the	O
activated	O
phenotype	O
of	O
these	O
cells	O
.	O

Upon	O
stimulation	O
with	O
mitogens	O
,	O
formation	O
of	O
the	O
transactivating	O
complex	O
,	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
,	O
occurs	O
with	O
normal	O
kinetics	O
in	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Yet	O
,	O
the	O
levels	O
of	O
the	O
activating	O
NF-AT	B-protein
complex	I-protein
never	O
reach	O
those	O
observed	O
in	O
similarly	O
stimulated	O
normal	O
T	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
nuclear	O
extracts	O
from	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
display	O
high	O
levels	O
of	O
a	O
novel	O
specific	O
binding	O
activity	O
at	O
the	O
NF-AT	B-DNA
site	I-DNA
,	O
which	O
is	O
present	O
at	O
much	O
lower	O
levels	O
in	O
freshly	O
isolated	O
normal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Upon	O
mitogenic	O
stimulation	O
,	O
the	O
binding	O
activity	O
of	O
the	O
novel	O
NF-AT-binding	B-protein
factor	I-protein
is	O
rapidly	O
down-regulated	O
in	O
normal	O
T	B-cell_type
cells	I-cell_type
,	O
but	O
persists	O
at	O
high	O
levels	O
in	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

These	O
two	O
abnormalities	O
at	O
the	O
NF-AT	B-DNA
site	I-DNA
provide	O
a	O
potential	O
mechanism	O
to	O
account	O
for	O
the	O
defect	O
in	O
IL-2	B-protein
production	O
from	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Cross-linking	O
of	O
CD30	B-protein
induces	O
HIV	O
expression	O
in	O
chronically	O
infected	O
T	B-cell_type
cells	I-cell_type
.	O

CD30	B-protein
,	O
a	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
family	O
,	O
is	O
expressed	O
constitutively	O
on	O
the	O
surface	O
of	O
the	O
human	O
T	O
cell	O
line	O
ACH-2	O
,	O
which	O
is	O
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV	O
)	O
-1	O
.	O

We	O
demonstrate	O
that	O
cross-linking	O
CD30	B-protein
with	O
an	O
anti-	O
CD30	B-protein
-specific	O
monoclonal	O
antibody	O
,	O
which	O
mimics	O
the	O
described	O
biological	O
activities	O
of	O
the	O
CD30	B-protein
ligand	I-protein
(	O
CD30L	B-protein
)	O
,	O
results	O
in	O
HIV	O
expression	O
.	O

CD30	B-protein
cross-linking	O
does	O
not	O
alter	O
proliferation	O
of	O
ACH-2	B-cell_line
cells	I-cell_line
and	O
the	O
induction	O
of	O
HIV	O
expression	O
is	O
not	O
mediated	O
by	O
endogenous	O
TNF	B-protein
alpha/beta	I-protein
.	O

Furthermore	O
,	O
cross-linking	O
of	O
CD30	B-protein
leads	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
enhanced	O
HIV	O
transcription	O
.	O

Thus	O
,	O
CD30	B-protein
-CD30L	B-protein
interactions	O
mediate	O
the	O
induction	O
of	O
HIV	O
expression	O
by	O
a	O
kappa	O
B-dependent	O
pathway	O
that	O
is	O
independent	O
of	O
TNF	B-protein
.	O

This	O
mechanism	O
may	O
be	O
important	O
in	O
the	O
activation	O
of	O
HIV	O
expression	O
from	O
latently	O
infected	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
especially	O
in	O
lymphoid	O
organs	O
where	O
cell	O
to	O
cell	O
contact	O
is	O
conducive	O
to	O
receptor-ligand	O
interactions	O
.	O

Human	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
transcription	O
directed	O
by	O
the	O
carboxyl	B-protein
terminus	I-protein
of	O
CIITA	B-DNA
,	O
one	O
of	O
the	O
defective	B-DNA
genes	I-DNA
in	O
type	O
II	O
MHC	B-protein
combined	O
immune	O
deficiency	O
.	O

Type	B-protein
II	I-protein
major	I-protein
histocompatibility	I-protein
complex	I-protein
combined	O
immune	O
deficiency	O
(	O
type	O
II	O
MHC	B-protein
CID	O
or	O
bare	O
lymphocyte	O
syndrome	O
)	O
is	O
a	O
congenital	O
immunodeficiency	O
disease	O
characterized	O
by	O
absent	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
.	O

Four	O
distinct	O
complementation	O
groups	O
have	O
been	O
identified	O
.	O

Recently	O
,	O
the	O
defective	B-DNA
gene	I-DNA
in	O
group	O
II	O
type	O
II	O
MHC	B-protein
CID	O
has	O
been	O
isolated	O
and	O
termed	O
CIITA	B-DNA
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
CIITA	B-DNA
is	O
an	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene-specific	I-DNA
transcription	I-DNA
activator	I-DNA
.	O

The	O
transcription	O
activation	O
function	O
is	O
provided	O
by	O
the	O
N-terminal	B-protein
acidic	I-protein
domain	I-protein
(	O
amino	B-protein
acids	I-protein
26-137	I-protein
)	O
,	O
which	O
is	O
experimentally	O
exchangeable	O
with	O
a	O
heterologous	B-protein
viral	I-protein
transcription-activating	I-protein
domain	I-protein
.	O

The	O
specificity	O
of	O
CIITA	B-protein
for	O
three	O
major	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
,	O
DR	B-DNA
,	O
DQ	B-DNA
and	O
DP	B-DNA
,	O
is	O
mediated	O
by	O
its	O
remaining	O
C-terminal	B-protein
residues	I-protein
(	O
amino	B-protein
acids	I-protein
317-1130	I-protein
)	O
.	O

The	O
transactivation	O
of	O
multiple	B-DNA
cis	I-DNA
elements	I-DNA
,	O
especially	O
S	B-DNA
and	O
X2	B-DNA
,	O
of	O
the	O
DR	B-DNA
alpha	I-DNA
proximal	I-DNA
promoter	I-DNA
in	O
group	B-cell_line
II	I-cell_line
CID	I-cell_line
cells	I-cell_line
is	O
CIITA	B-protein
dependent	O
.	O

Since	O
CIITA	B-protein
overexpression	O
in	O
normal	B-cell_type
cells	I-cell_type
did	O
not	O
increase	O
class	O
II	O
expression	O
,	O
we	O
propose	O
that	O
initiation	O
of	O
CIITA	B-protein
expression	O
serves	O
as	O
the	O
on-off	O
switch	O
,	O
while	O
availability	O
of	O
downstream	O
interactor	O
(	O
s	O
)	O
limits	O
transcription	O
.	O

Monocyte	O
tethering	O
by	O
P-selectin	B-protein
regulates	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
secretion	O
.	O

Signal	O
integration	O
and	O
NF-kappa	B-protein
B	I-protein
translocation	O
[	O
see	O
comments	O
]	O

Adhesion	B-protein
molecules	I-protein
that	O
tether	O
circulating	B-cell_type
leukocytes	I-cell_type
to	O
endothelial	B-cell_type
cells	I-cell_type
may	O
also	O
transduce	O
or	O
modulate	O
outside-in	O
signals	O
for	O
cellular	O
activation	O
,	O
providing	O
an	O
initial	O
regulatory	O
point	O
in	O
the	O
inflammatory	O
response	O
.	O

Adhesion	O
of	O
human	B-cell_type
monocytes	I-cell_type
to	O
P-selectin	B-protein
,	O
the	O
most	O
rapidly	O
expressed	O
endothelial	B-protein
tethering	I-protein
factor	I-protein
,	O
increased	O
the	O
secretion	O
of	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
by	O
the	O
leukocytes	B-cell_type
when	O
they	O
were	O
stimulated	O
with	O
platelet-activating	B-protein
factor	I-protein
.	O

Increased	O
cytokine	O
secretion	O
was	O
specifically	O
inhibited	O
by	O
G1	B-protein
,	O
an	O
anti-P-selectin	B-protein
mAb	I-protein
that	O
prevents	O
P-selectin	B-protein
from	O
binding	O
to	O
its	O
ligand	O
(	O
P-selectin	B-protein
glycoprotein	I-protein
ligand-1	I-protein
)	O
on	O
myeloid	B-cell_type
cells	I-cell_type
.	O

Moreover	O
,	O
tethering	O
by	O
P-selectin	B-protein
specifically	O
enhanced	O
nuclear	O
translocation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
required	O
for	O
expression	O
of	O
MCP-1	B-protein
,	O
TNF-alpha	B-protein
,	O
and	O
other	O
immediate-early	B-DNA
genes	I-DNA
.	O

These	O
results	O
demonstrate	O
that	O
P-selectin	B-protein
,	O
through	O
its	O
ligands	O
on	O
monocytes	B-cell_type
,	O
may	O
locally	O
regulate	O
cytokine	B-protein
secretion	O
in	O
inflamed	O
tissues	O
.	O

Functional	O
roles	O
of	O
in	B-DNA
vivo	I-DNA
footprinted	I-DNA
DNA	I-DNA
motifs	I-DNA
within	O
an	O
alpha-globin	B-DNA
enhancer	I-DNA
.	O

Erythroid	O
lineage	O
and	O
developmental	O
stage	O
specificities	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
human	B-DNA
alpha-like	I-DNA
globin	I-DNA
genes	I-DNA
,	O
embryonic	B-DNA
zeta	I-DNA
2	I-DNA
and	O
adult	B-DNA
alpha	I-DNA
,	O
during	O
erythroid	O
development	O
is	O
mediated	O
by	O
a	O
distal	B-DNA
enhancer	I-DNA
,	O
HS-40	B-DNA
.	O

Previous	O
protein-DNA	O
binding	O
studies	O
have	O
shown	O
that	O
HS-40	B-DNA
consists	O
of	O
multiple	O
nuclear	B-DNA
factor	I-DNA
binding	I-DNA
motifs	I-DNA
that	O
are	O
occupied	O
in	O
vivo	O
in	O
an	O
erythroid	O
lineage-	O
and	O
developmental	O
stage-specific	O
manner	O
.	O

We	O
have	O
systematically	O
analyzed	O
the	O
functional	O
roles	O
of	O
these	O
factor	B-DNA
binding	I-DNA
motifs	I-DNA
of	O
HS-40	B-DNA
by	O
site-directed	O
mutagenesis	O
and	O
transient	O
expression	O
assay	O
in	O
erythroid	B-cell_line
cell	I-cell_line
cultures	I-cell_line
.	O

Three	O
of	O
these	O
HS-40	B-DNA
enhancer	I-DNA
motifs	I-DNA
,	O
5'NF-E2/AP1	B-DNA
,	O
GT	B-DNA
II	I-DNA
,	O
and	O
GATA-1	B-DNA
(	I-DNA
c	I-DNA
)	I-DNA
,	O
positively	O
regulate	O
the	O
zeta	B-DNA
2-globin	I-DNA
promoter	I-DNA
activity	O
in	O
embryonic/fetal	B-cell_line
erythroid	I-cell_line
K562	I-cell_line
cells	I-cell_line
and	O
the	O
adult	B-DNA
alpha-globin	I-DNA
promoter	I-DNA
activity	O
in	O
adult	B-cell_line
erythroid	I-cell_line
MEL	I-cell_line
cells	I-cell_line
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
3'NF-E2/AP1	B-DNA
motif	I-DNA
is	O
able	O
to	O
exert	O
both	O
positive	O
and	O
negative	O
regulatory	O
effects	O
on	O
the	O
zeta	B-DNA
2-globin	I-DNA
promoter	I-DNA
activity	O
in	O
K562	B-cell_line
cells	I-cell_line
,	O
and	O
this	O
dual	O
function	O
appears	O
to	O
be	O
modulated	O
through	O
differential	O
binding	O
of	O
the	O
ubiquitous	B-protein
AP1	I-protein
factors	I-protein
and	O
the	O
erythroid-enriched	B-protein
NF-E2	I-protein
factor	I-protein
.	O

Mutation	O
in	O
the	O
GATA-1	B-DNA
(	I-DNA
d	I-DNA
)	I-DNA
motif	I-DNA
,	O
which	O
exhibits	O
an	O
adult	B-DNA
erythroid-specific	I-DNA
genomic	I-DNA
footprint	I-DNA
,	O
decreases	O
the	O
HS-40	B-DNA
enhancer	I-DNA
function	O
in	O
dimethyl	B-cell_line
sulfoxide-induced	I-cell_line
MEL	I-cell_line
cells	I-cell_line
but	O
not	O
in	O
K562	B-cell_line
cells	I-cell_line
.	O

These	O
studies	O
have	O
defined	O
the	O
regulatory	O
roles	O
of	O
the	O
different	O
HS-40	B-DNA
motifs	I-DNA
.	O

The	O
remarkable	O
correlation	O
between	O
genomic	O
footprinting	O
data	O
and	O
the	O
mutagenesis	O
results	O
also	O
suggests	O
that	O
the	O
erythroid	O
lineage-	O
and	O
developmental	O
stage-specific	O
regulation	O
of	O
human	B-DNA
alpha-like	I-DNA
globin	I-DNA
promoters	I-DNA
is	O
indeed	O
modulated	O
by	O
stable	O
binding	O
of	O
specific	B-protein
nuclear	I-protein
factors	I-protein
in	O
vivo	O
.	O

Nitric	O
oxide-stimulated	O
guanine	O
nucleotide	O
exchange	O
on	O
p21ras	B-protein
.	O

The	O
protooncogene	B-DNA
p21ras	I-DNA
,	O
a	O
monomeric	B-protein
G	I-protein
protein	I-protein
family	I-protein
member	I-protein
,	O
plays	O
a	O
critical	O
role	O
in	O
converting	O
extracellular	O
signals	O
into	O
intracellular	O
biochemical	O
events	O
.	O

Here	O
,	O
we	O
report	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
activates	O
p21ras	B-DNA
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
as	O
evidenced	O
by	O
an	O
increase	O
in	O
GTP-bound	B-protein
p21ras	I-protein
.	O

In	O
vitro	O
studies	O
using	O
pure	B-protein
recombinant	I-protein
p21ras	I-protein
demonstrate	O
that	O
the	O
activation	O
is	O
direct	O
and	O
reversible	O
.	O

Circular	O
dichroism	O
analysis	O
reveals	O
that	O
NO	O
induces	O
a	O
profound	O
conformational	O
change	O
in	O
p21ras	B-DNA
in	O
association	O
with	O
GDP/GTP	O
exchange	O
.	O

The	O
mechanism	O
of	O
activation	O
is	O
due	O
to	O
S-nitrosylation	O
of	O
a	O
critical	O
cysteine	O
residue	O
which	O
stimulates	O
guanine	O
nucleotide	O
exchange	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
p21ras	B-protein
is	O
essential	O
for	O
NO-induced	O
downstream	O
signaling	O
,	O
such	O
as	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
and	O
that	O
endogenous	O
NO	O
can	O
activate	O
p21ras	B-protein
in	O
the	O
same	O
cell	O
.	O

These	O
studies	O
identify	O
p21ras	B-DNA
as	O
a	O
target	O
of	O
the	O
same	O
cell	O
.	O

These	O
studies	O
identify	O
p21ras	B-DNA
as	O
a	O
target	O
of	O
NO	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
suggest	O
that	O
NO	O
activates	O
p21ras	B-DNA
by	O
an	O
action	O
which	O
mimics	O
that	O
of	O
guanine	B-protein
nucleotide	I-protein
exchange	I-protein
factors	I-protein
.	O

Interleukin-2	B-DNA
promoter	I-DNA
activity	O
in	O
Epstein-Barr	B-cell_line
virus-transformed	I-cell_line
B	I-cell_line
lymphocytes	I-cell_line
is	O
controlled	O
by	O
nuclear	B-protein
factor-chi	I-protein
B	I-protein
.	O

The	O
regulation	O
of	O
interleukin	B-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
gene	I-DNA
expression	O
has	O
been	O
investigated	O
mainly	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
the	O
predominant	O
producers	O
of	O
IL-2	B-protein
.	O

However	O
,	O
B	B-cell_type
cells	I-cell_type
can	O
also	O
synthesize	O
IL-2	B-protein
.	O

In	O
the	O
present	O
study	O
we	O
analyzed	O
the	O
control	O
of	O
IL-2	B-DNA
promoter	I-DNA
activity	O
in	O
Epstein-Barr	B-cell_line
virus	I-cell_line
(	I-cell_line
EBV	I-cell_line
)	I-cell_line
-transformed	I-cell_line
B	I-cell_line
cell	I-cell_line
clones	I-cell_line
which	O
are	O
capable	O
of	O
secreting	O
IL-2	B-protein
at	O
a	O
low	O
level	O
after	O
stimulation	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
the	O
Ca2+	O
ionophore	O
ionomycin	O
.	O

Transient	O
transfections	O
using	O
reporter	B-DNA
constructs	I-DNA
with	O
multiples	O
of	O
transcription	B-DNA
factor	I-DNA
binding	I-DNA
sites	I-DNA
from	O
the	O
IL-2	B-DNA
promoter	I-DNA
[	O
distal	B-protein
nuclear	I-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-AT	I-protein
,	O
proximal	B-protein
NF-AT	I-protein
,	O
AP-1/Octamer	B-protein
(	O
UPS	B-protein
)	O
or	O
NF-chi	B-protein
B	I-protein
(	O
TCEd	B-protein
)	O
sites	O
]	O
were	O
performed	O
.	O

In	O
EBV-transformed	B-cell_line
B	I-cell_line
clones	I-cell_line
,	O
the	O
chi	B-DNA
B	I-DNA
site	I-DNA
exerted	O
the	O
strongest	O
inducible	O
activity	O
;	O
the	O
NF-AT	B-DNA
binding	I-DNA
sites	I-DNA
showed	O
either	O
no	O
or	O
only	O
weak	O
activity	O
compared	O
to	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

An	O
IL-2	B-DNA
promoter	I-DNA
bearing	O
a	O
defective	O
NF-chi	B-DNA
B	I-DNA
site	I-DNA
was	O
completely	O
inactive	O
in	O
EBV-transformed	B-cell_line
B	I-cell_line
cells	I-cell_line
,	O
while	O
it	O
still	O
had	O
activity	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

In	O
seven	O
EBV-B	B-cell_line
cell	I-cell_line
clones	I-cell_line
or	O
lines	O
differing	O
in	O
their	O
capacity	O
to	O
secrete	O
IL-2	B-protein
,	O
the	O
activity	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
correlated	O
well	O
with	O
the	O
status	O
of	O
IL-2	B-protein
secretion	O
.	O

Similarly	O
,	O
a	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
promoter	I-DNA
,	O
whose	O
activity	O
is	O
controlled	O
through	O
chi	B-protein
B	I-protein
factors	I-protein
,	O
was	O
found	O
to	O
be	O
active	O
in	O
the	O
IL-2	B-cell_line
producing	I-cell_line
EBV-B	I-cell_line
cells	I-cell_line
,	O
but	O
inactive	O
in	O
the	O
non-IL-2-producing	B-cell_line
cells	I-cell_line
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
using	O
protein	O
extracts	O
from	O
EBV-B	B-cell_line
cells	I-cell_line
and	O
the	O
IL-2	B-protein
NF-chi	B-protein
B	I-protein
probe	O
revealed	O
the	O
constitutive	O
generation	O
of	O
chi	B-protein
B	I-protein
complexes	I-protein
in	O
IL-2-secreting	B-cell_line
cells	I-cell_line
consisting	O
mainly	O
of	O
heterodimeric	B-protein
p50/p65	I-protein
complexes	I-protein
.	O

A	O
weaker	O
chi	B-DNA
B	I-DNA
complex	O
formation	O
and	O
faster-migrating	O
complexes	O
were	O
detected	O
in	O
non-IL-2-secreting	B-cell_line
cells	I-cell_line
.	O

These	O
results	O
demonstrate	O
that	O
the	O
IL-2	B-DNA
NF-chi	I-DNA
B	I-DNA
site	I-DNA
is	O
indispensable	O
for	O
the	O
activity	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
EBV-transformed	B-cell_line
B	I-cell_line
cells	I-cell_line
,	O
whereas	O
other	O
transcription	B-protein
factors	I-protein
appear	O
to	O
be	O
less	O
important	O
for	O
IL-2	B-protein
expression	O
in	O
these	O
cells	O
.	O

Latent	B-protein
membrane	I-protein
protein-1	I-protein
induces	O
cyclin	B-protein
D2	I-protein
expression	O
,	O
pRb	B-protein
hyperphosphorylation	O
,	O
and	O
loss	O
of	O
TGF-beta	B-protein
1	I-protein
-mediated	O
growth	O
inhibition	O
in	O
EBV-positive	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

The	O
normal	O
cell	O
cycle	O
is	O
regulated	O
by	O
several	O
molecules	O
,	O
such	O
as	O
the	O
tumor-suppressor	B-protein
protein	I-protein
pRb	I-protein
,	O
the	O
G1	B-protein
cyclins	I-protein
,	O
the	O
cyclin-dependent	B-protein
kinases	I-protein
,	O
and	O
their	O
inhibitors	O
.	O

These	O
regulators	O
are	O
targeted	O
by	O
negative	O
growth	O
regulatory	O
signals	O
,	O
such	O
as	O
that	O
provided	O
by	O
TGF-beta	B-protein
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
presence	O
of	O
either	O
wild-type	O
EBV	O
or	O
its	O
transforming	B-protein
latent	I-protein
membrane	I-protein
protein-1	I-protein
(	O
LMP-1	B-protein
)	O
results	O
in	O
the	O
loss	O
of	O
TGF-beta	B-protein
1	I-protein
-mediated	O
growth	O
inhibition	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Chemical	O
cross-linking	O
with	O
125I-labeled	B-protein
TGF-beta	I-protein
1	I-protein
showed	O
an	O
essentially	O
normal	O
TGF-beta	B-protein
receptor	I-protein
profile	O
in	O
EBV-positive	B-cell_line
and	I-cell_line
EBV-negative	I-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
these	O
receptors	O
were	O
shown	O
to	O
be	O
functional	O
in	O
transducing	O
signals	O
,	O
as	O
evidenced	O
by	O
the	O
TGF-beta	B-protein
1	I-protein
-mediated	O
modulation	O
of	O
junB	B-DNA
gene	I-DNA
expression	O
.	O

However	O
,	O
TGF-beta	B-protein
1	I-protein
did	O
not	O
induce	O
dephosphorylation	O
of	O
pRb	B-protein
in	O
EBV	B-cell_line
(	I-cell_line
or	I-cell_line
LMP-1	I-cell_line
)	I-cell_line
-positive	I-cell_line
cells	I-cell_line
as	O
opposed	O
to	O
EBV-negative	B-cell_line
cells	I-cell_line
,	O
suggesting	O
a	O
dichotomy	O
in	O
the	O
TGF-beta	B-protein
1	I-protein
signaling	O
pathway	O
leading	O
to	O
separable	O
gene	O
regulatory	O
and	O
growth	O
inhibitory	O
responses	O
.	O

Furthermore	O
,	O
LMP-1	B-protein
was	O
found	O
to	O
induce	O
the	O
expression	O
of	O
cyclin	B-protein
D2	I-protein
;	O
normal	O
B	B-cell_type
cells	I-cell_type
or	O
EBV-negative	B-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
do	O
not	O
express	O
D-type	B-protein
cyclins	I-protein
.	O

Taken	O
together	O
,	O
these	O
data	O
point	O
to	O
a	O
potential	O
mechanism	O
underlying	O
EBV-mediated	O
B	O
cell	O
transformation	O
whereby	O
constitutive	O
induction	O
of	O
key	B-protein
cell	I-protein
cycle	I-protein
regulators	I-protein
by	O
LMP-1	B-protein
can	O
lead	O
to	O
pRb	B-protein
hyperphosphorylation	O
and	O
uncontrolled	O
cell	O
proliferation	O
.	O

Does	O
thyroidectomy	O
,	O
radioactive	O
iodine	O
therapy	O
,	O
or	O
antithyroid	O
drug	O
treatment	O
alter	O
reactivity	O
of	O
patients	O
'	O
T	B-cell_type
cells	I-cell_type
to	O
epitopes	O
of	O
thyrotropin	B-protein
receptor	I-protein
in	O
autoimmune	O
thyroid	O
diseases	O
?	O

The	O
effect	O
of	O
treatment	O
on	O
thyroid	O
antibody	O
production	O
and	O
T	O
cell	O
reactivity	O
to	O
thyroid	O
antigens	O
was	O
studied	O
in	O
15	O
patients	O
with	O
Graves	O
'	O
disease	O
(	O
GD	O
)	O
before	O
and	O
after	O
thyroidectomy	O
,	O
19	O
patients	O
with	O
GD	O
before	O
and	O
after	O
radioactive	O
iodine	O
(	O
RAI	O
)	O
therapy	O
,	O
and	O
9	O
patients	O
maintained	O
euthyroid	O
on	O
antithyroid	O
drugs	O
(	O
ATD	O
)	O
.	O

Twenty	O
subjects	O
matched	O
for	O
age	O
and	O
sex	O
without	O
known	O
thyroid	O
disease	O
served	O
as	O
controls	O
.	O

In	O
GD	O
patients	O
,	O
the	O
responses	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
and	O
TSH	B-cell_line
receptor	I-cell_line
(	I-cell_line
TSHR	I-cell_line
)	I-cell_line
-specific	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
to	O
recombinant	B-protein
human	I-protein
TSHR	I-protein
extracellular	I-protein
domain	I-protein
,	O
thyroglobulin	B-protein
,	O
and	O
TSHR	B-protein
peptides	O
were	O
examined	O
on	O
the	O
day	O
of	O
surgery	O
or	O
RAI	O
therapy	O
(	O
day	O
0	O
)	O
and	O
also	O
6-8	O
weeks	O
and	O
3-6	O
months	O
thereafter	O
.	O

Reactivity	O
to	O
TSHR	B-protein
peptides	O
before	O
surgery	O
was	O
heterogeneous	O
and	O
spanned	O
the	O
entire	O
extracellular	B-protein
domain	I-protein
.	O

Six	O
to	O
8	O
weeks	O
after	O
subtotal	O
thyroidectomy	O
,	O
the	O
number	O
of	O
patients	O
'	O
PBMC	B-cell_type
responding	O
to	O
any	O
peptide	O
and	O
the	O
average	O
number	O
of	O
recognized	O
peptides	O
decreased	O
.	O

A	O
further	O
decrease	O
in	O
the	O
T	O
cell	O
reactivity	O
to	O
TSHR	B-protein
peptides	O
was	O
observed	O
3-6	O
months	O
after	O
surgery	O
.	O

The	O
responses	O
of	O
PBMC	B-cell_type
from	O
Graves	O
'	O
patients	O
before	O
RAI	O
therapy	O
were	O
less	O
than	O
those	O
in	O
the	O
presurgical	O
group	O
.	O

Six	O
to	O
8	O
weeks	O
after	O
RAI	O
therapy	O
,	O
the	O
number	O
of	O
patients	O
responding	O
to	O
any	O
peptide	O
and	O
the	O
average	O
number	O
of	O
recognized	O
peptides	O
increased	O
.	O

Three	O
to	O
6	O
months	O
after	O
RAI	O
,	O
T	O
cell	O
responses	O
to	O
TSHR	B-protein
peptides	O
were	O
less	O
than	O
those	O
6-8	O
weeks	O
after	O
RAI	O
therapy	O
,	O
but	O
still	O
higher	O
than	O
the	O
values	O
on	O
day	O
0	O
.	O

Responses	O
of	O
PBMC	B-cell_type
from	O
patients	O
with	O
GD	O
,	O
maintained	O
euthyroid	O
on	O
ATD	O
,	O
were	O
lower	O
than	O
those	O
before	O
surgery	O
or	O
RAI	O
therapy	O
.	O

The	O
reactivity	O
of	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
different	O
groups	O
reflected	O
a	O
pattern	O
similar	O
to	O
PBMC	B-cell_type
after	O
treatment	O
.	O

TSHR	B-protein
antibody	I-protein
and	O
microsomal	B-protein
antibody	I-protein
levels	O
decreased	O
after	O
surgery	O
,	O
but	O
increased	O
after	O
RAI	O
therapy	O
.	O

The	O
difference	O
in	O
the	O
number	O
of	O
recognized	O
peptides	O
by	O
patients	O
'	O
PBMC	B-cell_type
before	O
RAI	O
and	O
surgery	O
may	O
reflect	O
the	O
effect	O
of	O
long	O
term	O
therapy	O
with	O
ATD	O
in	O
the	O
patients	O
before	O
RAI	O
vs.	O
the	O
shorter	O
period	O
in	O
patients	O
before	O
surgery	O
.	O

The	O
decreased	O
T	O
cell	O
reactivity	O
to	O
thyroid	B-protein
antigens	I-protein
after	O
thyroidectomy	O
could	O
be	O
the	O
result	O
of	O
removal	O
of	O
a	O
major	O
part	O
of	O
the	O
thyroid	O
gland	O
or	O
redistribution	O
of	O
suppressor-inducer	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
increased	O
T	O
cell	O
response	O
after	O
RAI	O
therapy	O
is	O
probably	O
epitope	O
specific	O
,	O
rather	O
than	O
a	O
response	O
to	O
the	O
whole	O
TSHR	B-protein
molecule	O
.	O

Synchronous	O
recognition	O
of	O
peptides	O
158-176	O
and	O
248-263	O
is	O
important	O
for	O
the	O
development	O
of	O
GD	O
,	O
and	O
the	O
loss	O
of	O
recognition	O
of	O
one	O
of	O
these	O
epitopes	B-protein
may	O
be	O
an	O
early	O
sign	O
of	O
immune	O
remission	O
and	O
a	O
predictor	O
of	O
euthyroidism	O
.	O

Circumvention	O
of	O
tolerance	O
for	O
the	O
nuclear	B-protein
T	I-protein
cell	I-protein
protein	I-protein
TCF-1	B-protein
by	O
immunization	O
of	O
TCF-1	B-protein
knock-out	O
mice	O
.	O

Molecular	O
events	O
that	O
underlie	O
the	O
well-defined	O
phenotypic	O
changes	O
of	O
the	O
differentiating	B-cell_type
thymocyte	I-cell_type
are	O
poorly	O
understood	O
.	O

A	O
candidate	O
gene	O
to	O
control	O
thymocyte	B-cell_type
differentiation	O
,	O
T	B-protein
cell	I-protein
factor-1	I-protein
(	O
TCF-1	B-protein
)	O
*	O
encodes	O
a	O
DNA-binding	B-protein
protein	I-protein
.	O

Its	O
mRNA	O
expression	O
pattern	O
is	O
complex	O
during	O
embryogenesis	O
,	O
yet	O
restricted	O
to	O
lymphocytes	B-cell_type
postnatally	O
.	O

Expression	O
studies	O
on	O
TCF-1	B-protein
protein	I-protein
have	O
been	O
hampered	O
by	O
the	O
difficulty	O
to	O
raise	O
antibodies	B-protein
due	O
to	O
extreme	O
evolutionary	O
conservation	O
.	O

TCF-1	B-protein
knock-out	O
mice	O
,	O
generated	O
recently	O
in	O
our	O
laboratory	O
,	O
have	O
strongly	O
decreased	O
numbers	O
of	O
thymocytes	B-cell_type
,	O
but	O
are	O
otherwise	O
normal	O
.	O

We	O
have	O
used	O
these	O
mice	O
to	O
generate	O
anti-TCF-1	B-protein
antibodies	I-protein
.	O

By	O
immunization	O
with	O
a	O
recombinant	B-protein
fusion	I-protein
protein	I-protein
,	O
we	O
show	O
that	O
TCF-1	B-protein
knock-out	O
mice	O
readily	O
yield	O
antiserum	O
titers	O
against	O
human	O
and	O
mouse	O
TCF-1	O
protein	O
.	O

Wild-type	O
littermates	O
remain	O
unresponsive	O
to	O
TCF-1	B-protein
while	O
they	O
mount	O
a	O
high-titer	O
antibody	O
response	O
to	O
the	O
fusion	B-protein
protein	I-protein
,	O
Maltose	B-protein
Binding	I-protein
Protein	I-protein
(	O
MBP	B-protein
)	O
.	O

Subsequently	O
,	O
TCF-1-specific	B-cell_line
hybridomas	I-cell_line
could	O
be	O
prepared	O
from	O
the	O
spleens	O
of	O
immunized	O
knock-out	O
mice	O
.	O

This	O
study	O
illustrates	O
the	O
almost	O
complete	O
tolerance	O
of	O
mice	O
for	O
human	B-protein
TCF-1	I-protein
and	O
demonstrates	O
that	O
this	O
tolerance	O
is	O
readily	O
broken	O
by	O
gene	O
knock-out	O
.	O

Furthermore	O
,	O
the	O
usefulness	O
of	O
knock-out	O
mice	O
for	O
the	O
generation	O
of	O
monoclonal	B-protein
antibodies	I-protein
against	O
the	O
gene	O
product	O
of	O
interest	O
is	O
underscored	O
.	O

The	O
transcription	B-protein
factor	I-protein
,	O
Nm23H2	B-protein
,	O
binds	O
to	O
and	O
activates	O
the	O
translocated	O
c-myc	B-DNA
allele	I-DNA
in	O
Burkitt	O
's	O
lymphoma	O
.	O

We	O
have	O
identified	O
an	O
in	O
vivo	O
footprint	O
over	O
the	O
PuF	B-DNA
site	I-DNA
on	O
the	O
translocated	O
c-myc	B-DNA
allele	I-DNA
in	O
Burkitt	O
's	O
lymphoma	O
cells	O
.	O

The	O
PuF	B-DNA
site	I-DNA
on	O
the	O
silent	B-DNA
normal	I-DNA
c-myc	I-DNA
allele	I-DNA
was	O
unoccupied	O
.	O

We	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
electrophoretic	O
mobility	O
shift	O
assay	O
with	O
antibody	O
,	O
UV	O
cross-linking	O
followed	O
by	O
SDS-gel	O
electrophoresis	O
,	O
and	O
Western	O
analysis	O
that	O
Nm23H2	B-protein
in	O
B	O
cell	O
nuclear	O
extracts	O
bound	O
to	O
the	O
c-myc	O
PuF	B-DNA
site	I-DNA
.	O

Transfection	O
experiments	O
with	O
c-myc	B-DNA
promoter	I-DNA
constructs	I-DNA
in	O
both	O
DHL-9	B-cell_line
and	O
Raji	B-cell_line
cells	I-cell_line
revealed	O
that	O
the	O
PuF	B-DNA
site	I-DNA
functioned	O
as	O
a	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
with	O
a	O
drop	O
in	O
activity	O
with	O
mutation	O
of	O
this	O
site	O
.	O

Access	O
to	O
this	O
site	O
is	O
blocked	O
in	O
the	O
normal	B-DNA
silent	I-DNA
c-myc	I-DNA
allele	I-DNA
;	O
these	O
data	O
suggest	O
that	O
the	O
Nm23H2	B-protein
protein	O
is	O
involved	O
in	O
deregulation	O
of	O
the	O
translocated	O
c-myc	B-DNA
allele	I-DNA
in	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
.	O

Identification	O
of	O
two	O
novel	O
regulatory	B-DNA
elements	I-DNA
within	O
the	O
5'-untranslated	B-DNA
region	I-DNA
of	O
the	O
human	B-DNA
A	I-DNA
gamma-globin	I-DNA
gene	I-DNA
.	O

Interaction	O
between	O
the	O
stage	B-DNA
selector	I-DNA
element	I-DNA
(	O
SSE	O
)	O
in	O
the	O
proximal	B-DNA
gamma-globin	I-DNA
promoter	I-DNA
and	O
hypersensitivity	B-DNA
site	I-DNA
2	I-DNA
in	O
the	O
locus	B-DNA
control	I-DNA
region	I-DNA
partly	O
mediates	O
the	O
competitive	O
silencing	O
of	O
the	O
beta-globin	B-DNA
promoter	I-DNA
in	O
the	O
fetal	O
developmental	O
stage	O
.	O

We	O
have	O
now	O
demonstrated	O
that	O
a	O
second	O
SSE-like	B-DNA
element	I-DNA
in	O
the	O
5'-untranslated	B-DNA
region	I-DNA
of	O
the	O
gamma-gene	B-DNA
also	O
contributes	O
to	O
this	O
competitive	O
silencing	O
of	O
the	O
beta-gene	B-DNA
.	O

Utilizing	O
transient	O
transfection	O
assays	O
in	O
the	O
fetal	B-cell_line
erythroid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
K562	B-cell_line
,	O
we	O
have	O
shown	O
that	O
the	O
core	B-DNA
enhancer	I-DNA
of	O
hypersensitivity	B-DNA
site	I-DNA
2	I-DNA
can	O
preferentially	O
interact	O
with	O
the	O
proximal	B-DNA
gamma-promoter	I-DNA
in	O
the	O
absence	O
of	O
the	O
SSE	B-DNA
,	O
completely	O
silencing	O
a	O
linked	B-DNA
beta-promoter	I-DNA
.	O

Mutation	O
of	O
a	O
20-base	O
pair	O
sequence	O
of	O
the	O
gamma-gene	B-DNA
5'-untranslated	I-DNA
region	I-DNA
(	O
UTR	B-DNA
)	O
led	O
to	O
derepression	O
of	O
beta-promoter	B-DNA
activity	O
.	O

A	O
marked	O
activation	O
of	O
gamma-promoter	B-DNA
activity	O
was	O
also	O
observed	O
with	O
this	O
mutation	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
repressor	O
.	O

Fine	O
mutagenesis	O
dissected	O
these	O
activities	O
to	O
different	O
regions	O
of	O
the	O
5'-UTR	B-DNA
.	O

The	O
stage	O
selector	O
activity	O
was	O
localized	O
to	O
a	O
region	O
centered	O
on	O
nucleotides	B-DNA
+13	I-DNA
to	I-DNA
+15	I-DNA
.	O

Electromobility	O
shift	O
assays	O
utilizing	O
this	O
sequence	O
demonstrated	O
binding	O
of	O
a	O
fetal	B-protein
and	I-protein
erythroid-specific	I-protein
protein	I-protein
.	O

The	O
repressor	O
activity	O
of	O
the	O
5'-UTR	B-DNA
was	O
localized	O
to	O
tandem	O
GATA-like	B-DNA
sites	I-DNA
,	O
which	O
appear	O
to	O
bind	O
a	O
complex	O
of	O
two	O
proteins	O
,	O
one	O
of	O
which	O
is	O
the	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
GATA-1	B-protein
.	O

These	O
results	O
indicate	O
that	O
the	O
5'-UTR	B-DNA
of	O
the	O
gamma-gene	B-DNA
contains	O
sequences	O
that	O
may	O
be	O
important	O
for	O
its	O
transcriptional	O
and	O
developmental	O
regulation	O
.	O

Coupling	O
of	O
a	O
signal	B-protein
response	I-protein
domain	I-protein
in	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
to	O
multiple	O
pathways	O
for	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

The	O
eukaryotic	B-protein
transcription	I-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
plays	O
a	O
central	O
role	O
in	O
the	O
induced	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
in	O
many	O
aspects	O
of	O
the	O
genetic	O
program	O
mediating	O
normal	O
T-cell	O
activation	O
and	O
growth	O
.	O

The	O
nuclear	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
is	O
tightly	O
regulated	O
from	O
the	O
cytoplasmic	O
compartment	O
by	O
an	O
inhibitory	B-protein
subunit	I-protein
called	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

This	O
cytoplasmic	O
inhibitor	O
is	O
rapidly	O
phosphorylated	O
and	O
degraded	O
in	O
response	O
to	O
a	O
diverse	O
set	O
of	O
NF-kappa	B-protein
B-inducing	I-protein
agents	I-protein
,	O
including	O
T-cell	B-protein
mitogens	I-protein
,	I-protein
proinflammatory	B-protein
cytokines	I-protein
,	O
and	O
viral	B-protein
transactivators	I-protein
such	O
as	O
the	O
Tax	B-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
.	O

To	O
explore	O
these	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
-dependent	O
mechanisms	O
for	O
NF-kappa	B-protein
B	I-protein
induction	O
,	O
we	O
identified	O
novel	O
mutants	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
that	O
uncouple	O
its	O
inhibitory	O
and	O
signal-transducing	O
functions	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Specifically	O
,	O
removal	O
of	O
the	O
N-terminal	B-protein
36	I-protein
amino	I-protein
acids	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
failed	O
to	O
disrupt	O
its	O
ability	O
to	O
form	O
latent	O
complexes	O
with	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
cytoplasm	O
.	O

However	O
,	O
this	O
deletion	O
mutation	O
prevented	O
the	O
induced	O
phosphorylation	O
,	O
degradative	O
loss	O
,	O
and	O
functional	O
release	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
from	O
NF-kappa	B-protein
B	I-protein
in	O
Tax-expressing	B-cell_line
cells	I-cell_line
.	O

Alanine	O
substitutions	O
introduced	O
at	O
two	O
serine	O
residues	O
positioned	O
within	O
this	O
N-terminal	B-protein
regulatory	I-protein
region	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
also	O
yielded	O
constitutive	O
repressors	O
that	O
escaped	O
from	O
Tax	B-protein
-induced	O
turnover	O
and	O
that	O
potently	O
inhibited	O
immune	O
activation	O
pathways	O
for	O
NF-kappa	B-protein
B	I-protein
induction	O
,	O
including	O
those	O
initiated	O
from	O
antigen	B-protein
and	I-protein
cytokine	I-protein
receptors	I-protein
.	O

In	O
contrast	O
,	O
introduction	O
of	O
a	O
phosphoserine	O
mimetic	O
at	O
these	O
sites	O
rectified	O
this	O
functional	O
defect	O
,	O
a	O
finding	O
consistent	O
with	O
a	O
causal	O
linkage	O
between	O
the	O
phosphorylation	O
status	O
and	O
proteolytic	O
stability	O
of	O
this	O
cytoplasmic	B-protein
inhibitor	I-protein
.	O

Together	O
,	O
these	O
in	O
vivo	O
studies	O
define	O
a	O
critical	O
signal	O
response	O
domain	O
in	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
that	O
coordinately	O
controls	O
the	O
biologic	O
activities	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
NF-kappa	B-protein
B	I-protein
in	O
response	O
to	O
viral	O
and	O
immune	O
stimuli	O
.	O

Growth	O
regulation	O
and	O
cellular	O
changes	O
during	O
differentiation	O
of	O
human	B-cell_line
prostatic	I-cell_line
cancer	I-cell_line
LNCaP	I-cell_line
cells	I-cell_line
as	O
induced	O
by	O
T	O
lymphocyte-conditioned	O
medium	O
.	O

Human	B-cell_line
prostatic	I-cell_line
epithelial	I-cell_line
cells	I-cell_line
from	O
an	O
androgen-dependent	B-cell_line
LNCaP	I-cell_line
cell	I-cell_line
line	I-cell_line
were	O
examined	O
in	O
response	O
to	O
conditioned	O
medium	O
(	O
CM	O
)	O
derived	O
from	O
phytohemagglutinin	B-cell_line
(	I-cell_line
PHA	I-cell_line
)	I-cell_line
-stimulated	I-cell_line
lymphocytes	I-cell_line
.	O

Addition	O
of	O
CM	O
caused	O
a	O
greater	O
than	O
70	O
%	O
reduction	O
of	O
cell	O
proliferation	O
by	O
cell	O
counting	O
and	O
cell	O
cycle	O
.	O

These	O
cells	O
showed	O
G1	O
phase	O
arrest	O
and	O
the	O
clonogenicity	O
was	O
reduced	O
.	O

The	O
growth-modulating	O
effect	O
was	O
dose-dependent	O
and	O
not	O
due	O
to	O
cell	O
lysis	O
or	O
apoptosis	O
.	O

The	O
binding	O
of	O
androgen	O
to	O
androgen	B-protein
receptor	I-protein
on	O
these	O
cells	O
showed	O
approximately	O
50	O
%	O
reduction	O
,	O
underlining	O
a	O
proliferation	O
reduction	O
mechanism	O
.	O

The	O
prostate-specific	B-protein
antigen	I-protein
(	O
PSA	B-protein
)	O
was	O
downregulated	O
to	O
approximately	O
75	O
%	O
during	O
the	O
process	O
.	O

Cell	O
morphology	O
showed	O
dendritic	O
processes	O
extending	O
from	O
cytoplasm	O
and	O
other	O
neuroendocrine	B-cell_type
cell	I-cell_type
characteristics	O
.	O

The	O
expression	O
of	O
several	O
cytoskeleton	B-protein
and	I-protein
intracellular	I-protein
proteins	I-protein
increased	O
as	O
determined	O
by	O
immunostaining	O
on	O
slides	O
and	O
by	O
ELISA	O
procedures	O
.	O

These	O
included	O
vimentin	B-protein
,	O
correlating	O
to	O
cell	O
shape	O
changes	O
,	O
cytokeratins	B-protein
8	I-protein
and	I-protein
18	I-protein
,	O
associated	O
with	O
differentiated	B-cell_type
cell	I-cell_type
types	I-cell_type
of	O
prostate	O
epithelia	O
,	O
and	O
neuron-specific	B-protein
enolase	I-protein
and	O
serotonin	O
,	O
associated	O
with	O
neuroendocrine	B-cell_type
cells	I-cell_type
.	O

From	O
these	O
cellular	O
changes	O
,	O
we	O
can	O
infer	O
that	O
the	O
cell	O
growth	O
was	O
modulated	O
along	O
with	O
induction	O
of	O
terminal	O
differentiation	O
.	O

Activated	O
T	B-cell_type
cells	I-cell_type
were	O
demonstrated	O
to	O
be	O
important	O
in	O
providing	O
the	O
modulating	O
activity	O
.	O

This	O
growth	B-protein
modulator	I-protein
was	O
semipurified	O
and	O
had	O
an	O
estimated	O
molecular	O
weight	O
13	O
,	O
000	O
to	O
24	O
,	O
000	O
Da	O
.	O

The	O
activity	O
was	O
determined	O
to	O
be	O
distinct	O
from	O
TGF	B-protein
,	O
TNF	B-protein
,	O
and	O
some	O
commonly	O
known	O
lymphokines	B-protein
.	O

The	O
interaction	O
between	O
lymphoid	B-cell_type
and	I-cell_type
prostatic	I-cell_type
cells	I-cell_type
in	O
growth	O
and	O
development	O
is	O
described	O
.	O

Platelet-activating	B-protein
factor	I-protein
stimulates	O
transcription	O
of	O
the	O
heparin-binding	B-protein
epidermal	I-protein
growth	I-protein
factor-like	I-protein
growth	I-protein
factor	I-protein
in	O
monocytes	B-cell_type
.	O

Correlation	O
with	O
an	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O

Human	O
peripheral	O
blood	O
monocytes	B-cell_type
responded	O
to	O
stimulation	O
of	O
platelet-activating	B-protein
factor	I-protein
(	O
PAF	B-protein
)	O
with	O
up-regulation	O
of	O
the	O
transcript	O
for	O
heparin-binding	B-protein
epidermal	I-protein
growth	I-protein
factor-like	I-protein
growth	I-protein
factor	I-protein
(	O
HB-EGF	B-protein
)	O
,	O
a	O
potent	B-protein
mitogen	I-protein
for	O
vascular	B-cell_type
smooth	I-cell_type
muscle	I-cell_type
cells	I-cell_type
.	O

This	O
function	O
of	O
PAF	B-protein
was	O
observed	O
at	O
nanomolar	O
concentrations	O
of	O
the	O
ligand	O
,	O
starting	O
at	O
30	O
min	O
after	O
stimulation	O
.	O

The	O
PAF	B-protein
-induced	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
was	O
accompanied	O
by	O
an	O
increase	O
in	O
kappa	O
B	O
binding	O
activity	O
.	O

These	O
functions	O
of	O
PAF	B-protein
appeared	O
to	O
be	O
mediated	O
through	O
the	O
cell	B-protein
surface	I-protein
PAF	I-protein
receptors	I-protein
,	O
as	O
two	O
PAF	B-protein
receptor	O
antagonists	O
,	O
WEB	O
2086	O
and	O
L-659	O
,	O
989	O
,	O
blocked	O
both	O
the	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
and	O
kappa	O
B	O
binding	O
activity	O
induced	O
by	O
PAF	B-protein
.	O

The	O
antagonists	O
,	O
however	O
,	O
had	O
no	O
effect	O
on	O
phorbol	O
ester-induced	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
and	O
kappa	O
B	O
binding	O
activity	O
.	O

Pretreatment	O
of	O
monocytes	B-cell_type
with	O
pertussis	O
toxin	O
inhibited	O
these	O
functions	O
of	O
PAF	B-protein
,	O
whereas	O
cholera	O
toxin	O
had	O
no	O
inhibitory	O
effect	O
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
an	O
inhibitor	O
for	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
markedly	O
reduced	O
PAF	B-protein
-stimulated	O
kappa	O
B	O
binding	O
activity	O
as	O
well	O
as	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
.	O

These	O
results	O
suggest	O
a	O
potential	O
role	O
of	O
PAF	B-protein
in	O
HB-EGF	B-protein
expression	O
and	O
provide	O
evidence	O
that	O
this	O
stimulation	O
may	O
occur	O
through	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O

Mapping	O
of	O
the	O
interaction	B-protein
site	I-protein
of	O
the	O
defective	B-protein
transcription	I-protein
factor	I-protein
in	O
the	O
class	B-cell_line
II	I-cell_line
major	I-cell_line
histocompatibility	I-cell_line
complex	I-cell_line
mutant	I-cell_line
cell	I-cell_line
line	I-cell_line
clone-13	I-cell_line
to	O
the	O
divergent	B-DNA
X2-box	I-DNA
.	O

We	O
have	O
previously	O
described	O
a	O
mutant	B-cell_line
B	I-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Clone-13	B-cell_line
,	I-cell_line
that	O
expresses	O
HLA-DQ	B-protein
in	O
the	O
absence	O
of	O
HLA-DR	B-protein
and	I-protein
-DP	I-protein
.	O

Several	O
criteria	O
indicated	O
that	O
the	O
defect	O
in	O
this	O
cell	O
line	O
influences	O
the	O
activity	O
of	O
an	O
isotype-specific	B-protein
transcription	I-protein
factor	I-protein
.	O

Indeed	O
,	O
transient	O
transfection	O
of	O
HLA-DRA	B-DNA
and	I-DNA
DQB	I-DNA
reporter	I-DNA
constructs	I-DNA
indicated	O
that	O
the	O
affected	O
factor	O
operates	O
via	O
cis-elements	B-DNA
located	O
between	O
-141	B-DNA
base	I-DNA
pairs	I-DNA
and	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O

A	O
series	O
of	O
hybrid	B-DNA
DRA/DQB	I-DNA
reporter	I-DNA
constructs	I-DNA
was	O
generated	O
to	O
further	O
map	O
the	O
relevant	O
cis-elements	B-DNA
in	O
this	O
system	O
.	O

Insertion	O
of	O
oligonucleotides	O
spanning	O
the	O
DQB	B-DNA
X-box	I-DNA
(	O
but	O
not	O
the	O
DQB-W	B-DNA
region	I-DNA
or	O
the	O
DQB	B-DNA
Y-box	I-DNA
)	O
upstream	B-DNA
of	I-DNA
-141	I-DNA
in	O
a	O
DRA	B-DNA
reporter	I-DNA
plasmid	I-DNA
rescued	O
expression	O
to	O
nearly	O
wild-type	O
levels	O
.	O

Substitution	O
promoters	O
were	O
then	O
generated	O
where	O
the	O
entire	O
X-box	B-DNA
,	O
or	O
only	O
the	O
X1-	B-DNA
or	I-DNA
X2-boxes	I-DNA
of	O
HLA-DRA	B-DNA
were	O
replaced	O
with	O
the	O
analogous	O
regions	O
of	O
HLA-DQB	B-DNA
.	O

The	O
DQB	B-DNA
X2-box	I-DNA
was	O
able	O
to	O
restore	O
expression	O
to	O
the	O
silent	B-DNA
DRA	I-DNA
reporter	I-DNA
construct	I-DNA
.	O

Moreover	O
,	O
replacement	O
of	O
the	O
DQB	B-DNA
X2-box	I-DNA
with	O
the	O
DRA	B-DNA
X2-box	I-DNA
markedly	O
diminished	O
the	O
activity	O
of	O
the	O
DQB	B-DNA
promoter	I-DNA
in	O
the	O
mutant	B-cell_line
cell	I-cell_line
.	O

None	O
of	O
the	O
hybrid	B-DNA
reporter	I-DNA
constructs	I-DNA
were	O
defective	O
when	O
transfected	O
into	O
the	O
wild-type	B-protein
,	O
HLA-DR/-DQ	B-cell_line
positive	I-cell_line
parental	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Jijoye	B-cell_line
.	O

These	O
studies	O
suggest	O
that	O
the	O
divergent	B-DNA
X2-box	I-DNA
of	O
the	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
promoters	I-DNA
plays	O
an	O
important	O
role	O
in	O
influencing	O
differential	O
expression	O
of	O
the	O
human	B-DNA
class	I-DNA
II	I-DNA
isotypes	I-DNA
.	O

Restoration	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
ZEBRA	I-protein
protein	I-protein
's	O
capacity	O
to	O
disrupt	O
latency	O
by	O
the	O
addition	O
of	O
heterologous	B-protein
activation	I-protein
regions	I-protein
.	O

The	O
ZEBRA	B-protein
protein	I-protein
has	O
a	O
unique	O
biological	O
function	O
among	O
herpesviral	B-protein
proteins	I-protein
.	O

It	O
is	O
responsible	O
for	O
the	O
disruption	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
latency	O
and	O
the	O
induction	O
of	O
the	O
lytic	O
cycle	O
.	O

ZEBRA	B-protein
is	O
a	O
bZIP	B-protein
transcriptional	I-protein
activator	I-protein
which	O
binds	O
as	O
a	O
dimer	O
to	O
7-bp	B-DNA
response	I-DNA
elements	I-DNA
within	O
EBV	B-DNA
promoters	I-DNA
and	O
is	O
directly	O
involved	O
in	O
the	O
stimulation	O
of	O
virus	O
replication	O
at	O
the	O
EBV	B-DNA
lytic	I-DNA
origin	I-DNA
.	O

We	O
have	O
employed	O
the	O
ZEBRA	B-protein
/EBV	O
biological	O
system	O
to	O
test	O
whether	O
a	O
heterologous	B-protein
activation	I-protein
domain	I-protein
can	O
substitute	O
for	O
another	O
activation	O
domain	O
(	O
the	O
ZEBRA	B-protein
domain	I-protein
)	O
.	O

The	O
ZEBRA	B-protein
activation	I-protein
region	I-protein
was	O
replaced	O
with	O
the	O
potent	O
acid	B-protein
activation	I-protein
region	I-protein
from	O
the	O
herpes	B-protein
simplex	I-protein
virus	I-protein
VP16	I-protein
protein	I-protein
or	O
with	O
the	O
activation	B-protein
region	I-protein
of	O
the	O
EBV	B-protein
R	I-protein
protein	I-protein
.	O

Both	O
chimeras	O
were	O
found	O
to	O
transactivate	O
model	O
and	O
native	O
promoters	O
at	O
equivalent	O
or	O
better	O
levels	O
than	O
ZEBRA	B-protein
itself	O
.	O

Activation	O
was	O
not	O
target-	O
or	O
cell-type	O
dependent	O
,	O
nor	O
was	O
it	O
dependent	O
on	O
the	O
presence	O
of	O
virus	O
.	O

These	O
activation	O
domains	O
restored	O
ZEBRA	B-protein
's	O
ability	O
to	O
induce	O
early	B-protein
antigen	I-protein
and	O
to	O
stimulate	O
origin	O
replication	O
to	O
levels	O
that	O
were	O
equal	O
to	O
or	O
greater	O
than	O
those	O
of	O
wild	O
type	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
specificities	O
of	O
some	O
of	O
the	O
known	O
biological	O
functions	O
of	O
ZEBRA	B-protein
are	O
not	O
dependent	O
upon	O
the	O
nature	O
of	O
the	O
activation	B-protein
domain	I-protein
present	I-protein
within	O
ZEBRA	B-protein
.	O

Interleukin	B-protein
4	I-protein
activates	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B-protein
(	I-protein
Stat	I-protein
)	I-protein
protein	I-protein
which	O
interacts	O
with	O
an	O
interferon-gamma	B-DNA
activation	I-DNA
site-like	I-DNA
sequence	I-DNA
upstream	O
of	O
the	O
I	B-DNA
epsilon	I-DNA
exon	I-DNA
in	O
a	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Evidence	O
for	O
the	O
involvement	O
of	O
Janus	B-protein
kinase	I-protein
3	I-protein
and	O
interleukin-4	B-protein
Stat	I-protein
.	O

Germ	B-RNA
line	I-RNA
C	I-RNA
transcripts	I-RNA
can	O
be	O
induced	O
by	O
IL-4	B-protein
in	O
the	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
BL-2	B-cell_line
.	O

Utilizing	O
a	O
IFN-gamma	B-DNA
activation	I-DNA
site-like	I-DNA
DNA	I-DNA
sequence	I-DNA
element	I-DNA
located	O
upstream	O
of	O
the	O
I	B-DNA
epsilon	I-DNA
exon	I-DNA
,	O
we	O
demonstrated	O
by	O
gel	O
mobility	O
shift	O
assays	O
that	O
IL-4	B-protein
induced	O
a	O
binding	O
activity	O
in	O
the	O
cytosol	O
and	O
nucleus	O
of	O
BL-2	B-cell_line
cells	I-cell_line
.	O

This	O
factor	O
was	O
designated	O
IL-4	B-protein
NAF	I-protein
(	O
IL-4-induced	B-protein
nuclear-activating	I-protein
factors	I-protein
)	O
and	O
was	O
identified	O
as	O
a	O
tyrosine	B-protein
phosphoprotein	I-protein
,	O
which	O
translocates	O
from	O
the	O
cytosol	O
to	O
the	O
nucleus	O
upon	O
IL-4	B-protein
treatment	O
.	O

Because	O
these	O
are	O
the	O
characteristics	O
of	O
a	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
Stat	I-protein
)	I-protein
protein	I-protein
,	O
we	O
determined	O
whether	O
antibodies	B-protein
to	I-protein
Stat	I-protein
proteins	I-protein
will	O
interfere	O
with	O
gel	O
mobility	O
shift	O
and	O
found	O
that	O
antibodies	B-protein
to	I-protein
IL-4	I-protein
Stat	I-protein
,	O
also	O
known	O
as	O
Stat6	B-protein
,	O
but	O
not	O
antibodies	B-protein
to	O
other	O
Stat	B-protein
proteins	I-protein
,	O
interfere	O
with	O
the	O
formation	O
of	O
the	O
IL-4	B-protein
NAF	I-protein
complex	I-protein
.	O

Congruous	O
with	O
the	O
involvement	O
of	O
a	O
Stat	B-protein
protein	I-protein
,	O
IL-4	B-protein
induced	O
robust	O
Janus	B-protein
kinase	I-protein
3	I-protein
(	O
JAK3	B-protein
)	O
activity	O
in	O
BL-2	B-cell_line
cells	I-cell_line
.	O

Cotransfection	O
of	O
JAK3	B-protein
with	O
IL-4	B-protein
Stat	I-protein
into	O
COS-7	B-cell_line
cells	I-cell_line
produced	O
an	O
intracellular	O
activity	O
which	O
bound	O
the	O
same	O
IFN-gamma	B-DNA
activation	I-DNA
site-like	I-DNA
sequence	I-DNA
and	O
comigrated	O
with	O
IL-4	B-protein
NAF	I-protein
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

These	O
results	O
show	O
that	O
IL-4	B-protein
NAF	I-protein
is	O
IL-4	B-protein
Stat	I-protein
,	O
which	O
is	O
activated	O
by	O
JAK3	B-protein
in	O
response	O
to	O
IL-4	B-protein
receptor	O
engagement	O
.	O

Does	O
activation	O
of	O
the	O
TAL1	B-DNA
gene	I-DNA
occur	O
in	O
a	O
majority	O
of	O
patients	O
with	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
?	O
A	O
pediatric	O
oncology	O
group	O
study	O
.	O

Almost	O
25	O
%	O
of	O
patients	O
with	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T-ALL	O
)	O
have	O
tumor-specific	O
rearrangements	O
of	O
the	O
TAL1	B-DNA
gene	I-DNA
.	O

Although	O
TAL1	B-protein
expression	O
has	O
not	O
been	O
observed	O
in	O
normal	B-cell_type
lymphocytes	I-cell_type
,	O
TAL1	B-protein
gene	I-protein
products	I-protein
are	O
readily	O
detected	O
in	O
leukemic	B-cell_type
cells	I-cell_type
that	O
harbor	O
a	O
rearranged	B-DNA
TAL1	I-DNA
allele	I-DNA
.	O

Hence	O
,	O
it	O
has	O
been	O
proposed	O
that	O
ectopic	O
expression	O
of	O
TAL1	B-protein
promotes	O
the	O
development	O
of	O
T-ALL	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
TAL1	B-protein
is	O
expressed	O
in	O
the	O
leukemic	B-cell_type
cells	I-cell_type
of	O
most	O
patients	O
with	O
T-ALL	O
,	O
including	O
many	O
that	O
do	O
not	O
display	O
an	O
apparent	O
TAL1	B-DNA
gene	I-DNA
alteration	O
.	O

A	O
polymorphic	O
dinucleotide	O
repeat	O
in	O
the	O
transcribed	O
sequences	O
of	O
TAL1	B-protein
was	O
used	O
to	O
determine	O
the	O
allele	O
specificity	O
of	O
TAL1	B-protein
transcription	O
in	O
primary	B-cell_type
T-ALL	I-cell_type
cells	I-cell_type
.	O

Monoallelic	O
expression	O
of	O
TAL1	B-protein
was	O
observed	O
in	O
the	O
leukemic	B-cell_type
cells	I-cell_type
of	O
all	O
patients	O
(	O
8	O
of	O
8	O
)	O
bearing	O
a	O
TAL1	B-DNA
gene	I-DNA
rearrangement	O
.	O

In	O
the	O
leukemic	B-cell_type
cells	I-cell_type
of	O
patients	O
without	O
detectable	O
TAL1	B-protein
rearrangements	O
,	O
TAL1	B-protein
transcription	O
occurred	O
in	O
either	O
a	O
monoallelic	O
(	O
3	O
of	O
7	O
patients	O
)	O
or	O
a	O
biallelic	O
(	O
4	O
of	O
7	O
patients	O
)	O
fashion	O
.	O

Thus	O
,	O
TAL1	B-protein
activation	O
in	O
these	O
patients	O
may	O
result	O
from	O
subtle	O
alterations	O
in	O
cis-acting	B-DNA
regulatory	I-DNA
sequences	I-DNA
(	O
affecting	O
expression	O
of	O
a	O
single	B-DNA
TAL1	I-DNA
allele	I-DNA
)	O
or	O
changes	O
in	O
trans-acting	O
factors	O
that	O
control	O
TAL1	B-protein
transcription	O
(	O
affecting	O
expression	O
of	O
both	O
TAL1	B-DNA
alleles	I-DNA
)	O
.	O

Expression	O
of	O
erythroid-specific	B-DNA
genes	I-DNA
in	O
acute	O
megakaryoblastic	O
leukaemia	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
's	O
syndrome	O
.	O

Acute	O
megakaryoblastic	O
leukaemia	O
(	O
M7	O
)	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
's	O
syndrome	O
(	O
TMD	O
)	O
are	O
characterized	O
by	O
rapid	O
growth	O
of	O
abnormal	B-cell_type
blast	I-cell_type
cells	I-cell_type
which	O
express	O
megakaryocytic	B-protein
markers	I-protein
.	O

To	O
clarify	O
properties	O
of	O
the	O
blast	B-cell_type
cells	I-cell_type
in	O
M7	O
and	O
TMD	O
cases	O
,	O
we	O
examined	O
erythroid	O
markers	O
expression	O
in	O
blasts	B-cell_type
from	O
six	O
cases	O
with	O
M7	O
and	O
seven	O
cases	O
with	O
TMD	O
in	O
this	O
study	O
.	O

Erythroid-specific	B-RNA
mRNAs	I-RNA
encoding	O
gamma-globin	B-protein
and	O
erythroid	B-protein
delta-aminolevulinate	I-protein
synthase	I-protein
were	O
found	O
to	O
be	O
expressed	O
in	O
blasts	B-cell_type
from	O
most	O
of	O
these	O
cases	O
,	O
indicating	O
that	O
majorities	O
of	O
the	O
blasts	B-cell_type
in	O
M7	O
and	O
TMD	O
cases	O
have	O
erythroid	O
and	O
megakaryocytic	O
phenotypes	O
.	O

We	O
also	O
found	O
that	O
mRNAs	B-RNA
encoding	O
GATA-1	B-protein
and	O
GATA-2	B-protein
are	O
expressed	O
in	O
all	O
these	O
cases	O
.	O

These	O
results	O
suggest	O
that	O
M7	B-cell_type
blasts	I-cell_type
and	O
TMD	B-cell_type
blasts	I-cell_type
correspond	O
to	O
the	O
erythroid/megakaryocytic	B-cell_type
bipotential	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

Expression	O
of	O
Ah	B-protein
receptor	I-protein
(	O
TCDD	B-protein
receptor	I-protein
)	O
during	O
human	O
monocytic	O
differentiation	O
.	O

We	O
have	O
previously	O
found	O
a	O
high	O
expression	O
of	O
human	B-RNA
Ah	I-RNA
receptor	I-RNA
(	I-RNA
TCDD	I-RNA
receptor	I-RNA
)	I-RNA
mRNA	I-RNA
in	O
peripheral	B-cell_type
blood	I-cell_type
cells	I-cell_type
of	O
individuals	O
.	O

In	O
this	O
paper	O
,	O
the	O
expression	O
of	O
this	O
gene	O
in	O
blood	B-cell_type
cells	I-cell_type
was	O
first	O
investigated	O
in	O
fractions	O
of	O
nucleated	B-cell_type
cells	I-cell_type
,	O
revealing	O
predominant	O
expression	O
of	O
the	O
Ah	B-DNA
receptor	I-DNA
gene	I-DNA
in	O
the	O
monocyte	B-cell_type
fraction	I-cell_type
.	O

Then	O
the	O
expression	O
levels	O
of	O
AhR	B-RNA
mRNA	I-RNA
in	O
various	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
examined	O
together	O
with	O
those	O
of	O
Arnt	B-protein
and	O
P450IA1	B-protein
.	O

AhR	B-protein
was	O
expressed	O
at	O
high	O
levels	O
in	O
monocytoid	B-cell_line
U937	I-cell_line
,	O
THP1	B-cell_line
,	O
and	O
HEL/S	B-cell_line
cells	I-cell_line
,	O
and	O
at	O
moderate	O
levels	O
in	O
promyelocytic	B-cell_line
HL60	I-cell_line
cells	I-cell_line
and	O
erythroblastic	B-cell_line
HEL	I-cell_line
cells	I-cell_line
.	O

However	O
,	O
it	O
was	O
not	O
detected	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
MOLT4	B-cell_line
(	O
T	B-cell_type
cell	I-cell_type
)	O
and	O
BALL1	B-cell_line
(	O
B	B-cell_type
cell	I-cell_type
)	O
,	O
nor	O
in	O
K562	B-cell_line
erythroblasts	I-cell_line
.	O

Furthermore	O
,	O
a	O
specific	O
induction	O
of	O
AhR	B-protein
during	O
monocytic	O
differentiation	O
was	O
investigated	O
in	O
HL60	B-cell_line
and	O
HEL	B-cell_line
cells	I-cell_line
.	O

HL60	B-cell_line
cells	I-cell_line
were	O
induced	O
to	O
differentiate	O
toward	O
monocytes-macrophages	B-cell_type
by	O
incubation	O
with	O
phorbol	O
ester	O
,	O
showing	O
a	O
5-	O
to	O
2-fold	O
increase	O
of	O
AhR	B-RNA
mRNA	I-RNA
.	O

The	O
incubation	O
with	O
transforming	B-protein
growth	I-protein
factor	I-protein
beta	I-protein
1	I-protein
and	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
resulted	O
in	O
a	O
5-	O
to	O
7-fold	O
increase	O
of	O
AhR	B-RNA
mRNA	I-RNA
.	O

The	O
HEL	B-cell_line
cells	I-cell_line
also	O
exhibited	O
a	O
similar	O
elevation	O
of	O
AhR	B-RNA
mRNA	I-RNA
level	O
,	O
when	O
they	O
had	O
differentiated	O
toward	O
monocyte-macrophage	B-cell_type
cells	I-cell_type
by	O
these	O
combined	O
inducers	O
,	O
but	O
little	O
change	O
in	O
the	O
mRNA	O
level	O
was	O
observed	O
when	O
the	O
cells	O
were	O
induced	O
to	O
differentiate	O
into	O
other	O
cell	O
types	O
.	O

Treatment	O
of	O
the	O
differentiated	B-cell_line
HL60	I-cell_line
cells	I-cell_line
with	O
3-methylcholanthrene	O
,	O
a	O
ligand	O
of	O
AhR	B-protein
,	O
induced	O
the	O
expression	O
of	O
the	O
P450IA1	B-protein
gene	O
.	O

These	O
results	O
indicated	O
that	O
expression	O
of	O
AhR	B-RNA
mRNA	I-RNA
was	O
significantly	O
induced	O
during	O
monocytic	O
differentiation	O
and	O
that	O
the	O
differentiated	B-cell_type
cells	I-cell_type
were	O
responsive	O
to	O
xenobiotics	O
.	O

Our	O
results	O
suggest	O
that	O
AhR	B-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
function	O
of	O
monocytes	B-cell_type
and	O
also	O
in	O
the	O
eventual	O
activation	O
of	O
environmental	O
carcinogens	O
.	O

Neutrophils	B-cell_type
and	O
monocytes	B-cell_type
express	O
high	O
levels	O
of	O
PU.1	B-protein
(	O
Spi-1	B-protein
)	O
but	O
not	O
Spi-B	B-protein
.	O

PU.1	B-protein
(	O
the	O
Spi-1	B-DNA
oncogene	I-DNA
)	O
and	O
Spi-B	B-protein
are	O
closely	O
related	O
members	O
of	O
the	O
ets	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
,	O
sharing	O
similar	O
DNA	O
binding	O
specificities	O
mediated	O
by	O
similar	O
DNA	B-protein
binding	I-protein
domains	I-protein
.	O

PU.1	B-protein
and	O
Spi-B	B-protein
have	O
been	O
previously	O
described	O
as	O
being	O
predominantly	O
expressed	O
coordinately	O
in	O
macrophages	B-cell_type
and	O
B	B-cell_type
cells	I-cell_type
,	O
but	O
their	O
expression	O
in	O
early	O
hematopoietic	O
stages	O
and	O
during	O
the	O
course	O
of	O
myeloid	O
differentiation	O
to	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
or	O
to	O
neutrophils	B-cell_type
has	O
not	O
been	O
extensively	O
investigated	O
.	O

Here	O
,	O
we	O
report	O
that	O
PU.1	B-RNA
mRNA	I-RNA
is	O
upregulated	O
during	O
myeloid	O
differentiation	O
of	O
human	B-cell_line
purified	I-cell_line
CD34+	I-cell_line
cells	I-cell_line
and	O
murine	B-cell_line
multipotential	I-cell_line
FDCP-mix	I-cell_line
A4	I-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
PU.1	B-protein
is	O
upregulated	O
as	O
an	O
early	O
event	O
during	O
differentiation	O
of	O
multipotential	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

PU.1	B-protein
expression	O
is	O
maintained	O
at	O
stable	O
levels	O
during	O
differentiation	O
of	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
U937	B-cell_line
and	O
HL-60	B-cell_line
to	O
monocytic	B-cell_type
and	I-cell_type
neutrophilic	I-cell_type
cells	I-cell_type
.	O

PU.1	B-protein
is	O
expressed	O
at	O
highest	O
levels	O
in	O
mature	B-cell_type
human	I-cell_type
monocytes	I-cell_type
and	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
neutrophils	I-cell_type
.	O

In	O
contrast	O
to	O
PU.1	B-protein
,	O
significant	O
levels	O
of	O
Spi-B	B-RNA
mRNA	I-RNA
and	O
protein	O
are	O
found	O
only	O
in	O
some	O
B-cell	B-cell_line
lines	I-cell_line
and	O
spleen	O
but	O
are	O
not	O
found	O
in	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
neutrophils	B-cell_type
,	O
or	O
macrophages	B-cell_type
.	O

In	O
vitro	O
translated	O
Spi-B	B-protein
protein	I-protein
can	O
bind	O
to	O
PU.1	B-DNA
binding	I-DNA
sites	I-DNA
in	O
myeloid	B-DNA
promoters	I-DNA
and	O
transactivate	O
these	O
promoters	B-DNA
in	O
nonmyeloid	B-cell_type
cells	I-cell_type
.	O

Therefore	O
,	O
although	O
PU.1	B-protein
and	O
Spi-B	B-protein
may	O
bind	O
to	O
similar	O
DNA	O
control	O
elements	O
and	O
have	O
redundancy	O
of	O
transactivation	O
function	O
in	O
vitro	O
,	O
the	O
lack	O
of	O
significant	O
levels	O
of	O
Spi-B	B-protein
in	O
myeloid	B-cell_type
cells	I-cell_type
makes	O
it	O
unlikely	O
that	O
Spi-B	B-protein
plays	O
a	O
significant	O
role	O
in	O
myeloid	O
lineage	O
development	O
and	O
gene	O
expression	O
.	O

In	O
contrast	O
,	O
PU.1	B-protein
is	O
expressed	O
at	O
high	O
levels	O
not	O
only	O
in	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
but	O
also	O
in	O
neutrophils	B-cell_type
,	O
indicating	O
that	O
PU.1	B-protein
can	O
activate	O
gene	O
expression	O
in	O
both	O
major	B-cell_type
myeloid	I-cell_type
lineages	I-cell_type
.	O

Identification	O
of	O
a	O
major	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
located	O
5	O
'	O
to	O
the	O
human	B-DNA
zeta-globin	I-DNA
gene	I-DNA
.	O

The	O
function	O
of	O
the	O
zeta-globin	B-DNA
promoter	I-DNA
was	O
studied	O
using	O
a	O
series	O
of	O
zeta-globin	B-DNA
promoter	I-DNA
deletion	I-DNA
constructs	I-DNA
to	O
drive	O
luciferase	B-protein
expression	O
in	O
transiently	B-cell_line
transfected	I-cell_line
human	I-cell_line
erythroleukemia	I-cell_line
cells	I-cell_line
.	O

The	O
promoters	B-DNA
were	O
used	O
without	O
enhancers	B-DNA
,	O
or	O
with	O
enhancers	B-DNA
derived	O
from	O
the	O
beta-globin	B-DNA
locus	I-DNA
control	I-DNA
region	I-DNA
and	O
the	O
alpha-globin	B-DNA
HS-40	I-DNA
enhancer	I-DNA
.	O

When	O
transfected	O
into	O
K562	B-cell_line
cells	I-cell_line
,	O
which	O
express	O
zeta-globin	B-protein
,	O
comparable	O
amounts	O
of	O
activity	O
were	O
obtained	O
from	O
the	O
-557	B-DNA
and	I-DNA
-417	I-DNA
zeta-luciferase	I-DNA
constructs	I-DNA
and	O
the	O
alpha-luciferase	B-DNA
constructs	I-DNA
when	O
no	O
enhancers	B-DNA
or	O
the	O
alpha-globin	B-DNA
locus	I-DNA
enhancers	I-DNA
were	O
used	O
.	O

When	O
the	O
constructs	O
were	O
transfected	O
into	O
OCIM1	B-cell_line
cells	I-cell_line
,	O
which	O
do	O
not	O
express	O
zeta-globin	B-protein
,	O
the	O
zeta-globin	B-DNA
promoters	I-DNA
were	O
at	O
best	O
20	O
%	O
as	O
active	O
as	O
the	O
alpha-globin	B-DNA
promoters	I-DNA
.	O

When	O
sequences	B-DNA
from	I-DNA
-417	I-DNA
to	I-DNA
-207	I-DNA
5	I-DNA
'	I-DNA
to	O
the	O
zeta-globin	B-RNA
mRNA	I-RNA
cap	I-RNA
site	I-RNA
were	O
deleted	O
,	O
up	O
to	O
95	O
%	O
of	O
the	O
zeta-globin	B-DNA
promoter	I-DNA
activity	O
was	O
lost	O
in	O
K562	B-cell_line
cells	I-cell_line
.	O

Reinsertion	O
of	O
these	O
sequences	O
into	O
zeta-luciferase	B-DNA
constructs	I-DNA
missing	O
the	O
-417	O
to	O
-207	O
region	O
showed	O
that	O
the	O
sequences	O
lack	O
classical	O
enhancer	O
activity	O
.	O

Point	O
mutation	O
of	O
a	O
GATA-1	B-DNA
site	I-DNA
at	O
-230	O
reduced	O
promoter	O
activity	O
by	O
37	O
%	O
.	O

Point	O
mutation	O
of	O
a	O
CCACC	B-DNA
site	I-DNA
at	O
-240	O
had	O
no	O
effect	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
that	O
the	O
-230	B-DNA
GATA-1	I-DNA
site	I-DNA
has	O
a	O
relatively	O
low	O
affinity	O
for	O
GATA-1	B-protein
.	O

These	O
experiments	O
show	O
the	O
presence	O
of	O
a	O
strong	O
positive-acting	B-DNA
element	I-DNA
,	O
located	O
between	O
-417	B-DNA
and	I-DNA
-207	I-DNA
bp	I-DNA
5	I-DNA
'	I-DNA
to	O
the	O
zeta-globin	B-DNA
mRNA	I-DNA
cap	I-DNA
site	I-DNA
,	O
is	O
necessary	O
for	O
high-level	O
promoter	O
activity	O
in	O
K562	B-cell_line
cells	I-cell_line
.	O

This	O
element	O
requires	O
GATA-1	B-protein
and	O
additional	B-protein
unknown	I-protein
factors	I-protein
for	O
maximal	O
activity	O
.	O

Analysis	O
of	O
the	O
role	O
of	O
protein	B-protein
kinase	I-protein
C-alpha	I-protein
,	I-protein
-epsilon	I-protein
,	I-protein
and	I-protein
-zeta	I-protein
in	O
T	O
cell	O
activation	O
.	O

T	B-cell_type
cells	I-cell_type
express	O
multiple	O
isotypes	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
and	O
although	O
it	O
is	O
well	O
accepted	O
that	O
PKCs	B-protein
have	O
an	O
important	O
role	O
in	O
T	O
cell	O
activation	O
,	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
individual	O
PKC	B-protein
isotypes	I-protein
.	O

To	O
address	O
this	O
issue	O
,	O
mutationally	O
active	O
PKC-alpha	B-protein
,	I-protein
-epsilon	I-protein
,	I-protein
or	I-protein
-zeta	I-protein
have	O
been	O
transfected	O
into	O
T	B-cell_type
cells	I-cell_type
and	O
the	O
consequences	O
for	O
T	O
cell	O
activation	O
determined	O
.	O

p21ras	B-protein
plays	O
an	O
essential	O
role	O
in	O
T	O
cell	O
activation	O
.	O

Accordingly	O
,	O
the	O
effects	O
of	O
the	O
constitutively	B-protein
active	I-protein
PKCs	I-protein
were	O
compared	O
to	O
the	O
effects	O
of	O
mutationally	O
activated	O
p21ras	B-protein
.	O

The	O
data	O
indicate	O
that	O
PKC-epsilon	B-protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
PKC-alpha	B-protein
but	O
not	O
-zeta	B-protein
,	O
can	O
regulate	O
the	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
and	O
nuclear	O
factor	B-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT-1	B-protein
)	O
.	O

The	O
ability	O
of	O
PKC-epsilon	B-protein
to	O
induce	O
transactivation	O
of	O
NF-AT-1	B-protein
and	O
AP-1	B-protein
was	O
similar	O
to	O
the	O
stimulatory	O
effect	O
of	O
a	O
constitutively	B-protein
activated	I-protein
p21ras	I-protein
.	O

PKC-epsilon	B-protein
,	O
but	O
not	O
PKC-alpha	B-protein
nor	O
activated	O
p21ras	B-protein
,	O
was	O
able	O
to	O
induce	O
NF-KB	B-protein
activity	O
.	O

Phorbol	O
esters	O
induce	O
expression	O
of	O
CD69	B-protein
whereas	O
none	O
of	O
the	O
activated	B-protein
PKC	I-protein
isotypes	I-protein
tested	O
were	O
able	O
to	O
have	O
this	O
effect	O
.	O

Activated	O
Src	B-protein
and	O
p21ras	B-protein
were	O
able	O
to	O
induce	O
CD69	B-protein
expression	O
.	O

These	O
results	O
indicate	O
selective	O
functions	O
for	O
different	O
PKC	B-protein
isotypes	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

Moreover	O
,	O
the	O
data	O
comparing	O
the	O
effects	O
of	O
activated	B-protein
Ras	I-protein
and	O
PKC	B-protein
mutants	I-protein
suggest	O
that	O
PKC-alpha	B-protein
,	O
p21ras	B-protein
,	O
and	O
PKC-epsilon	B-protein
are	O
not	O
positioned	O
linearly	O
on	O
a	O
single	O
signal	O
transduction	O
pathway	O
.	O

Differences	O
in	O
binding	O
of	O
glucocorticoid	B-protein
receptor	I-protein
to	O
DNA	O
in	O
steroid-resistant	O
asthma	O
.	O

Although	O
glucocorticosteroids	O
are	O
a	O
very	O
effective	O
treatment	O
for	O
asthma	O
and	O
other	O
chronic	O
inflammatory	O
diseases	O
,	O
a	O
small	O
proportion	O
of	O
patients	O
are	O
resistant	O
to	O
their	O
therapeutic	O
effects	O
.	O

The	O
molecular	O
mechanism	O
for	O
this	O
steroid	O
resistance	O
is	O
unclear	O
.	O

Steroid	O
resistance	O
can	O
not	O
be	O
explained	O
by	O
pharmacokinetic	O
mechanisms	O
,	O
by	O
a	O
defect	O
in	O
the	O
binding	O
of	O
steroids	O
to	O
glucocorticoid	B-protein
receptors	I-protein
,	O
nor	O
by	O
defective	O
nuclear	O
translocation	O
of	O
this	O
receptor	O
,	O
thereby	O
suggesting	O
that	O
the	O
molecular	O
abnormality	O
lies	O
distal	O
to	O
nuclear	O
translocation	O
.	O

We	O
examined	O
the	O
ability	O
of	O
nuclear	O
translocated	O
glucocorticoid	B-protein
receptors	I-protein
to	O
bind	O
to	O
their	O
DNA	B-DNA
binding	I-DNA
sites	I-DNA
(	O
GRE	B-DNA
)	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
in	O
PBMC	B-cell_type
from	O
patients	O
with	O
steroid-sensitive	O
and	O
steroid-resistant	O
asthma	O
.	O

The	O
binding	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
to	O
DNA	O
in	O
these	O
patients	O
was	O
also	O
studied	O
using	O
Scatchard	O
analysis	O
.	O

Dexamethasone	O
induced	O
a	O
significant	O
rapid	O
and	O
sustained	O
twofold	O
increase	O
in	O
GRE	B-DNA
binding	O
in	O
PBMCs	B-cell_type
from	O
steroid-sensitive	O
asthmatic	O
patients	O
and	O
nonasthmatic	O
individuals	O
,	O
but	O
this	O
was	O
markedly	O
reduced	O
in	O
steroid-resistant	O
asthmatic	O
patients	O
.	O

Scatchard	O
analysis	O
of	O
glucocorticoid	B-protein
receptor	I-protein
-	O
GRE	B-DNA
binding	O
showed	O
no	O
change	O
in	O
binding	O
affinity	O
but	O
did	O
show	O
a	O
reduced	O
number	O
of	O
receptors	B-protein
available	O
for	O
DNA	O
binding	O
in	O
the	O
steroid-resistant	O
patients	O
.	O

These	O
results	O
suggest	O
that	O
the	O
ability	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
to	O
bind	O
to	O
GRE	B-DNA
is	O
impaired	O
in	O
steroid-resistant	O
patients	O
because	O
of	O
a	O
reduced	O
number	O
of	O
receptors	B-protein
available	O
for	O
binding	O
to	O
DNA	O
.	O

Interleukin-5	B-protein
signaling	O
in	O
human	B-cell_type
eosinophils	I-cell_type
involves	O
JAK2	B-protein
tyrosine	I-protein
kinase	I-protein
and	O
Stat1	B-protein
alpha	I-protein
.	O

Signaling	O
by	O
a	O
wide	O
variety	O
of	O
cytokines	B-protein
,	O
including	O
interferons	B-protein
,	O
interleukins	B-protein
,	O
and	O
growth	B-protein
factors	I-protein
,	O
involves	O
activation	O
of	O
JAK	B-protein
kinases	I-protein
and	O
Stat	B-protein
(	I-protein
Signal	I-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	I-protein
proteins	I-protein
.	O

At	O
present	O
,	O
not	O
much	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
by	O
which	O
interleukin-5	B-protein
(	O
IL-5	B-protein
)	O
exerts	O
its	O
diverse	O
biologic	O
effects	O
.	O

Human	B-cell_type
eosinophils	I-cell_type
are	O
one	O
of	O
the	O
most	O
important	O
target	B-cell_type
cells	I-cell_type
for	O
IL-5	B-protein
and	O
were	O
used	O
here	O
to	O
study	O
IL-5	B-protein
signaling	O
in	O
a	O
primary	B-cell_type
human	I-cell_type
cell	I-cell_type
.	O

IL-5	B-protein
induced	O
rapid	O
and	O
transient	O
tyrosine	O
phosphorylation	O
of	O
JAK2	B-protein
.	O

Moreover	O
,	O
IL-5	B-protein
induced	O
at	O
least	O
two	O
DNA-binding	B-protein
complexes	I-protein
,	O
using	O
nuclear	O
extracts	O
from	O
normal	O
human	B-cell_type
eosinophils	I-cell_type
and	O
the	O
IL-6/interferon-gamma	B-DNA
response	I-DNA
element	I-DNA
of	O
the	O
ICAM-1	B-DNA
promoter	I-DNA
(	O
ICAM-1	B-DNA
pIRE	I-DNA
)	O
in	O
an	O
electromobility	O
shift	O
assay	O
.	O

From	O
supershift	O
experiments	O
it	O
was	O
concluded	O
that	O
one	O
DNA-binding	B-protein
complex	I-protein
contained	O
Stat1	B-protein
alpha	I-protein
,	O
probably	O
as	O
a	O
homodimer	O
.	O

Both	O
DNA-binding	B-protein
complexes	I-protein
were	O
inhibited	O
by	O
a	O
phosphotyrosine	B-protein
antibody	I-protein
(	O
4G10	B-protein
)	O
,	O
suggesting	O
that	O
tyrosine	O
phosphorylation	O
is	O
required	O
for	O
complex	O
formation	O
.	O

IL-3	B-protein
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
induced	O
,	O
similar	O
to	O
IL-5	B-protein
,	O
two	O
DNA-binding	B-protein
complexes	I-protein
in	O
human	B-cell_type
eosinophils	I-cell_type
,	O
including	O
Stat1	B-protein
alpha	I-protein
.	O

These	O
data	O
show	O
for	O
the	O
first	O
time	O
that	O
molecular	O
mechanisms	O
of	O
IL-5	B-protein
signaling	O
in	O
human	B-cell_type
eosinophils	I-cell_type
involve	O
members	O
of	O
the	O
JAK	B-protein
kinase	I-protein
family	I-protein
as	O
well	O
as	O
members	O
of	O
the	O
Stat	B-protein
family	I-protein
.	O

Infection	O
and	O
replication	O
of	O
Tat-	O
human	O
immunodeficiency	O
viruses	O
:	O
genetic	O
analyses	O
of	O
LTR	B-DNA
and	O
tat	B-protein
mutations	I-protein
in	O
primary	B-cell_type
and	I-cell_type
long-term	I-cell_type
human	I-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

Tat	B-protein
is	O
an	O
essential	O
regulatory	B-protein
protein	I-protein
for	O
the	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

Mutations	O
in	O
the	O
tat	B-DNA
gene	I-DNA
have	O
been	O
shown	O
to	O
block	O
HIV	O
replication	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Several	O
studies	O
have	O
established	O
that	O
Tat	B-protein
releases	O
an	O
elongation	B-protein
block	I-protein
to	O
the	O
transcription	O
of	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
;	O
however	O
,	O
it	O
is	O
not	O
known	O
whether	O
this	O
mechanism	O
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
block	O
to	O
HIV	O
replication	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
when	O
Tat	B-protein
is	O
absent	O
.	O

It	O
is	O
possible	O
that	O
Tat	B-protein
is	O
also	O
needed	O
for	O
other	O
functions	O
during	O
HIV	O
replication	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
we	O
studied	O
several	O
tat	B-protein
mutants	I-protein
,	O
including	O
two	O
stop	B-protein
codon	I-protein
mutants	I-protein
and	O
one	O
deletion	B-protein
mutant	I-protein
using	O
replication-competent	B-DNA
HIV-1	I-DNA
constructs	I-DNA
carrying	O
wild-type	B-DNA
or	I-DNA
mutant	I-DNA
LTRs	I-DNA
with	O
modifications	O
in	O
the	O
NF-kappa	B-DNA
B	I-DNA
and/or	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
Tat-	O
HIV-1	O
with	O
wild-type	B-DNA
LTRs	I-DNA
can	O
replicate	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
and	O
the	O
virus	O
produced	O
from	O
HeLa	B-cell_line
cells	I-cell_line
can	O
infect	O
primary	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
macrophages	B-cell_type
.	O

It	O
was	O
found	O
that	O
the	O
propagation	O
of	O
the	O
Tat	B-protein
mutants	I-protein
containing	O
wild-type	B-DNA
LTRs	I-DNA
was	O
less	O
efficient	O
than	O
that	O
of	O
the	O
LTR-modified	B-protein
Tat	I-protein
mutants	I-protein
.	O

Large	O
amounts	O
of	O
viral	B-RNA
RNA	I-RNA
and	O
particles	O
were	O
synthesized	O
in	O
infections	O
established	O
using	O
the	O
tat	B-protein
mutants	I-protein
that	O
contain	O
modified	B-DNA
LTRs	I-DNA
.	O

However	O
,	O
this	O
efficient	O
propagation	O
of	O
the	O
LTR-modified	B-protein
tat	I-protein
mutants	I-protein
was	O
restricted	O
to	O
some	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
have	O
been	O
transformed	O
with	O
other	O
viruses	O
.	O

Thus	O
,	O
despite	O
its	O
essential	O
role	O
for	O
releasing	O
an	O
elongation	B-protein
block	I-protein
,	O
Tat	B-protein
is	O
not	O
otherwise	O
absolutely	O
required	O
for	O
synthesis	O
of	O
full-length	B-RNA
HIV	I-RNA
transcripts	I-RNA
and	O
assembly	O
of	O
virus	O
particles	O
.	O

Direct	O
sequencing	O
of	O
the	O
viral	B-DNA
genomes	I-DNA
and	O
reinfection	O
kinetics	O
showed	O
no	O
evidence	O
of	O
wild-type	O
reversion	O
even	O
after	O
prolonged	O
infection	O
with	O
the	O
Tat	B-protein
-virus	O
.	O

The	O
implications	O
for	O
in	O
vivo	O
HIV-1	O
replication	O
and	O
potential	O
application	O
of	O
this	O
system	O
to	O
the	O
study	O
of	O
alternative	O
Tat	B-protein
function	O
are	O
discussed	O
.	O

Functional	O
roles	O
of	O
the	O
transcription	B-protein
factor	I-protein
Oct-2A	I-protein
and	O
the	O
high	B-protein
mobility	I-protein
group	I-protein
protein	I-protein
I/Y	B-protein
in	O
HLA-DRA	B-DNA
gene	I-DNA
expression	O
.	O

The	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
gene	I-DNA
HLA-DRA	B-DNA
is	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
and	O
in	O
antigen-presenting	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
,	O
HLA-DRA	B-DNA
gene	I-DNA
expression	O
is	O
inducible	O
in	O
a	O
variety	O
of	O
cell	O
types	O
by	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
.	O

Here	O
we	O
show	O
that	O
the	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
Oct-2A	I-protein
plays	O
a	O
critical	O
role	O
in	O
HLA-DRA	B-DNA
gene	I-DNA
expression	O
in	O
class	B-cell_line
II-positive	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
that	O
the	O
high	B-protein
mobility	I-protein
group	I-protein
protein	I-protein
(	O
HMG	B-protein
)	O
I/Y	B-protein
binds	O
to	O
multiple	O
sites	O
within	O
the	O
DRA	B-DNA
promoter	I-DNA
,	O
including	O
the	O
Oct-2A	B-DNA
binding	I-DNA
site	I-DNA
.	O

Coexpression	O
of	O
HMG	B-protein
I/Y	I-protein
and	O
Oct-2	B-protein
in	O
cell	B-cell_line
lines	I-cell_line
lacking	O
Oct-2	B-protein
results	O
in	O
high	O
levels	O
of	O
HLA-DRA	B-DNA
gene	I-DNA
expression	O
,	O
and	O
in	O
vitro	O
DNA-binding	O
studies	O
reveal	O
that	O
HMG	O
I/Y	B-protein
stimulates	O
Oct-2A	B-protein
binding	O
to	O
the	O
HLA-DRA	B-DNA
promoter	I-DNA
.	O

Thus	O
,	O
Oct-2A	B-protein
and	O
HMG	B-protein
I/Y	I-protein
may	O
synergize	O
to	O
activate	O
HLA-DRA	B-DNA
expression	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

By	O
contrast	O
,	O
Oct-2A	B-protein
is	O
not	O
involved	O
in	O
the	O
IFN-gamma	B-protein
induction	O
of	O
the	O
HLA-DRA	B-DNA
gene	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
but	O
antisense	B-DNA
HMG	I-DNA
I/Y	I-DNA
dramatically	O
decreases	O
the	O
level	O
of	O
induction	O
.	O

We	O
conclude	O
that	O
distinct	O
sets	O
of	O
transcription	B-protein
factors	I-protein
are	O
involved	O
in	O
the	O
two	O
modes	O
of	O
HLA-DRA	B-DNA
expression	O
,	O
and	O
that	O
HMG	B-protein
I/Y	I-protein
may	O
be	O
important	O
for	O
B	O
cell-specific	O
expression	O
,	O
and	O
is	O
essential	O
for	O
IFN-gamma	B-protein
induction	O
.	O

Heterogeneous	O
expression	O
of	O
Epstein-Barr	B-protein
virus	I-protein
latent	I-protein
proteins	I-protein
in	O
endemic	O
Burkitt	O
's	O
lymphoma	O
.	O

Epstein-Barr	B-cell_type
virus	I-cell_type
(	I-cell_type
EBV	I-cell_type
)	I-cell_type
-infected	I-cell_type
cells	I-cell_type
may	O
sustain	O
three	O
distinct	O
forms	O
of	O
virus	O
latency	O
.	O

In	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
six	O
EBV-encoded	B-protein
nuclear	I-protein
antigens	I-protein
(	O
EBNA1	B-protein
,	I-protein
2	I-protein
,	I-protein
3A	I-protein
,	I-protein
3B	I-protein
,	I-protein
3C	I-protein
,	I-protein
-LP	I-protein
)	O
,	O
three	O
latent	B-protein
membrane	I-protein
proteins	I-protein
(	O
LMP1	B-protein
,	O
2A	B-protein
,	O
2B	B-protein
)	O
,	O
and	O
two	O
nuclear	B-RNA
RNAs	I-RNA
(	O
EBERs	B-RNA
)	O
are	O
expressed	O
.	O

This	O
form	O
of	O
latency	O
,	O
termed	O
latency	O
III	O
,	O
is	O
also	O
encountered	O
in	O
some	O
posttransplant	O
lymphoproliferative	O
disorders	O
.	O

In	O
EBV-positive	O
cases	O
of	O
Hodgkin	O
's	O
disease	O
,	O
the	O
EBERs	B-RNA
,	O
EBNA1	B-protein
,	O
and	O
the	O
LMPs	B-protein
are	O
expressed	O
(	O
latency	O
II	O
)	O
,	O
whereas	O
in	O
Burkitt	O
's	O
lymphoma	O
(	O
BL	O
)	O
only	O
the	O
EBERs	B-RNA
and	O
EBNA1	B-protein
have	O
been	O
detected	O
(	O
latency	O
I	O
)	O
.	O

We	O
have	O
studied	O
the	O
expression	O
of	O
EBV	B-protein
proteins	I-protein
in	O
17	O
cases	O
of	O
EBV-positive	O
endemic	O
BL	O
by	O
immunohistology	O
.	O

Expression	O
of	O
LMP1	B-protein
was	O
seen	O
in	O
variable	O
proportions	O
of	O
tumor	B-cell_type
cells	I-cell_type
in	O
two	O
cases	O
and	O
EBNA2	B-protein
was	O
detected	O
in	O
some	O
tumor	B-cell_type
cells	I-cell_type
in	O
three	O
other	O
cases	O
.	O

Also	O
,	O
the	O
BZLF1	B-protein
trans-activator	I-protein
protein	I-protein
was	O
expressed	O
in	O
a	O
few	O
tumor	B-cell_type
cells	I-cell_type
in	O
6	O
cases	O
,	O
indicating	O
entry	O
into	O
the	O
lytic	O
cycle	O
.	O

A	O
phenotypic	O
drift	O
from	O
latency	O
I	O
to	O
latency	O
III	O
has	O
been	O
observed	O
previously	O
in	O
some	O
BL	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Our	O
results	O
suggest	O
that	O
a	O
similar	O
phenomenon	O
may	O
occur	O
in	O
BL	O
in	O
vivo	O
and	O
indicate	O
that	O
the	O
operational	O
definition	O
of	O
EBV	O
latencies	O
is	O
not	O
easily	O
applied	O
to	O
human	O
tumors	O
.	O

The	O
activation	O
of	O
the	O
Jak	B-protein
-STAT	B-protein
1	I-protein
signaling	O
pathway	O
by	O
IL-5	B-protein
in	O
eosinophils	B-cell_type
.	O

The	O
intracellular	O
signal	O
transduction	O
of	O
IL-5	B-protein
in	O
eosinophils	B-cell_type
is	O
unknown	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
involvement	O
of	O
the	O
newly	O
discovered	O
Jak	B-protein
-STAT	B-protein
pathway	O
in	O
the	O
IL-5	B-protein
signal	O
transduction	O
mechanism	O
.	O

Eosinophils	B-cell_type
were	O
purified	O
from	O
peripheral	O
blood	O
by	O
discontinuous	O
Percoll	O
gradients	O
and	O
stimulated	O
with	O
IL-5	B-protein
.	O

The	O
involvement	O
of	O
Jak	B-protein
2	I-protein
was	O
investigated	O
by	O
immunoprecipitation	O
followed	O
by	O
immunoblotting	O
for	O
tyrosine	O
phosphorylation	O
.	O

The	O
activation	O
of	O
Jak	B-protein
2	I-protein
was	O
studied	O
by	O
autophosphorylation	O
of	O
the	O
immunoprecipitated	B-protein
kinase	I-protein
.	O

Jak	B-protein
2	I-protein
was	O
tyrosine	O
phosphorylated	O
within	O
1	O
to	O
3	O
min	O
after	O
stimulation	O
of	O
eosinophils	B-cell_type
with	O
IL-5	B-protein
.	O

Further	O
,	O
the	O
immunoprecipitated	B-protein
Jak	I-protein
2	I-protein
obtained	O
from	O
IL-5-stimulated	B-cell_line
cells	I-cell_line
underwent	O
autophosphorylation	O
.	O

Jak	B-protein
2	I-protein
coprecipitated	O
with	O
the	O
beta-subunit	O
of	O
the	O
IL-5	B-protein
receptor	I-protein
,	O
suggesting	O
a	O
physical	O
association	O
of	O
the	O
kinase	B-protein
with	O
the	O
receptor	O
.	O

The	O
nuclear	B-protein
factor	I-protein
STAT-1	I-protein
(	O
p91	B-protein
)	O
was	O
investigated	O
by	O
immunoprecipitation	O
followed	O
by	O
immunoblotting	O
for	O
tyrosine	O
phosphorylation	O
.	O

STAT-1	B-protein
was	O
tyrosine	O
phosphorylated	O
within	O
15	O
min	O
of	O
IL-5	B-protein
stimulation	O
.	O

The	O
presence	O
of	O
STAT-1	B-protein
in	O
the	O
nuclear	O
extract	O
was	O
studied	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

IL-5	B-protein
induced	O
two	O
proteins	O
that	O
bound	O
to	O
the	O
gamma-activating	B-DNA
sequence	I-DNA
.	O

In	O
the	O
presence	O
of	O
an	O
anti-STAT-1	B-protein
Ab	I-protein
,	O
the	O
band	O
was	O
supershifted	O
.	O

Thus	O
,	O
we	O
demonstrated	O
that	O
IL-5	B-protein
activated	O
the	O
Jak	B-protein
2	I-protein
-STAT	B-protein
1	I-protein
signaling	O
pathway	O
in	O
eosinophils	B-cell_type
.	O

We	O
speculate	O
that	O
the	O
Jak	B-protein
2	I-protein
-STAT	B-protein
1	I-protein
pathway	O
may	O
be	O
involved	O
in	O
the	O
activation	O
of	O
IL-5-inducible	B-DNA
genes	I-DNA
in	O
eosinophils	B-cell_type
.	O

Reduced	O
mitogenic	O
stimulation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
as	O
a	O
prognostic	O
parameter	O
for	O
the	O
course	O
of	O
breast	O
cancer	O
:	O
a	O
prospective	O
longitudinal	O
study	O
.	O

Immunosuppression	O
has	O
been	O
often	O
associated	O
with	O
the	O
course	O
of	O
malignant	O
diseases	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
proliferation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
in	O
response	O
to	O
mitogenic	O
stimulation	O
with	O
phytohaemagglutinin	B-protein
(	O
PHA	B-protein
)	O
was	O
assessed	O
prospectively	O
in	O
90	O
patients	O
with	O
stage	O
I-III	O
breast	O
cancer	O
.	O

Whereas	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
derived	O
from	O
patients	O
with	O
breast	O
cancer	O
preoperatively	O
was	O
significantly	O
decreased	O
when	O
compared	O
with	O
data	O
obtained	O
in	O
healthy	O
control	O
individuals	O
(	O
P	O
<	O
0.001	O
)	O
,	O
the	O
degree	O
of	O
the	O
defect	O
in	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
depended	O
upon	O
the	O
tumour	O
burden	O
as	O
manifested	O
by	O
tumour	O
size	O
and	O
axillary	O
lymph	O
node	O
involvement	O
(	O
P	O
<	O
0.003	O
in	O
each	O
case	O
)	O
.	O

PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
dropped	O
significantly	O
in	O
patients	O
who	O
received	O
adjuvant	O
chemotherapy	O
consisting	O
of	O
cyclophosphamide	O
,	O
methotrexate	O
and	O
fluorouracil	O
(	O
CMF	O
)	O
after	O
an	O
observation	O
period	O
of	O
6	O
months	O
(	O
P	O
<	O
0.01	O
)	O
,	O
but	O
not	O
in	O
patients	O
under	O
adjuvant	O
treatment	O
with	O
tamoxifen	O
only	O
.	O

After	O
an	O
additional	O
6	O
months	O
(	O
i.e.	O
12	O
months	O
after	O
surgery	O
)	O
,	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
was	O
similar	O
in	O
patients	O
after	O
adjuvant	O
chemotherapy	O
with	O
CMF	O
and	O
in	O
those	O
receiving	O
continued	O
adjuvant	O
tamoxifen	O
treatment	O
(	O
P	O
>	O
0.1	O
)	O
,	O
but	O
in	O
all	O
patients	O
still	O
significantly	O
decreased	O
as	O
compared	O
with	O
healthy	O
controls	O
(	O
P	O
<	O
0.001	O
)	O
.	O

When	O
data	O
obtained	O
preoperatively	O
and	O
after	O
12	O
months	O
were	O
compared	O
,	O
it	O
was	O
found	O
that	O
out	O
of	O
23	O
patients	O
whose	O
PBMCs	B-cell_type
had	O
experienced	O
a	O
drop	O
in	O
their	O
PHA	B-protein
-induced	O
proliferation	O
,	O
14	O
(	O
61	O
%	O
)	O
had	O
developed	O
metastatic	O
disease	O
within	O
the	O
subsequent	O
24	O
months	O
(	O
i.e.	O
36	O
months	O
after	O
surgery	O
)	O
.	O

In	O
contrast	O
,	O
out	O
of	O
59	O
patients	O
whose	O
PBMCs	B-cell_type
showed	O
an	O
increase	O
in	O
their	O
PHA	B-protein
-induced	O
proliferation	O
within	O
the	O
first	O
12	O
months	O
after	O
surgery	O
,	O
only	O
one	O
(	O
2	O
%	O
)	O
presented	O
with	O
disease	O
progression	O
.	O

We	O
thus	O
conclude	O
that	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
derived	O
from	O
patients	O
with	O
breast	O
cancer	O
depends	O
upon	O
the	O
tumour	O
load	O
and	O
is	O
a	O
good	O
clinical	O
predictor	O
for	O
the	O
further	O
course	O
of	O
the	O
disease	O
.	O

Activation	O
of	O
transcription	O
by	O
binding	O
of	O
NF-E1	B-protein
(	O
YY1	B-protein
)	O
to	O
a	O
newly	O
identified	O
element	O
in	O
the	O
first	O
exon	O
of	O
the	O
human	B-DNA
DR	I-DNA
alpha	I-DNA
gene	I-DNA
.	O

A	O
previously	O
unrecognized	O
element	O
,	O
located	O
downstream	O
of	O
the	O
start	B-DNA
site	I-DNA
of	I-DNA
transcription	I-DNA
in	O
the	O
first	O
exon	B-DNA
of	O
the	O
DR	B-DNA
alpha	I-DNA
gene	I-DNA
,	O
has	O
been	O
defined	O
that	O
enhances	O
promoter	O
activity	O
up	O
to	O
eightfold	O
in	O
a	O
position-dependent	O
manner	O
.	O

Mutations	O
in	O
this	O
DNA-binding	B-DNA
site	I-DNA
abolished	O
binding	O
of	O
a	O
nuclear	B-protein
factor	I-protein
in	O
human	O
B	O
cell	O
nuclear	O
extract	O
and	O
decreased	O
the	O
activity	O
of	O
the	O
DR	B-DNA
alpha	I-DNA
promoter	I-DNA
to	O
a	O
basal	O
level	O
.	O

Significant	O
sequence	O
homology	O
of	O
this	O
element	B-DNA
was	O
found	O
in	O
the	O
DNA	O
of	O
the	O
DR	B-DNA
beta	I-DNA
,	I-DNA
DP	I-DNA
alpha	I-DNA
and	I-DNA
-beta	I-DNA
,	I-DNA
and	I-DNA
DQ	I-DNA
alpha	I-DNA
genes	I-DNA
,	O
always	O
located	O
downstream	O
of	O
the	O
transcriptional	B-DNA
start	I-DNA
site	I-DNA
.	O

The	O
nuclear	O
factor	O
binds	O
to	O
the	O
DR	B-DNA
alpha	I-DNA
and	I-DNA
DP	I-DNA
alpha	I-DNA
element	I-DNA
but	O
not	O
to	O
the	O
element	O
in	O
the	O
DQ	B-DNA
alpha	I-DNA
gene	I-DNA
.	O

It	O
was	O
identified	O
as	O
NF-E1	B-protein
(	O
YY1	B-protein
)	O
.	O

This	O
protein	O
,	O
previously	O
identified	O
by	O
its	O
binding	O
to	O
the	O
Ig	B-DNA
kappa	I-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
and	O
the	O
Ig	B-DNA
heavy	I-DNA
chain	I-DNA
mu	I-DNA
E1	I-DNA
site	I-DNA
,	O
thus	O
also	O
appears	O
to	O
be	O
quite	O
important	O
in	O
the	O
regulation	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
expression	O
.	O

Transcriptional	O
activity	O
of	O
core	B-protein
binding	I-protein
factor-alpha	I-protein
(	I-protein
AML1	I-protein
)	I-protein
and	I-protein
beta	I-protein
subunits	O
on	O
murine	B-DNA
leukemia	I-DNA
virus	I-DNA
enhancer	I-DNA
cores	I-DNA
.	O

Core	B-protein
binding	I-protein
factor	I-protein
(	O
CBF	B-protein
)	O
,	O
also	O
known	O
as	O
polyomavirus	B-protein
enhancer-binding	I-protein
protein	I-protein
2	I-protein
and	O
SL3	B-protein
enhancer	I-protein
factor	I-protein
1	I-protein
,	O
is	O
a	O
mammalian	B-protein
transcription	I-protein
factor	I-protein
that	O
binds	O
to	O
an	O
element	O
termed	O
the	O
core	O
within	O
the	O
enhancers	B-DNA
of	O
the	O
murine	O
leukemia	O
virus	O
family	O
of	O
retroviruses	O
.	O

The	O
core	B-DNA
elements	I-DNA
of	O
the	O
SL3	O
virus	O
are	O
important	O
genetic	O
determinants	O
of	O
the	O
ability	O
of	O
this	O
virus	O
to	O
induce	O
T-cell	O
lymphomas	O
and	O
the	O
transcriptional	O
activity	O
of	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

CBF	B-protein
consists	O
of	O
two	O
subunits	O
,	O
a	O
DNA	B-protein
binding	I-protein
subunit	I-protein
,	O
CBF	B-protein
alpha	I-protein
,	O
and	O
a	O
second	O
subunit	O
,	O
CBF	B-protein
beta	I-protein
,	O
that	O
stimulates	O
the	O
DNA	O
binding	O
activity	O
of	O
CBF	B-protein
alpha	I-protein
.	O

One	O
of	O
the	O
genes	O
that	O
encodes	O
a	O
CBF	B-protein
alpha	I-protein
subunit	I-protein
is	O
AML1	B-protein
,	O
also	O
called	O
Cbf	B-protein
alpha	I-protein
2	I-protein
.	O

This	O
locus	O
is	O
rearranged	O
by	O
chromosomal	O
translocations	O
in	O
human	O
myeloproliferative	O
disorders	O
and	O
leukemias	O
.	O

An	O
exogenously	O
expressed	O
Cbf	B-protein
alpha	I-protein
2-encoded	I-protein
subunit	I-protein
(	O
CBF	B-protein
alpha	I-protein
2-451	I-protein
)	O
stimulated	O
transcription	O
from	O
the	O
SL3	B-DNA
enhancer	I-DNA
in	O
P19	B-protein
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O

Activity	O
was	O
mediated	O
through	O
the	O
core	B-DNA
elements	I-DNA
.	O

Three	O
different	O
isoforms	O
of	O
CBF	B-protein
beta	I-protein
were	O
also	O
tested	O
for	O
transcriptional	O
activity	O
on	O
the	O
SL3	B-DNA
enhancer	I-DNA
.	O

The	O
longest	O
form	O
,	O
CBF	B-protein
beta-187	I-protein
,	O
increased	O
the	O
transcriptional	O
stimulation	O
by	O
CBF	B-protein
alpha	I-protein
2-451	I-protein
twofold	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
although	O
it	O
had	O
no	O
effect	O
in	O
P19	B-cell_line
cells	I-cell_line
.	O

Transcriptional	O
activation	O
by	O
CBF	B-protein
beta	I-protein
required	O
binding	O
to	O
the	O
CBF	B-protein
alpha	I-protein
subunit	I-protein
,	O
as	O
a	O
form	O
of	O
CBF	B-protein
beta	I-protein
that	O
lacked	O
binding	O
ability	O
,	O
CBF	B-protein
beta-148	I-protein
,	O
failed	O
to	O
increase	O
activity	O
.	O

These	O
results	O
indicated	O
that	O
at	O
least	O
in	O
certain	O
cell	O
types	O
,	O
the	O
maximum	O
activity	O
of	O
CBF	B-protein
required	O
both	O
subunits	O
.	O

They	O
also	O
provided	O
support	O
for	O
the	O
hypothesis	O
that	O
CBF	B-protein
is	O
a	O
factor	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
that	O
is	O
responsible	O
for	O
recognition	O
of	O
the	O
SL3	B-DNA
cores	I-DNA
.	O

We	O
also	O
examined	O
whether	O
CBF	B-protein
could	O
distinguish	O
a	O
1-bp	O
difference	O
between	O
the	O
enhancer	O
core	O
of	O
SL3	O
and	O
the	O
core	O
of	O
the	O
nonleukemogenic	O
virus	O
,	O
Akv	O
.	O

This	O
difference	O
strongly	O
affects	O
transcription	O
in	O
T	O
cells	O
and	O
leukemogenicity	O
of	O
SL3	B-DNA
.	O

However	O
,	O
no	O
combination	O
of	O
CBF	B-protein
alpha	I-protein
and	O
CBF	B-protein
beta	I-protein
subunits	O
that	O
we	O
tested	O
was	O
able	O
to	O
distinguish	O
the	O
1-bp	O
difference	O
in	O
transcription	O
assays	O
.	O

Thus	O
,	O
a	O
complete	O
understanding	O
of	O
how	O
T	B-cell_type
cells	I-cell_type
recognize	O
the	O
SL3	B-DNA
core	I-DNA
remains	O
to	O
be	O
elucidated	O
.	O

Interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	I-protein
inhibits	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
activation	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

IL-10	B-protein
and	O
IL-4	B-protein
suppress	O
cytokine	B-protein
synthesis	O
by	O
different	O
mechanisms	O
.	O

Our	O
previous	O
studies	O
in	O
human	B-cell_type
monocytes	I-cell_type
have	O
demonstrated	O
that	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	I-protein
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-stimulated	O
production	O
of	O
inflammatory	B-protein
cytokines	I-protein
,	O
IL-1	B-protein
beta	I-protein
,	O
IL-6	B-protein
,	O
IL-8	B-protein
,	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
by	O
blocking	O
gene	O
transcription	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
,	O
we	O
now	O
show	O
that	O
,	O
in	O
monocytes	O
stimulated	O
with	O
LPS	O
or	O
TNF	B-protein
alpha	I-protein
,	O
IL-10	B-protein
inhibits	O
nuclear	O
stimulation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
involved	O
in	O
the	O
expression	O
of	O
inflammatory	B-DNA
cytokine	I-DNA
genes	I-DNA
.	O
Several	O
other	O
transcription	B-protein
factors	I-protein
including	O
NF-	O
IL-6	B-protein
,	O
AP-1	B-protein
,	O
AP-2	B-protein
,	O
GR	B-protein
,	O
CREB	B-protein
,	O
Oct-1	B-protein
,	O
and	O
Sp-1	B-protein
are	O
not	O
affected	O
by	O
IL-10	B-protein
.	O

This	O
selective	O
inhibition	O
by	O
IL-10	B-protein
of	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
occurs	O
rapidly	O
and	O
in	O
a	O
dose-dependent	O
manner	O
and	O
correlates	O
well	O
with	O
IL-10	B-protein
's	O
cytokine	B-protein
synthesis	O
inhibitory	O
activity	O
in	O
terms	O
of	O
both	O
kinetics	O
and	O
dose	O
responsiveness	O
.	O

Furthermore	O
,	O
compounds	O
such	O
as	O
tosylphenylalanyl	O
chloromethyl	O
ketone	O
and	O
pyrrolidinedithiocarbamate	O
that	O
are	O
known	O
to	O
selectively	O
inhibit	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
block	O
cytokine	O
gene	O
transcription	O
in	O
LPS-stimulated	B-cell_line
monocytes	I-cell_line
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
inhibition	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
may	O
be	O
an	O
important	O
mechanism	O
for	O
IL-10	B-protein
suppression	O
of	O
cytokine	O
gene	O
transcription	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

IL-4	B-protein
,	O
another	O
cytokine	B-protein
that	O
inhibits	O
cytokine	B-RNA
mRNA	I-RNA
accumulation	O
in	O
monocytes	B-cell_type
,	O
shows	O
little	O
inhibitory	O
effect	O
on	O
LPS-induced	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
.	O

Further	O
examination	O
reveals	O
that	O
,	O
unlike	O
IL-10	B-protein
,	O
IL-4	B-protein
enhances	O
mRNA	B-RNA
degradation	O
and	O
does	O
not	O
suppress	O
cytokine	O
gene	O
transcription	O
.	O

These	O
data	O
indicate	O
that	O
IL-10	B-protein
and	O
IL-4	B-protein
inhibit	O
cytokine	B-protein
production	O
by	O
different	O
mechanisms	O
.	O

LMP-1	B-protein
activates	O
NF-kappa	B-protein
B	I-protein
by	O
targeting	O
the	O
inhibitory	B-protein
molecule	I-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

LMP-1	B-protein
,	O
an	O
Epstein-Barr	B-protein
virus	I-protein
membrane	I-protein
protein	I-protein
expressed	O
during	O
latent	O
infection	O
,	O
has	O
oncogenic	O
properties	O
,	O
as	O
judged	O
from	O
its	O
ability	O
to	O
transform	O
B	O
lymphocytes	B-cell_type
and	O
rodent	B-cell_type
fibroblasts	I-cell_type
.	O

LMP-1	B-protein
induces	O
the	O
expression	O
of	O
bcl2	B-DNA
,	O
an	O
oncogene	B-DNA
which	O
protects	O
cells	O
from	O
apoptosis	O
,	O
as	O
well	O
as	O
of	O
genes	O
encoding	O
other	O
proteins	O
involved	O
in	O
cell	O
regulation	O
and	O
growth	O
control	O
.	O

The	O
mechanisms	O
by	O
which	O
LMP-1	B-protein
upregulates	O
these	O
proteins	O
is	O
unknown	O
,	O
but	O
it	O
is	O
plausible	O
that	O
LMP-1	B-protein
modifies	O
signal	O
transduction	O
pathways	O
that	O
result	O
in	O
the	O
activation	O
of	O
one	O
or	O
more	O
transcription	B-protein
factors	I-protein
that	O
ultimately	O
regulate	O
transcription	O
of	O
oncogenic	B-DNA
genes	I-DNA
.	O

NF-kappa	B-protein
B	I-protein
,	O
a	O
transcription	B-protein
factor	I-protein
controlling	O
the	O
expression	O
of	O
genes	B-DNA
involved	O
in	O
cell	O
activation	O
and	O
growth	O
control	O
,	O
has	O
been	O
shown	O
to	O
be	O
activated	O
by	O
LMP-1	B-protein
.	O

The	O
mechanism	O
(	O
s	O
)	O
regulating	O
this	O
activation	O
remains	O
unknown	O
.	O

Our	O
data	O
indicate	O
that	O
increased	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
and	O
functional	O
activity	O
are	O
present	O
in	O
B-lymphoid	B-cell_type
cells	I-cell_type
stably	O
or	O
transiently	O
expressing	O
LMP-1	B-protein
.	O

I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
selectively	O
modified	O
in	O
LMP-1-expressing	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

A	O
phosphorylated	O
form	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
increased	O
protein	O
turnover-degradation	O
correlate	O
with	O
increased	O
NF-kappa	B-protein
B	I-protein
nuclear	O
translocation	O
.	O

This	O
results	O
in	O
increased	O
transcription	O
of	O
NF-kappa	B-DNA
B-dependent-genes	I-DNA
,	O
including	O
those	O
encoding	O
p105	B-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
(	O
MAD3	B-DNA
)	O
.	O

These	O
results	O
indicate	O
that	O
LMP-1	B-protein
activates	O
NF-kappa	B-protein
B	I-protein
in	O
B-cell	B-cell_line
lines	I-cell_line
by	O
targeting	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

Identification	O
of	O
the	O
pathways	O
activated	O
by	O
LMP-1	B-protein
to	O
result	O
in	O
posttranslational	O
modifications	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
will	O
aid	O
in	O
determining	O
the	O
role	O
of	O
this	O
virus-host	O
cell	O
protein	O
interaction	O
in	O
Epstein-Barr	O
virus-mediated	O
oncogenesis	O
.	O

Identification	O
of	O
human	B-DNA
TR2	I-DNA
orphan	I-DNA
receptor	I-DNA
response	I-DNA
element	I-DNA
in	O
the	O
transcriptional	B-DNA
initiation	I-DNA
site	I-DNA
of	O
the	O
simian	B-DNA
virus	I-DNA
40	I-DNA
major	I-DNA
late	I-DNA
promoter	I-DNA
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Nov	O
3	O
;	O
270	O
(	O
44	O
)	O
:	O
26721	O
]	O

A	O
DNA	B-DNA
response	I-DNA
element	I-DNA
(	O
TR2RE-SV40	B-DNA
)	O
for	O
the	O
TR2	B-protein
orphan	I-protein
receptor	I-protein
,	O
a	O
member	O
of	O
the	O
steroid-thyroid	B-protein
hormone	I-protein
receptor	I-protein
superfamily	I-protein
,	O
has	O
been	O
identified	O
in	O
the	O
simian	B-DNA
virus	I-DNA
40	I-DNA
(	I-DNA
SV40	I-DNA
)	I-DNA
+55	I-DNA
region	I-DNA
(	O
nucleotide	B-DNA
numbers	I-DNA
368-389	I-DNA
,	O
5'-GTTAAGGTTCGTAGGTCATGGA-3	O
'	O
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
,	O
using	O
in	O
vitro	O
translated	O
TR2	B-protein
orphan	I-protein
receptor	I-protein
with	O
a	O
molecular	O
mass	O
of	O
67	B-protein
kilodaltons	I-protein
,	O
showed	O
a	O
specific	O
binding	O
with	O
high	O
affinity	O
(	O
dissociation	O
constant	O
=	O
9	O
nM	O
)	O
for	O
this	O
DNA	O
sequence	O
.	O

DNA-swap	O
experiments	O
using	O
chloramphenicol	B-protein
acetyl-transferase	I-protein
assay	O
demonstrated	O
that	O
androgen	O
can	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
SV40	B-DNA
early	I-DNA
promoter	I-DNA
via	O
the	O
interaction	O
between	O
this	O
TR2RE-SV40	B-DNA
and	O
the	O
chimeric	B-protein
receptor	I-protein
AR/TR2/AR	I-protein
with	O
the	O
DNA-binding	B-protein
domain	I-protein
of	O
the	O
TR2	B-protein
orphan	I-protein
receptor	I-protein
flanked	O
by	O
the	O
N-terminal	B-protein
and	I-protein
androgen-binding	I-protein
domains	I-protein
of	O
the	O
androgen	B-protein
receptor	I-protein
.	O

In	O
addition	O
,	O
this	O
TR2RE-SV40	B-DNA
can	O
function	O
as	O
a	O
repressor	O
to	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
both	O
SV40	B-DNA
early	I-DNA
and	I-DNA
late	I-DNA
promoters	I-DNA
.	O

Together	O
,	O
these	O
data	O
suggest	O
the	O
TR2RE-SV40	B-DNA
may	O
represent	O
the	O
first	O
identified	O
natural	O
DNA	B-DNA
response	I-DNA
element	I-DNA
for	O
the	O
TR2	B-protein
orphan	I-protein
receptor	I-protein
that	O
may	O
function	O
as	O
a	O
repressor	O
for	O
the	O
SV40	O
gene	O
expression	O
.	O

Detection	O
of	O
the	O
chromosome	B-RNA
16	I-RNA
CBF	I-RNA
beta-MYH11	I-RNA
fusion	I-RNA
transcript	I-RNA
in	O
myelomonocytic	O
leukemias	O
.	O

Karyotypic	O
detection	O
of	O
chromosomal	O
16	O
abnormalities	O
classically	O
associated	O
with	O
AML	O
M4Eo	O
can	O
be	O
difficult	O
.	O

Characterization	O
of	O
the	O
two	O
genes	O
involved	O
in	O
the	O
inv	O
(	O
16	O
)	O
(	O
p13q22	O
)	O
,	O
CBF	B-DNA
beta	I-DNA
and	O
MYH11	B-DNA
,	O
has	O
allowed	O
the	O
detection	O
of	O
fusion	B-RNA
transcripts	I-RNA
by	O
reverse-transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
.	O

We	O
have	O
analyzed	O
CBF	B-RNA
beta-MYH11	I-RNA
fusion	I-RNA
transcripts	I-RNA
by	O
RT-PCR	O
in	O
myelomonocytic	O
leukemias	O
,	O
with	O
or	O
without	O
eosinophilia	O
,	O
to	O
determine	O
whether	O
their	O
presence	O
correlates	O
with	O
morphology	O
.	O

Fifty-three	O
cases	O
(	O
11	O
AML	O
M4Eo	O
;	O
1	O
AML	O
M4	O
with	O
atypical	B-cell_type
abnormal	I-cell_type
eosinophils	I-cell_type
(	O
AML	O
M4	O
``	O
Eo	O
''	O
)	O
;	O
29	O
AML	O
M4	O
;	O
8	O
AML	O
M5	O
;	O
3	O
CMML	O
;	O
and	O
1	O
AML	O
M2	O
with	O
eosinophilia	O
)	O
were	O
analyzed	O
.	O

All	O
11	O
typical	O
AML	O
M4Eo	O
were	O
CBF	B-DNA
beta	I-DNA
-MYH11	B-DNA
positive	O
.	O

The	O
single	O
case	O
of	O
AML	O
M4	O
with	O
distinctive	O
eosinophil	O
abnormalities	O
was	O
negative	O
by	O
karyotype	O
,	O
RT-PCR	O
and	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

Three	O
of	O
29	O
(	O
10	O
%	O
)	O
AML	O
M4	O
without	O
abnormal	B-cell_type
eosinophils	I-cell_type
were	O
CBF	B-DNA
beta	I-DNA
-MYH11	B-DNA
positive	O
,	O
1	O
of	O
which	O
did	O
not	O
show	O
any	O
apparent	O
chromosome	B-DNA
16	I-DNA
abnormalities	O
by	O
classical	O
metaphase	O
analysis	O
(	O
2	O
not	O
tested	O
)	O
.	O

Both	O
cases	O
tested	O
also	O
showed	O
MYH11	B-DNA
genomic	O
rearrangement	O
.	O

None	O
of	O
the	O
other	O
leukemias	O
were	O
RT-PCR	O
positive	O
.	O

Follow-up	O
of	O
three	O
patient	O
showed	O
residual	O
positivity	O
in	O
apparent	O
complete	O
remission	O
.	O

These	O
data	O
show	O
that	O
CBF	B-RNA
beta-MYH11	I-RNA
fusion	I-RNA
transcripts	I-RNA
occur	O
not	O
only	O
in	O
the	O
vast	O
majority	O
of	O
typical	O
AML	O
M4Eo	O
,	O
but	O
also	O
in	O
approximately	O
10	O
%	O
of	O
AML	O
M4	O
without	O
eosinophilic	O
abnormalities	O
,	O
a	O
much	O
higher	O
incidence	O
than	O
the	O
sporadic	O
reports	O
of	O
chromosome	B-DNA
16	I-DNA
abnormalities	O
in	O
AML	O
M4	O
would	O
suggest	O
.	O

Taken	O
together	O
with	O
the	O
detection	O
of	O
CBF	B-DNA
beta	I-DNA
-	O
MYH11	B-RNA
transcripts	I-RNA
in	O
the	O
absence	O
of	O
apparent	O
chromosome	B-DNA
16	I-DNA
abnormalities	O
by	O
classical	O
banding	O
techniques	O
,	O
these	O
data	O
show	O
that	O
additional	O
screening	O
by	O
either	O
RT-PCR	O
or	O
FISH	O
should	O
be	O
performed	O
in	O
all	O
AML	O
M4	O
,	O
regardless	O
of	O
morphologic	O
features	O
,	O
to	O
allow	O
accurate	O
evaluation	O
of	O
the	O
prognostic	O
importance	O
of	O
this	O
fusion	B-RNA
transcript	I-RNA
.	O

HIV-1	B-protein
Tat	I-protein
potentiates	O
TNF	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
cytotoxicity	O
by	O
altering	O
the	O
cellular	O
redox	O
state	O
.	O

This	O
study	O
demonstrates	O
that	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV-1	I-protein
)	I-protein
Tat	I-protein
protein	I-protein
amplifies	O
the	O
activity	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
,	O
a	O
cytokine	O
that	O
stimulates	O
HIV-1	O
replication	O
through	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

In	O
HeLa	B-cell_line
cells	I-cell_line
stably	O
transfected	O
with	O
the	O
HIV-1	B-DNA
tat	I-DNA
gene	I-DNA
(	O
HeLa-tat	B-cell_line
cells	I-cell_line
)	O
,	O
expression	O
of	O
the	O
Tat	B-protein
protein	I-protein
enhanced	O
both	O
TNF	B-protein
-induced	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
TNF	B-protein
-mediated	O
cytotoxicity	O
.	O

A	O
similar	O
potentiation	O
of	O
TNF	B-protein
effects	O
was	O
observed	O
in	O
Jurkat	O
T	O
cells	O
and	O
HeLa	B-cell_line
cells	I-cell_line
treated	O
with	O
soluble	O
Tat	B-protein
protein	I-protein
.	O

TNF	B-protein
-mediated	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
cytotoxicity	O
involves	O
the	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
.	O

Therefore	O
,	O
Tat	B-protein
-mediated	O
effects	O
on	O
the	O
cellular	O
redox	O
state	O
were	O
analyzed	O
.	O

In	O
both	O
T	B-cell_type
cells	I-cell_type
and	O
HeLa	B-cell_line
cells	I-cell_line
HIV-1	B-protein
Tat	I-protein
suppressed	O
the	O
expression	O
of	O
Mn-dependent	B-protein
superoxide	I-protein
dismutase	I-protein
(	O
Mn-SOD	B-protein
)	O
,	O
a	O
mitochondrial	B-protein
enzyme	I-protein
that	O
is	O
part	O
of	O
the	O
cellular	O
defense	O
system	O
against	O
oxidative	O
stress	O
.	O

Thus	O
,	O
Mn-SOD	B-protein
RNA	O
protein	O
levels	O
and	O
activity	O
were	O
markedly	O
reduced	O
in	O
the	O
presence	O
of	O
Tat	B-protein
.	O

Decreased	O
Mn-SOD	B-protein
expression	O
was	O
associated	O
with	O
decreased	O
levels	O
of	O
glutathione	O
and	O
a	O
lower	O
ratio	O
of	O
reduced	O
:	O
oxidized	O
glutathione	O
.	O

A	O
truncated	O
Tat	B-protein
protein	I-protein
(	O
Tat1-72	B-protein
)	O
,	O
known	O
to	O
transactivate	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
,	O
no	O
longer	O
affected	O
Mn-SOD	B-protein
expression	O
,	O
the	O
cellular	O
redox	O
state	O
or	O
TNF	B-protein
-mediated	O
cytotoxicity	O
.	O

Thus	O
,	O
our	O
experiments	O
demonstrate	O
that	O
the	O
C-terminal	B-protein
region	I-protein
of	O
HIV-1	B-protein
Tat	I-protein
is	O
required	O
to	O
suppress	O
Mn-SOD	B-protein
expression	O
and	O
to	O
induce	O
pro-oxidative	O
conditions	O
reflected	O
by	O
a	O
drop	O
in	O
reduced	O
glutathione	O
(	O
GSH	B-protein
)	O
and	O
the	O
GSH	O
:	O
oxidized	O
GSH	O
(	O
GSSG	O
)	O
ratio	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
use	O
of	O
glucocorticoids	O
in	O
acute	O
lymphoblastic	O
leukemia	O
of	O
childhood	O
.	O

Molecular	O
,	O
cellular	O
,	O
and	O
clinical	O
considerations	O
.	O

Glucocorticoids	O
have	O
been	O
included	O
in	O
almost	O
all	O
treatment	O
regimens	O
for	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
for	O
decades	O
.	O

However	O
,	O
optimal	O
agents	O
,	O
doses	O
,	O
and/or	O
schedules	O
have	O
yet	O
to	O
be	O
defined	O
despite	O
extensive	O
clinical	O
application	O
.	O

New	O
data	O
on	O
the	O
pharmacokinetics	O
,	O
pharmacodynamics	O
,	O
and	O
molecular	O
mechanisms	O
of	O
action	O
of	O
glucocorticoids	O
have	O
suggested	O
alternative	O
approaches	O
in	O
ALL	O
.	O

These	O
suggest	O
that	O
prolonged	O
,	O
i.e.	O
28	O
day	O
,	O
glucocorticoid	O
therapy	O
may	O
be	O
unnecessary	O
as	O
exposure	O
to	O
glucocorticoid	O
induces	O
down-regulation	O
of	O
glucocorticoid	B-protein
receptors	I-protein
.	O

Dexamethasone	O
may	O
be	O
superior	O
to	O
prednisone	O
in	O
conventional	O
equi-effective	O
doses	O
.	O

Blast	O
sensitivity	O
to	O
glucocorticoids	O
correlates	O
closely	O
with	O
sensitivity	O
to	O
other	O
,	O
putatively	O
non-cross-resisting	O
agents	O
and	O
with	O
outcome	O
after	O
multi-agent	O
therapy	O
,	O
suggesting	O
overlapping	O
mechanisms	O
of	O
action	O
,	O
and	O
focusing	O
attention	O
on	O
the	O
determinants	O
of	O
the	O
threshold	O
for	O
apoptosis	O
.	O

Increasing	O
success	O
in	O
the	O
treatment	O
of	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
has	O
led	O
to	O
increasing	O
awareness	O
of	O
avascular	O
necrosis	O
of	O
bone	O
as	O
a	O
potentially	O
disabling	O
sequela	O
of	O
glucocorticoid	O
therapy	O
,	O
especially	O
in	O
adolescent	O
and	O
young	O
adult	O
patients	O
.	O

Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
protein	I-protein
2	I-protein
transactivation	O
of	O
the	O
latent	B-DNA
membrane	I-DNA
protein	I-DNA
1	I-DNA
promoter	I-DNA
is	O
mediated	O
by	O
J	B-protein
kappa	I-protein
and	O
PU.1	B-protein
.	O

Expression	O
of	O
the	O
Epstein-Barr	B-DNA
virus	I-DNA
(	I-DNA
EBV	I-DNA
)	I-DNA
latent	I-DNA
membrane	I-DNA
protein	I-DNA
1	I-DNA
(	I-DNA
LMP-1	I-DNA
)	I-DNA
oncogene	I-DNA
is	O
regulated	O
by	O
the	O
EBV	B-protein
nuclear	I-protein
protein	I-protein
2	I-protein
(	I-protein
EBNA-2	I-protein
)	I-protein
transactivator	I-protein
.	O

EBNA-2	B-protein
is	O
known	O
to	O
interact	O
with	O
the	O
cellular	B-protein
DNA-binding	I-protein
protein	I-protein
J	B-protein
kappa	I-protein
and	O
is	O
recruited	O
to	O
promoters	B-DNA
containing	O
the	O
GTGGGAA	O
J	B-DNA
kappa	I-DNA
recognition	I-DNA
sequence	I-DNA
.	O

The	O
minimal	B-DNA
EBNA-2-responsive	I-DNA
LMP-1	I-DNA
promoter	I-DNA
includes	O
one	O
J	B-DNA
kappa-binding	I-DNA
site	I-DNA
,	O
and	O
we	O
now	O
show	O
that	O
mutation	O
of	O
that	O
site	O
,	O
such	O
that	O
J	B-protein
kappa	I-protein
can	O
not	O
bind	O
,	O
reduces	O
EBNA-2	B-protein
responsiveness	O
by	O
60	O
%	O
.	O

To	O
identify	O
other	O
factors	O
which	O
interact	O
with	O
the	O
LMP-1	B-DNA
EBNA-2	I-DNA
response	I-DNA
element	I-DNA
(	O
E2RE	B-DNA
)	O
,	O
a	O
-236/-145	B-DNA
minimal	I-DNA
E2RE	I-DNA
was	O
used	O
as	O
a	O
probe	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

The	O
previously	O
characterized	O
factors	O
J	B-protein
kappa	I-protein
,	O
PU.1	B-protein
,	O
and	O
AML1	B-protein
bind	O
to	O
the	O
LMP-1	B-DNA
E2RE	I-DNA
,	O
along	O
with	O
six	O
other	O
unidentified	O
factors	O
(	O
LBF2	B-protein
to	O
LBF7	B-protein
)	O
.	O

Binding	O
sites	O
were	O
mapped	O
for	O
each	O
factor	O
.	O

LBF4	B-protein
is	O
B-	O
and	O
T-cell	O
specific	O
and	O
recognizes	O
the	O
PU.1	B-DNA
GGAA	I-DNA
core	I-DNA
sequence	I-DNA
as	O
shown	O
by	O
methylation	O
interference	O
.	O

LBF4	B-protein
has	O
a	O
molecular	O
mass	O
of	O
105	O
kDa	O
and	O
is	O
probably	O
unrelated	O
to	O
PU.1	B-protein
.	O

LBF2	B-protein
was	O
found	O
only	O
in	O
epithelial	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
whereas	O
LBF3	B-protein
,	O
LBF5	B-protein
,	O
LBF6	B-protein
,	O
and	O
LBF7	B-protein
were	O
not	O
cell	O
type	O
specific	O
.	O

Mutations	O
of	O
the	O
AML1-	B-DNA
or	I-DNA
LBF4-binding	I-DNA
sites	I-DNA
had	O
no	O
effect	O
on	O
EBNA-2	B-protein
transactivation	O
,	O
whereas	O
mutation	O
of	O
the	O
PU.1-binding	B-DNA
site	I-DNA
completely	O
eliminated	O
EBNA-2	B-protein
responses	O
.	O

A	O
gst-EBNA-2	B-protein
fusion	I-protein
protein	I-protein
specifically	O
depleted	O
PU.1	B-protein
from	O
nuclear	O
extracts	O
and	O
bound	O
in	O
vitro	O
translated	O
PU.1	B-protein
,	O
providing	O
biochemical	O
evidence	O
for	O
a	O
direct	O
EBNA-2	B-protein
-PU.1	B-protein
interaction	O
.	O

Thus	O
,	O
EBNA-2	B-protein
transactivation	O
of	O
the	O
LMP-1	B-DNA
promoter	I-DNA
is	O
dependent	O
on	O
interaction	O
with	O
at	O
least	O
two	O
distinct	O
sequence-specific	O
DNA-binding	B-protein
proteins	I-protein
,	O
J	B-protein
kappa	I-protein
and	O
PU.1	B-protein
.	O

LBF3	B-protein
,	O
LBF5	B-protein
,	O
LBF6	B-protein
,	O
or	O
LBF7	B-protein
may	O
also	O
be	O
involved	O
,	O
since	O
their	O
binding	O
sites	O
also	O
contribute	O
to	O
EBNA-2	B-protein
responsiveness	O
.	O

Lymphocyte	B-protein
glucocorticoid	I-protein
receptor	I-protein
:	O
predictor	O
of	O
sertraline	O
response	O
in	O
adolescent	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O

Major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
in	O
adolescents	O
demonstrates	O
resistance	O
to	O
tricyclic	O
antidepressants	O
and	O
absence	O
of	O
hypercortisolemia	O
.	O

The	O
efficacy	O
of	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SRIs	O
)	O
is	O
uncertain	O
,	O
and	O
response	O
predictors	O
are	O
unavailable	O
.	O

Abnormal	O
fast	O
feedback	O
and	O
negative	O
feedback	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
implicates	O
a	O
dampened	O
limbic-hippocampal	B-protein
glucocorticoid	I-protein
type	I-protein
II	I-protein
receptor	I-protein
(	O
GCII	B-protein
)	O
.	O

We	O
hypothesized	O
that	O
lymphocyte	B-protein
GCII	I-protein
is	O
altered	O
in	O
adolescent	O
MDD	O
and	O
could	O
serve	O
as	O
a	O
marker	O
for	O
response	O
to	O
SRIs	O
.	O

In	O
an	O
open-label	O
study	O
,	O
adolescents	O
(	O
n	O
=	O
20	O
)	O
meeting	O
DSM-III-R	O
criteria	O
for	O
MDD	O
showed	O
baseline	O
lymphocyte	B-protein
GCII	I-protein
sites	I-protein
per	O
cell	O
(	O
sites/cell	O
)	O
values	O
of	O
793	O
+/-	O
106	O
versus	O
2	O
,	O
563	O
+/-	O
499	O
(	O
+/-	O
SEM	O
)	O
for	O
matched	O
controls	O
(	O
n	O
=	O
18	O
)	O
(	O
t	O
=	O
3.5	O
;	O
df	O
=	O
36	O
;	O
p	O
<	O
.001	O
)	O
.	O

GCII	B-protein
was	O
bimodally	O
distributed	O
,	O
with	O
SRI	O
responders	O
differing	O
from	O
nonresponders	O
(	O
t	O
=	O
3.9	O
;	O
df	O
=	O
14	O
;	O
p	O
<	O
.001	O
)	O
.	O

GCII	B-protein
accurately	O
classified	O
90	O
percent	O
of	O
sertraline	O
responders	O
and	O
80	O
percent	O
of	O
nonresponders	O
.	O

Only	O
SRI	O
responders	O
showed	O
GCII	B-protein
sites/cell	O
upregulated	O
after	O
6	O
weeks	O
of	O
treatment	O
(	O
t	O
=	O
2.1	O
,	O
df	O
=	O
10	O
;	O
p	O
<	O
.05	O
)	O
.	O

The	O
role	O
of	O
NFATp	B-protein
in	O
cyclosporin	B-DNA
A-sensitive	I-DNA
tumor	I-DNA
necrosis	I-DNA
factor-alpha	I-DNA
gene	I-DNA
transcription	O
.	O

The	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
(	I-DNA
TNF	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
is	O
an	O
immediate	O
early	O
gene	O
in	O
activated	O
T	B-cell_type
cells	I-cell_type
,	O
in	O
that	O
it	O
is	O
rapidly	O
induced	O
without	O
a	O
requirement	O
for	O
protein	O
synthesis	O
.	O

Maximal	O
induction	O
of	O
TNF	B-RNA
alpha	I-RNA
mRNA	I-RNA
can	O
be	O
induced	O
by	O
treatment	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
calcium	O
ionophores	O
alone	O
,	O
via	O
a	O
calcineurin	B-protein
-dependent	O
process	O
that	O
is	O
blocked	O
by	O
cyclosporin	O
A	O
.	O

We	O
have	O
previously	O
identified	O
a	O
promoter	B-DNA
element	I-DNA
,	O
kappa	B-DNA
3	I-DNA
,	O
that	O
is	O
required	O
for	O
calcium-stimulated	O
,	O
cyclosporin	O
A-sensitive	O
induction	O
of	O
the	O
TNF	B-DNA
alpha	I-DNA
gene	I-DNA
in	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
kappa	B-protein
3	I-protein
binding	I-protein
factor	I-protein
contains	O
NFATp	B-protein
,	O
a	O
cyclosporin-sensitive	B-protein
DNA-binding	I-protein
protein	I-protein
required	O
for	O
interleukin-2	B-DNA
gene	I-DNA
transcription	O
.	O

NFATp	B-protein
binds	O
to	O
two	O
sites	O
within	O
the	O
kappa	B-DNA
3	I-DNA
element	I-DNA
,	O
and	O
occupancy	O
of	O
both	O
sites	O
is	O
required	O
for	O
TNF	B-protein
alpha	O
gene	O
induction	O
.	O

Thus	O
,	O
although	O
the	O
kappa	B-DNA
3	I-DNA
element	I-DNA
has	O
little	O
sequence	O
similarity	O
to	O
other	O
NFATp-binding	B-DNA
sites	I-DNA
,	O
it	O
appears	O
to	O
function	O
as	O
a	O
cyclosporin-sensitive	B-DNA
promoter	I-DNA
element	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
by	O
virtue	O
of	O
its	O
ability	O
to	O
bind	O
NFATp	B-protein
.	O

The	O
involvement	O
of	O
NFATp	B-protein
in	O
transcriptional	O
activation	O
of	O
both	O
the	O
interleukin-2	B-protein
and	O
TNF	B-DNA
alpha	I-DNA
genes	I-DNA
suggests	O
that	O
this	O
factor	O
plays	O
an	O
important	O
role	O
in	O
the	O
coordinate	O
induction	O
of	O
multiple	O
cytokine	B-DNA
genes	I-DNA
,	O
starting	O
at	O
the	O
earliest	O
stages	O
of	O
T	O
cell	O
activation	O
.	O

Regulation	O
and	O
specificity	O
of	O
MNDA	B-protein
expression	O
in	O
monocytes	B-cell_type
,	O
macrophages	B-cell_type
,	O
and	O
leukemia/B	B-cell_line
lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
expression	O
of	O
the	O
human	B-protein
myeloid	I-protein
cell	I-protein
nuclear	I-protein
differentiation	I-protein
antigen	I-protein
(	O
MNDA	B-protein
)	O
was	O
observed	O
specifically	O
in	O
cells	O
of	O
the	O
granulocyte-macrophage	O
lineage	O
in	O
our	O
earlier	O
reports	O
.	O

The	O
specificity	O
of	O
MNDA	B-protein
expression	O
for	O
cells	O
in	O
the	O
granulocyte-macrophage	O
lineage	O
was	O
reexamined	O
in	O
cell	B-cell_line
lines	I-cell_line
established	O
from	O
patients	O
with	O
Philadelphia	O
chromosome-positive	O
chronic	O
myeloid	O
leukemia	O
.	O

Cell	O
lines	O
that	O
expressed	O
MNDA	B-protein
exhibited	O
myeloid	O
cell	O
features	O
and	O
granulocyte	O
or	O
monocyte	O
differentiation	O
could	O
be	O
induced	O
in	O
vitro	O
,	O
while	O
cell	O
lines	O
exhibiting	O
properties	O
of	O
very	O
early	O
stage	O
cells	O
or	O
multipotential	B-cell_type
cells	I-cell_type
did	O
not	O
express	O
MNDA	B-protein
.	O

Cells	O
originating	O
from	O
cases	O
of	O
Burkitt	O
's	O
lymphoma	O
were	O
negative	O
.	O

By	O
contrast	O
,	O
three	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
immortalized	O
in	O
vitro	O
with	O
Epstein-Barr	O
virus	O
)	O
were	O
weakly	O
positive	O
and	O
MNDA	B-protein
was	O
up-regulated	O
by	O
interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
treatment	O
.	O

As	O
we	O
reported	O
previously	O
,	O
MNDA	B-RNA
mRNA	I-RNA
level	O
in	O
adherent	O
monocytes	B-cell_type
is	O
elevated	O
by	O
IFN-alpha	B-protein
;	O
in	O
this	O
study	O
,	O
we	O
further	O
assessed	O
MNDA	B-protein
expression	O
in	O
in	O
vitro	O
monocyte-derived	O
macrophages	B-cell_type
.	O

Three	O
additional	O
agents	O
(	O
endotoxin	O
,	O
phytohemagglutinin	B-protein
,	O
and	O
phorbol	O
ester	O
)	O
and	O
other	O
conditions	O
that	O
affect	O
function	O
,	O
cytokine	B-protein
production	O
,	O
differentiation	O
,	O
and/or	O
growth	O
of	O
monocytes	B-cell_type
were	O
examined	O
for	O
their	O
ability	O
to	O
alter	O
MNDA	B-protein
expression	O
.	O

The	O
results	O
varied	O
with	O
the	O
agent	O
,	O
cell	O
type	O
,	O
and	O
stage	O
of	O
differentiation	O
.	O

Changes	O
in	O
MNDA	B-protein
expression	O
occurred	O
slowly	O
(	O
hours	O
to	O
days	O
)	O
,	O
suggesting	O
that	O
MNDA	B-protein
could	O
mediate	O
changes	O
realized	O
over	O
a	O
long	O
period	O
.	O

The	O
results	O
also	O
reveal	O
a	O
discordance	O
in	O
certain	O
MNDA	B-cell_line
positive	I-cell_line
cells	I-cell_line
between	O
steady-state	O
levels	O
or	O
changes	O
in	O
levels	O
of	O
protein	O
and	O
mRNA	B-RNA
indicating	O
that	O
the	O
regulation	O
of	O
MNDA	B-protein
expression	O
occurs	O
at	O
more	O
than	O
one	O
point	O
.	O

Changes	O
in	O
MNDA	B-protein
expression	O
are	O
consistent	O
with	O
a	O
role	O
in	O
opposing	O
macrophage	O
differentiation	O
and	O
activation	O
of	O
monocytes	B-cell_type
/macrophages	B-cell_type
.	O

DNA-binding	O
studies	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
(	O
EBNA-2	B-protein
)	O
:	O
evidence	O
for	O
complex	O
formation	O
by	O
latent	B-protein
membrane	I-protein
protein	I-protein
gene	I-protein
promoter-binding	I-protein
proteins	I-protein
in	O
EBNA-2-positive	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
(	O
EBNA-2	B-protein
)	O
protein	O
is	O
essential	O
for	O
the	O
immortalization	O
of	O
human	B-cell_type
primary	I-cell_type
B	I-cell_type
cells	I-cell_type
by	O
EBV	O
.	O

EBNA-2	B-protein
trans-activates	O
cellular	B-DNA
and	I-DNA
viral	I-DNA
genes	I-DNA
like	O
CD23	B-DNA
,	O
c-fgr	B-DNA
,	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	O
LMP1	B-protein
)	O
and	O
terminal	B-protein
protein	I-protein
1	I-protein
(	O
TP1	B-protein
)	O
.	O

Trans-activation	O
of	O
the	O
TP1	B-DNA
promoter	I-DNA
and	O
of	O
the	O
BamHI	B-DNA
C	I-DNA
promoter	I-DNA
has	O
already	O
been	O
investigated	O
in	O
detail	O
and	O
appears	O
to	O
be	O
mediated	O
via	O
protein-protein	O
interactions	O
and	O
not	O
by	O
direct	O
binding	O
of	O
EBNA-2	B-protein
type	I-protein
A	I-protein
(	O
of	O
EBV	O
type	O
1	O
)	O
to	O
the	O
DNA	O
.	O

EBNA-2	B-protein
is	O
able	O
to	O
trans-activate	O
the	O
expression	O
of	O
the	O
LMP	B-DNA
gene	I-DNA
in	O
several	O
cell	O
lines	O
.	O

Various	O
reports	O
have	O
delineated	O
the	O
cis-acting	B-DNA
elements	I-DNA
of	O
the	O
LMP	B-DNA
promoter	I-DNA
through	O
which	O
EBNA-2	B-protein
mediates	O
trans-activation	O
.	O

To	O
determine	O
whether	O
EBNA-2	B-protein
also	O
trans-activates	O
the	O
LMP	B-DNA
promoter	I-DNA
by	O
protein-protein	O
interactions	O
,	O
we	O
performed	O
a	O
series	O
of	O
gel	O
retardation	O
assays	O
and	O
competition	O
experiments	O
with	O
LMP	B-DNA
promoter	I-DNA
fragments	I-DNA
of	O
different	O
sizes	O
.	O

We	O
determined	O
that	O
the	O
protein-binding	B-DNA
region	I-DNA
on	O
the	O
LMP	B-DNA
promoter	I-DNA
was	O
within	O
a	O
42	B-DNA
bp	I-DNA
fragment	I-DNA
encompassing	O
nucleotides	O
-135	O
to	O
-176	O
relative	O
to	O
the	O
LMP	B-DNA
transcriptional	I-DNA
start	I-DNA
site	I-DNA
.	O

None	O
of	O
the	O
DNA	O
fragments	O
investigated	O
indicated	O
interaction	O
of	O
EBNA-2	B-protein
with	O
the	O
DNA	O
via	O
protein-protein	O
interactions	O
.	O

No	O
significant	O
differences	O
between	O
EBNA-2	B-protein
-positive	O
and	O
EBNA-2	B-protein
-negative	O
nuclear	O
extracts	O
could	O
be	O
seen	O
in	O
the	O
gel	O
retardation	O
assay	O
under	O
conditions	O
that	O
clearly	O
showed	O
binding	O
of	O
EBNA-2A	B-protein
to	O
the	O
TP1	B-DNA
promoter	I-DNA
.	O

However	O
,	O
analysis	O
of	O
sucrose	O
gradient	O
fractions	O
in	O
the	O
gel	O
retardation	O
assay	O
provided	O
evidence	O
that	O
the	O
LMP	B-protein
promoter-binding	I-protein
proteins	I-protein
form	O
a	O
complex	O
of	O
higher	O
M	O
(	O
r	O
)	O
in	O
EBNA-2-positive	B-cell_type
cell	I-cell_type
extracts	O
.	O

These	O
complexes	O
were	O
destroyed	O
by	O
detergent	O
.	O

We	O
deduce	O
from	O
these	O
results	O
that	O
EBNA-2-positive	B-cell_line
cells	I-cell_line
might	O
indeed	O
contain	O
specific	B-protein
complexes	I-protein
bound	O
to	O
the	O
LMP	B-DNA
promoter	I-DNA
which	O
are	O
,	O
however	O
,	O
too	O
labile	O
to	O
be	O
detected	O
in	O
a	O
standard	O
gel	O
retardation	O
assay	O
.	O

Simultaneous	O
activation	O
of	O
Ig	B-protein
and	O
Oct-2	B-protein
synthesis	O
and	O
reduction	O
of	O
surface	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
by	O
IL-6	B-protein
.	O

Terminal	O
differentiation	O
of	O
B	B-cell_type
cells	I-cell_type
to	O
plasma	B-cell_type
cells	I-cell_type
in	O
vivo	O
is	O
characterized	O
by	O
secretion	O
of	O
Ig	B-protein
and	O
extinction	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
on	O
the	O
cell	O
surface	O
.	O

We	O
show	O
that	O
IL-6	B-protein
signaling	O
leads	O
to	O
marked	O
increases	O
in	O
the	O
synthesis	O
and	O
secretion	O
of	O
Ig	B-protein
in	O
clonal	B-cell_line
human	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
newly	O
isolated	B-cell_type
polyclonal	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
in	O
vitro	O
.	O

The	O
IL-6-induced	B-cell_line
cells	I-cell_line
resemble	O